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Summary
Quantifying the pro- and antimutagenic roles of DNA
damage and repair
Nadezda Volkova
Genome integrity is essential to the survival of any living organism. The genome
is constantly challenged by a multitude of endogenous and exogenous mutagenic factors
such as environmental exposures or replication errors. Therefore, evolution has supplied
cells with a number of repair mechanisms to protect their genetic information; however,
excessive exposures or defects in the repair machinery can lead to the accumulation of
deleterious mutations which may cause a range of diseases including cancer.
Di↵erent mutational processes often leave behind characteristic patterns of mutations,
so-called mutational signatures. Mutational signature analysis of tumours has gained a lot
of attention recently, because it may reveal carcinogenic exposures and also therapeutic
vulnerabilities. So far, over 50 mutational signatures have been identified using pattern
recognition in large cancer cohorts, reflecting the action of a range of known mutagenic
processes, such as UV light, tobacco smoke or mismatch repair deficiency, but for many
mutational signatures an underlying generative process is still unknown. The search for
the causes behind a given mutational signature is further complicated by the fact that
every alteration in the DNA results from failed or incorrect repair of a DNA lesion, hence
there are two factors which jointly shape the mutational spectrum of any mutagenic
process.
In this thesis, I quantify the variability of mutational signatures in model organisms
and in human cancer and explore the diversity of DNA damage-repair interactions. Using
data from a large mutagenesis screen in C. elegans, including over 50 DNA repair deficient
genetic backgrounds, 12 genotoxins and nearly 200 combinations thereof, I characterise
the mutational spectra and genomic features of a range of DNA repair deficiencies, and
describe the mutational signatures of genotoxins across multiple genetic backgrounds.
Importantly, the mutagenic contributions of genetic and mutagenic factors can vary de-
v
pending on the DNA repair components available: over 35% of genotoxin-knockout com-
binations demonstrated a measurable e↵ect on the mutation rate compared to expected
values, and about 10% also presented a new mutational spectrum.
Analysis of mutational signatures in cancer exomes demonstrates the relevance of C.
elegans results to cancer investigation. Mismatch repair deficiency patterns extracted
from C. elegans are comparable to those in gastrointestinal tumours, and help to dis-
sect convoluted mutational processes. The antagonism between DNA damage and repair
drives variability in cancer genomes as well: the observed interaction e↵ects were low in
magnitude, but evolutionary considerations suggest that cancer risk may be substantially
elevated even by small increases in mutagenicity.
In summary, this thesis presents the first comprehensive analysis of mutagenic DNA
damage-repair interactions using experimental and cancer data. The results show that
mutations result from the opposing pro- and anti-mutagenic forces of DNA damage and
repair, which shape mutational signatures in highly variable ways. This variation has
to be acknowledged and integrated into mutational signature analysis to ensure reliable
interpretation and applicability in clinical oncology. Lastly, the cross-species comparison
shows that the fundamental laws of mutagenesis are acting similarly across eukaryotic
organisms reminding that many mutational processes fuelling tumorigenesis are not ex-
clusive to cancer, but also drive variation and the evolution of species.
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Chapter 1
Introduction
Every system which stores and transmits information is prone to compression loss
and transmission errors. According to Shannon’s noisy-channel coding theorem, there is
a maximum limit of error-free transmission rate for every channel with a certain noise
rate, which makes it impossible to send over a signal completely error-free in presence
of noise. In this regard, a genome of a cell is no di↵erent: DNA has to be copied every
time a cell divides, which exposes the valuable genetic information to damage induced by
the environment and to errors arising via replication. The task of correctly propagating
genetic information is crucial to the survival of a species, yet it is the inevitability of
random errors that drives the evolution. It is the balance between the two that allows
for the development of such huge diversity of life forms capable of adapting to changing
environments.
Moreover, DNA within a living cell experiences pressures other than replication. Func-
tional regions are constantly accessed by various enzymes conducting transcription or
regulation thereof. Various exogenous mutagens are capable of altering the chemical or
physical structure of DNA, even when it is tightly compressed. For gamete production,
DNA may have to undergo crossover, mixing the information between the two copies with
a risk of loss or alteration of genetic information. The chemical environment of the cell also
poses a threat to genome stability via spontaneous hydrolysis reactions and the presence
of reactive oxygen species which can modify DNA bases. The chance of acquiring damage
is low for each individual nucleotide, but becomes high when considered on the scale of 12
billion bases of a diploid genome. To cope with a multitude of damage-inducing processes,
cells have developed a rich toolkit of DNA repair mechanisms which aim to restore the
DNA to the original state when possible, or at least minimise the consequences of DNA
alterations.
There is a long history of understanding how di↵erent traits can be inherited and
modified. The first principles of evolution and heredity were laid as a foundation of
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genetics in the 19th century with Charles Darwin’s seminal manuscript on the origins of
species and the works of Gregor Mendel, which were rediscovered by Hugo de Vries at
the end of 19th century. The concept of mutation and its e↵ects on the organism were
further enhanced by the brilliant experiments conducted by the lab of Thomas Morgan
in the early 20th century.
The discovery of mutagenic abilities of X-rays in the 1920s opened the door for mu-
tagenesis experiments and led to the formulation of “target theory”, a unified theory of
mutation. In the 1930s, with the discovery of chemical mutagens and the introduction
of micro-organisms as a model system, experimental studies of mutations reached a new
level allowing for the characterisation of mutagenic properties of di↵erent substances.
The DNA structure discovered by Watson and Crick in 1953 gave the mutagenesis field
biochemical and biophysical perspectives.
The introduction of sequencing in the 1970-s allowed scientists to look at mutations
at the single-base resolution. Thousands of studies were conducted, identifying mutations
in individual genes and characterising their types and origins. Finally, the late 20th to
early 21st century’s era of high-throughput sequencing flooded genetics with an enormous
amount of data on mutations in model organisms, human germ line (such as the 1000
Genomes project and UK Biobank), as well as cancer (including TCGA, ICGC, MSK-
IMPACT).
Mutation acquisition is one of the most basic biological processes underlying adap-
tation, immunity, and disease, but despite of this, many aspects of it are still poorly
understood. In the Section 1.1 I will provide an extensive overview of known sources
and types of DNA damage as well as DNA repair mechanisms. The mutations resulting
from the tussle of DNA damage and repair do not just a↵ect individual genes or genome
regions, but also generate patterns which can reveal the mechanistic principles of mutage-
nesis. A review of the recognition and utility of such patterns will be presented in Section
1.2. Lastly, in Section 1.3 I will point out several underexplored aspects of mutational
signatures which I will address in this thesis work.
1.1 DNA damage and DNA repair
A common feature of any living organism is the ability to pass on their genetic in-
formation in the form of DNA. The fidelity of DNA replication may be challenged by a
multitude of endogenous and exogenous damaging factors. To protect the genome from
deleterious mutations, cells are equipped with a range of DNA repair mechanisms to pre-
serve the DNA in its original unaltered state, or at least to repair major lesions that would
make replication impossible at a cost of less damaging mutations.
2
Mutations are alterations in the DNA sequence, and they result from unrepaired (or
incorrectly repaired) lesions: damage to the chemical or physical structure of the double
helix or its components conferred by spontaneous reactions, polymerase errors, exoge-
nous agents or endogenous mutagenic processes. Such mutations can be measured on
the genome-wide scale using next-generation sequencing (NGS), which allows detecting
changes at a single-base resolution in the DNA sequence by comparing it to the reference.
In this section, I will describe the most common types and sources of DNA damage and
the mutations they cause, as well as give an overview of the pathways which conduct
DNA damage sensing and repair. For clarity, the term DNA damage in this chapter will
only refer to the primary damage (lesions and nucleotide modifications), whereas in the
chapters to follow, this term will denote both the primary damage and the mutations
caused by a particular mutational process.
1.1.1 Types of DNA damage
Damage to DNA is occurring constantly: the nuclear DNA of an average cell of the
human body experiences over 70,000 damage episodes per day, most of which are being
e ciently repaired, as the resulting mutation rate is as low as 10 10 mutations per base
per cell division, corresponding to less than one mutation per genome (Bernstein et al.
2013). Apart from being a source of important changes for evolution and adaptation,
DNA damage is involved in many processes less beneficial to an individual organism: it
is implicated in ageing (Hoeijmakers 2009), and it is the main component of neoplastic
development (Stratton, Campbell, and Futreal 2009).
Despite a high number of damage instances occurring in a cell over a single cell cycle,
most of this damage in a healthy cell will be correctly repaired (Sancar et al. 2004). Only
the lesions that manage to persist through the replication, or large-scale events with a
higher chance of incorrect restoration (of DNA), will result in a somatic mutation in one
or both of the daughter cells. If the damage is excessive and cannot be repaired within a
reasonable time frame, it can trigger cell cycle arrest in proliferating cells and put them
in senescence, forcing them to stop dividing until the damage is repaired. If the damage
still cannot be repaired, damaged cells will undergo programmed cell death – apoptosis
(Hoeijmakers 2009). The estimates of the steady-state number of DNA lesions, i.e. when
there is a balance between lesion formation and repair, report about 30,000 abasic sites
being present in an average cell of a rat. However, this number may vary substantially
across di↵erent tissues (Swenberg et al. 2010).
DNA damage types range from chemical modifications a↵ecting an individual DNA
base to the changes in the spatial structure of DNA (Ward 1994). These kinds of damage
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Sources of DNA damage Type of damage
Spontaneous hydrolysis Apurunic / apyrimidinic sites
Methylation of DNA bases 5-methylcytosine
Deamination of DNA bases
Cytosine Uracil
5-meC Thymine
5-hydroxymeC 5-hydroxymeU
Adenine Hypoxanthine
Guanine Xanthine
ROS/RNS 8-oxoguanine, abasic sites, SSBs, deamina-
tion
Replicative errors Mismatches
Alkylating agents Base alkylation
PAHs Bulky adducts
Intercalating agents DNA structure distortion: Double- and
single-strand breaks
Crosslinking agents Intra- and interstrand crosslinks, DNA-
protein crosslinks, monoadducts
UV-light
Direct damage CPDs, 6-4PPs
Indirect damage Oxidative damage
Ionising radiation
Direct damage Double- and single-strand breaks
Indirect damage Oxidative damage
Transposons Translocations, insertions
Translesion synthesis Mismatches (mostly with adenines)
Table 1.1: Types of DNA damaging agents and the damage they incur.
can be induced by a wide range of agents, some of which are listed in Table 1.1. Some of
this damage can only be induced by external genotoxic agents, but there are also many
internal processes that can cause damage to the DNA.
1.1.2 Endogenous sources of DNA damage
Many normal cellular processes can generate DNA damage by promoting chemical re-
actions between cell metabolites and DNA, or by directly producing the chemicals capable
of altering the DNA structure or conformation (Tomasetti, Vogelstein, and Parmigiani
2013).
Spontaneous reactions
The structure of DNA relies on a huge amount of chemical bonds with varying stability
(Lindahl 1993). Hydrolysis is a reaction cleaving the N-glycosidic bond of a nucleic acid
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base. This happens spontaneously at a rate of 10,000 events per human cell per day, and it
is mostly depurination as purines are more susceptible to loss due to hydrolysis (Lindahl
and Barnes 2000). Apurinic or more generally abasic sites are mutagenic because the
gap in the DNA strand must be filled upon replication, and the enzymes performing this
reaction have low accuracy (Sale, Lehmann, and Woodgate 2012).
In addition, DNA bases and their modifications can spontaneously lose an amine
group. Spontaneous deamination of cytosine turns it into uracil, which happens about
70-200 times per human cell per day (Lindahl 1993). Cells also possess a special system
of enzymes deaminating cytosines in single-stranded DNA as a part of viral protection
or somatic hypermutation mechanisms (Knisbacher, Gerber, and Levanon 2016), namely
AID and APOBEC. As cytosines in ssDNA are turned into uracils, they have to be excised
by special enzymes ensuring there is no uracil in the DNA. Depending on whether a uracil
or an abasic site is left in the DNA upon the next replication, it can lead to C>T or C>G
mutations, respectively (Taylor et al. 2013).
Deamination of adenine happens less often and leads to hypoxanthine, a base mod-
ification that can pair with cytosine (Karran and Lindahl 1980). Guanines can also be
spontaneously deaminated producing xanthine - a base that typically pairs with cytosine
and is not mutagenic (Lindahl 1993).
In mammals, an additional source of mutations is DNA methylation. 5-methylcytosine
is prone to spontaneous deamination which results in thymine, a DNA base that cannot
be detected by glycosylases and creates a mismatch mostly detectable by the mismatch
repair system. O↵-target methylation of 3-position in cytosine can also be mutagenic
(Delaney and Essigmann 2004).
Replication errors
Replication is one of the most essential and complex processes in the cell, which can
also generate mutations as a result of nucleotide misincorporation or polymerase slippage.
Stalling of replication fork can lead to double-strand breaks (DSBs) that can be lethal
to the cell (Jackson 2002), while replication-transcription collisions create deletions or
duplications and base substitutions at promoters of the genes (Sankar et al. 2016).
Typically, replication starts at special positions in the genome termed origins of replica-
tion, 30,000 to 50,000 of which are activated in a human cell during cell division (Prioleau
and MacAlpine 2016). Helicases open the double-stranded DNA, forming a replication
fork. Then, three kinds of replicative polymerases are recruited: polymerase ↵, which
serves as replicative primase, and leading strand polymerase " and lagging strand poly-
merase  .
Three mechanisms are employed by the cells to ensure the fidelity of replication.
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Firstly, the replicative polymerases typically have high selectivity towards the right nu-
cleotide (Kunkel and Bebenek 2000). If they do insert a wrong one, these polymerases
have an exonuclease domain that allows detecting and removing a mismatch straight
away. However, this system is not perfect and can miss about one mismatch per 10 Mbps
(Kunkel and Bebenek 2000), and cannot deal with situations where the repetitive sequence
context causes the newly synthesised and template strand to bind at the wrong repeat
resulting in a set of unpaired bases in one strand. Hence, there is a third mechanism
called mismatch repair that screens the DNA for such errors right after replication and
repairs them in the newly synthesised DNA.
The availability of the substrate for polymerases can also have an impact on the error
rate. Total depletion of nucleotide (dNTP) pool can lead to replication failure and cell
death (Laureti et al. 2013). It has been reported that the mutations attributable to
polymerase errors are enriched in late replicating regions, which may be also connected
to the decreased availability of dNTPs (Koren et al. 2012).
Moreover, DNA bases can exist in several isomers which are chemically identical but
can potentially pair with wrong bases. The normal DNA usually contains the keto form
of bases, but it can turn into enol and imino forms upon a tautomeric shift. These
events, however, are rare under normal physiological conditions (Abou-Zied, Jimenez,
and Romesberg 2001).
Prolonged exposure of single-stranded DNA to the cell environments can also cause
damage to the DNA. Repetitive regions can form various secondary structures while left
single-stranded during replication leading to replication stalling and deletions or insertions
upon replication restart (Huang et al. 2017b). Similarly, overexpression of APOBEC en-
zymes can lead to APOBEC-mediated cytosine deamination during replication, generating
a pattern of mutations often found in cancers (Roberts et al. 2013).
Oxidative damage
Chemically reactive substances containing oxygen such as peroxides, superoxides, hy-
droxyl radicals, singlet oxygen, or alpha-oxygen can trigger oxidative damage to the DNA.
Reactive oxygen species (ROS) are metabolites stemming from multiple normal chemical
reactions in the cell and participate in cell signalling and homeostasis. Typically, they are
produced as a by product of oxidative phosphorylation in mitochondria, but can arise also
in response to environmental stress such as ionising radiation, heavy metals and pollutants
(Devasagayam et al. 2004).
ROS can induce base modifications such as 8-oxoG, abasic sites and DNA breaks,
and take part in the creation of aldehydes that can crosslink DNA. In total, they can
generation over 20 types of DNA lesions (De Bont and Van Larebeke 2004). On average,
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natural oxidative damage causes about 12,000 lesions per human cell per day (De Bont
and Van Larebeke 2004).
Mobile genetic elements
Transposons and other mobile genetic elements can move across the genome potentially
disrupting the structure of a gene or functional element. The relocation of these elements
causes DNA damage response, which can, in turn, recruit an error-prone repair pathway
to repair the damage. Mobile genetic elements can cause gene duplications and fusions
(Izsva´k, Wang, and Ivics 2009).
1.1.3 Exogenous agents incurring DNA damage
Various physical, chemical or biological agents can induce DNA damage, either directly
or indirectly. Pathogenicity of exposure can stem from the damage to the cell and its
functions (cytotoxicity), or from damage caused to the DNA (genotoxicity). Many of the
substances listed as carcinogens are genotoxins causing mutagenic alterations of the DNA
(Health and Services 2016). I describe the most common exogenous genotoxins implied
in human cancer development below.
Alkylating agents
Alkylating agents are chemicals capable of transferring an alkyl group to a DNA nu-
cleotide. These agents may be monofunctional if they have only one binding site, or
bifunctional if they can bind to two bases (or a base and a di↵erent molecule) (Watson
1964). Some alkylating agents such as quinones or ethylene oxide can occur naturally in
the environment (Moore and Czerniak 1981, Garry et al. 1979), but most are chemically
produced compounds often used as chemotherapy drugs (e.g. temozolomide, cyclophos-
phamide, mustard gas derivatives) due to their genotoxic capabilities (Kondo et al. 2010).
Monofunctional alkylating agents add an alkyl group to DNA bases causing base
modifications that can result in base substitutions, single-strand breaks (SSBs), or stalled
replication fork. In contrast, bifunctional alkylating agents create DNA or DNA-protein
crosslinks and monoadducts leading to DNA breaks and replication fork stalling (Kondo
et al. 2010).
Platinum-based cross-linking agents
Another class of drugs commonly used in cancer treatment are platinum-based agents
such as cisplatin, oxaliplatin or carboplatin (Rabik and Dolan 2007). Due to the struc-
ture of their molecules, they can bind to more than one DNA base creating intra- and
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interstrand crosslinks. Similar to bifunctional alkylating agents, they can also form bulky
adducts and DNA-protein complexes. They mostly act on the adjacent N-7 position of
guanine (Cohen and Lippard 2001). These chemicals are also termed ’alkylation-like’ due
to the similarity between their mechanism of action and that of bifunctional alkylating
agents. If crosslinks remain unrepaired, they stall replication fork and cause single- and
double-strand breaks.
Intercalating agents
Intercalating agents is a class of molecules that can fit themselves in between the DNA
base pairs. Some of these agents are small enough to cause just a frameshift mutation
during replication, and others can lead to transcription and replication blockage (Wakelin
1986). Alternatively, intercalating agents can target topoisomerase II (Nitiss 2009). Dur-
ing DNA replication or transcription, DNA helicases unwind the DNA to provide access
to DNA or RNA polymerases. This intensifies the torsion of the double helix creating
tangles and supercoils (Liu and Wang 1987, Vogelstein, Pardoll, and Co↵ey 1980). These
structures are typically resolved by type II topoisomerase that cuts both DNA strands,
unwinds the torsion and re-ligates the ends. Intercalating agents can interfere with this
breakage-reunion process causing topoisomerase-mediated rearrangements (Nitiss 2009).
Polycyclic aromatic hydrocarbons
Polycyclic aromatic hydrocarbons (PAHs) are a type of chemicals often found in food,
pollutants or fuel derivatives. They represent fused aromatic rings and are typically
produced by the burning process. Many of them are highly carcinogenic, particularly so
the benzo-[a]-pyrene, a component of tobacco smoke, and a food contaminant aflatoxin
(Bo↵etta, Jourenkova, and Gustavsson 1997, Kew 2013).
In the process of being metabolised within the cell, PAHs turn into active molecules
that can bind to DNA bases and create bulky adducts deforming the double helix and
blocking transcription and replication (Xue and Warshawsky 2005).
Ionising radiation
Ionising radiation (IR) is a class of high-energy electromagnetic waves that can desta-
bilise the structure of atoms in the human body, as well as alter otherwise inert molecules
within the cell, turning them into reactive species (Lomax, Folkes, and O’Neill 2013).
Exposure to IR occurs during diagnostic radiology, cancer radiotherapy, and also as a
consequence of environmental, occupational or accidental irradiation. IR has been long
ago showed to be genotoxic and carcinogenic (Little 1993). Currently, radiotherapy is
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one of the most e↵ective cancer treatments applied to nearly 40% of UK cancer patients
(Mayles 2010).
The main e↵ect of IR on the cells is the DNA damage, mostly comprised of DSBs,
which triggers senescence, apoptosis or other forms of cell death (Lomax, Folkes, and
O’Neill 2013). IR can break chemical bonds, including those in DNA’s and sugar phos-
phate backbone, leading to single- and double-strand breaks. In addition to direct harm,
IR exposure modifies water and other organic molecules, turning them into reactive oxy-
gen species and inducing oxidative damage (Lomax, Folkes, and O’Neill 2013).
Ultraviolet light exposure
Sun exposure is one of the main factors of skin cancer development. Sunlight represents
UV-light irradiation composed of waves with di↵erent wavelengths. 95% of it consists
of UV-A, the waves with lowest energy. Another 5% is UV-B, waves of intermediate
wavelength. The short waves carrying the most energy, UV-C, are typically filtered by
the ozone layer, but can be dangerous in areas with ozone layer anomalies (Herman et al.
1996).
UV exposure can cause both direct and indirect DNA damage. Direct damage comes
in the form of cyclobutane pyrimidine dimers (CPDs) mostly a↵ecting thymines and 6,4-
photoproducts (6,4-PP) involving a cytosine and a thymine (Ikehata and Ono 2011). 6,4-
PPs are more mutagenic than CPDs but occur at a third of the rate. Both of these lesions
are typically repaired by the nucleotide excision repair, otherwise they stall replication
fork and error-prone translesion synthesis has to be recruited (Sale 2013). Exposure to UV
light can also cause indirect, or ’dark’ damage: it has the right energy to excite electrons
in molecules, leading to the formation of reactive chemical species and increasing the
degree of oxidative stress (Ikehata and Ono 2011).
Biological agents
Viruses and bacteria can also induce DNA damage and are implicated in cancer devel-
opment. Microbes can directly produce genotoxins (Zˇgur-Bertok 2013, Grasso and Frisan
2015) or cause prolonged inflammation that can result in elevated levels of oxidative
stress (Kalisperati et al. 2017). Viruses can integrate their DNA into the host genome,
disrupting the host’s genes or triggering the production of viral enzymes damaging the
host’s DNA (Luftig 2014). About 12% of cancers worldwide are thought to be caused by
oncoviruses (Schiller and Lowy 2010), most notably by Epstein-Barr virus, hepatitis B,
several types of human papillomavirus, and mastadenovirus (Zapatka et al. 2018).
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Figure 1.1: A schematic depiction of di↵erent types of DNA damage with a list of sources
that cause it, as well as corresponding DNA repair pathways. Adapted from Tasaki et al.
2018.
1.1.4 DNA repair pathways
Repairing various types of DNA alterations reviewed in the previous section requires
a broad range of DNA repair pathways. In total, over 80 enzymes are directly involved in
DNA repair, along with over two hundred proteins being indirectly involved via regulation
and recruitment of DNA repair components (Alberts et al. 2007).
DNA repair in most instances starts with damage sensing via DNA damage response
enzymes or the dedicated components of the respective pathways. Upon detecting the
damage, di↵erent DNA repair mechanisms are deployed depending on the scale of damage,
e.g. whether it involves a single DNA strand, or is a double-strand break. If the damage
is excessive or persists for too long, DNA damage checkpoints may trigger senescence or
apoptosis as a last resort to preserve the integrity of the organism.
DNA damage response
After recognition of DNA damage by the enzymes capable to bind to DNA ends or
adducts, DNA damage response (DDR) is triggered by activating the phosphatidylinositol
3-kinase-like protein kinases (PIKKs) ATM, ATR and DNA-PKs (other DNA-dependent
protein kinases), or the poly(ADP)ribose polymerase (PARP) family proteins (Ciccia and
Elledge 2010).
ATM and DNA-PKs are sensitive to the agents causing double-strand breaks. ATM
subsequently activates the Chk2 kinase to transfer the signal downstream in the DDR
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pathway. ATR is mostly recruited to the single-stranded DNA regions at stalled replica-
tion forks and DSBs, and has Chk1 serving as its signal transducer. Chk1/2 kinases, in
turn, activate DNA repair factors and TP53, which regulates the expression of multiple
factors a↵ecting growth arrest, cell cycle arrest and apoptosis (Jackson and Bartek 2009).
PARP proteins can be activated by both single- and double-stranded breaks, and their
function is to recruit DDR factors to chromatin at DNA breaks (Ciccia and Elledge 2010).
The primary function of damage signalling proteins is to trigger the signalling cascade
leading to cell cycle arrest, to allow more time for damage repair or induce apoptosis
when the damage is excessive (Giglia-Mari, Zotter, and Vermeulen 2011). They mostly
phosphorylate and thus activate other DNA repair enzymes or e↵ectors – the proteins that
can regulate the expression of the proteins triggering senescence or apoptosis (Giglia-Mari,
Zotter, and Vermeulen 2011). DDR genes, especially e↵ectors such as TP53 and PTEN,
are the most often mutated genes across all cancer types (Knijnenburg et al. 2018). Germ
line defects in these genes predispose individuals to all types of cancer (Jackson and Bartek
2009).
Single strand repair
Lesions that only involve one strand of DNA can be repaired by four DNA repair path-
ways: direct repair (DR), base excision repair (BER), nucleotide excision repair (NER)
and mismatch repair (MMR).
Direct repair. Most of the damage types require excision of the damaged base or
nucleotide, but several types of damage can be repaired by direct reversal, or direct repair.
Single-stranded nicks that only involve a break of phosphodiester bond without damage to
5’ phosphate or 3’ hydroxyl groups can be ligated back by DNA ligases. The Ada enzymes
in E. coli can remove alkyl groups from O4-alkylthymines and O6-alkylguanines. Many
organisms, from bacteria to animals, possess an ability to reverse cyclobutyl dimers in-
duced by UV-light exposure via photoreactivation – a light-dependent enzymatic reaction
resolving the dimer back to its original state.
Humans, however, lack photoreactivation (Li, Kim, and Sancar 1993), and only have
two major types of proteins conducting direct repair: O6-methylguanine-DNA methyl-
transferase (MGMT) which repairs alkylation of O6-methylguanines, and ALKBH family
Fe(II)/↵-ketoglutarate dioxygenases (FeKGDs) that can directly reverse adenine and cy-
tosine methylation damage in DNA and RNA, such as 3-methylcytosine. Other damage
to human DNA has to be processed via more complex repair pathways.
Base excision repair. Damaged nucleotide bases in cases when the damage is rela-
tively minor are repaired by a mechanism called base excision repair. It is a well-conserved
pathway that strongly relies on the activity of various DNA glycosylases with di↵erent
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specificities. In most organisms, BER can repair small lesions resulting from oxidation and
deamination of di↵erent bases, such as 5-hydroxycytosine, 8-oxoguanine, thymine glycol,
uracil (deaminated cytosine) and hypoxanthine (deaminated adenine), as well as a num-
ber of methylated bases such as 3-methyladenine, 7-methylguanine, and 2-methylcytosine
(Robertson et al. 2009, Wilson III and Bohr 2007). In humans, a total of 11 di↵erent DNA
glycosylases capable of processing damaged nuclear DNA have been identified (Krokan
and Bjør˚as 2013).
Typically, base excision repair involves removal of one or several damaged nucleotides
creating an abasic site, which is then converted into a single-stranded break by the
apurinic/apyrimidinic endonuclease (APEX1), followed by gap-filling via DNA re-synthesis.
A sub-part of BER that deals with ligating single-strand breaks (SSBs) is often referred
to as a separate SSB repair system (Caldecott 2008).
BER functions in two modes depending on the scale of the damage. The dominant
pathway is normally the short-patch BER, which only a↵ects a single nucleotide. Long-
patch BER results in the creation and filling of a 2-10 bp long gap and is thought to
be the dominant post-replicative BER pathway in dividing cells (Robertson et al. 2009,
Krokan and Bjør˚as 2013).
Defects in base excision repair are often involved in disease and carcinogenesis. Bial-
lelic loss or silencing of MBD4, which encodes a DNA glycosylase protecting from 5-
methylcytosine deamination damage, leads to extremely high rates of C>T transitions at
CpG sites and predisposes to leukemias (Sanders et al. 2018), and is often occurring in
MMR-deficient colorectal cancers (Tricarico et al. 2015a). Deficiency in OGG1, NTHL1,
NEIL1, MUTYH glycosylases recognising oxidative damage leads to an excess of C>A
mutations (due to replication over lesions such as 8-oxoguanine) and a higher risk of colon
cancer (Krokan and Bjør˚as 2013).
Nucleotide excision repair. A more complex and versatile DNA repair pathway
is nucleotide excision repair (NER). Being a truly multipurpose DNA repair mechanism,
it can repair a range of lesions including photodimers, DNA structure distorting lesions
and bulky adducts introduced by mutagens (Nouspikel 2009). Over 25 polypeptides are
involved in NER, most of which are evolutionary conserved across di↵erent organisms.
NER possesses two subsystems which can process the damage in untranscribed and
transcribed regions of the genome, respectively. The first system is called global genome
NER (GG-NER). Its main component is the XPC-HR23B protein complex, which is con-
stantly scanning the genome of a eukaryotic cell in search of structural DNA modifications
(Nouspikel 2009). Upon encountering DNA damage, TFIIH is recruited, which opens a
denaturation bubble and employs XPF and XPG endonucleases to either side of the lesion
to excise a 24-32 base-pair long stretch of nucleotides. The gap is then filled by PCNA
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in combination with replicative DNA polymerase  , and chromosomal nicks are sealed by
XRCC1 and DNA ligases (Petruseva, Evdokimov, and Lavrik 2014).
Another modality, transcription-coupled NER (TC-NER), is recruited to a stalled
DNA-dependent RNA polymerase (typically RNA polymerase II). Specialised TC-NER
enzymes, including CSA and CSB, perform the translocation of the RNA polymerase,
and the further repair proceeds the same way as GG-NER (Hanawalt and Spivak 2008).
TC-NER only repairs the damage on the transcribed (non-coding) DNA strand; hence,
when both GG-NER and TC-NER are active, a transcriptional strand bias may be ob-
served, meaning that the damage on the transcribed strand is removed more e ciently
than the damage occurring on the untranscribed strand. This imbalance was observed
in cells treated with UV and tobacco smoke metabolites, as well as in human cancers
associated with these exposures (McGregor et al. 1991, Denissenko et al. 1998, Hollstein
et al. 1991).
Germline defects in NER components have been long known to lead to very severe
disease phenotypes such as xeroderma pigmentosum, Cockayne syndrome and trichoth-
iodystrophy (Boer and Hoeijmakers 2000).
Mismatch repair. Fidelity of replication is ensured via multiple mechanisms. The
replicative polymerases Pol " and Pol   possess high selectivity against mismatches as
well as a 3’-exonuclease activity, which allows the polymerases to remove the last inserted
nucleotide if it caused a mismatch. Nevertheless, they still have an error rate of about 10 5
to 10 4 depending on the nucleotide, local chromosomal properties and DNA polymerase
(Kunkel and Bebenek 2000). Hence, they are backed up by an additional back-up repair
pathway – mismatch repair.
The recognition of mismatches is typically executed by MutS protein complexes, first
found in bacteria (Hsieh and Yamane 2008). In eukaryotes, there are two complexes,
MutS-↵ and MutS- , which have di↵erent substrate specificity due to structure of their
mismatch binding sites: MutS-↵ preferentially detects base-base mismatches and short
1-2bp indels, and MutS-  handles larger indels up to 15 bp (Drummond et al. 1995,
Habraken et al. 1996, Genschel et al. 1998). MutS proteins form a clamp sliding along
the genome, which is activated upon an encounter with a mismatch, and loads the other
repair complex MutL to license excision.
The MutS/MutL complex then slides away from the mismatch in order to generate
single-stranded nicks on the nascent DNA that will initiate the DNA repair (Gradia et al.
1999, Kadyrov et al. 2006). The DNA strand containing a mismatch is normally removed
by EXO-1 exonuclease, and the resulting gap is filled by lagging strand polymerase  
(Goellner, Putnam, and Kolodner 2015).
The MMR system should be exclusively removing the mismatches from the newly
13
synthesised strand. The strand recognition mechanism is not clear for most organisms,
but the leading candidate is PCNA: it has to be recruited to the repair site to enable the
endonuclease activation, but it can also discriminate between the new and the old strands
based on its loading orientation (Pluciennik et al. 2010).
Germline defects in MMR genes cause conditions associated with a high risk of cancer
development, and somatic alterations are also often found in tumours (Bonneville et al.
2017).
Translesion synthesis. If DNA damage is encountered during DNA synthesis, it
has to be overcome by the mechanism called translesion synthesis (TLS). A specialised
set of DNA polymerases is capable to adapt modified DNA as a template and perform
the synthesis by inserting a base opposite the lesion: Y-family polymerases ⌘, , ◆ (Sale,
Lehmann, and Woodgate 2012), B-family polymerases ⇣ and REV1 (Gan et al. 2008),
and A-family polymerase ✓ (Seki, Marini, and Wood 2003).
TLS polymerases have more flexibility in templates, but are less accurate and have
no proofreading ability, therefore their error rates reach 10 4 to 10 1 (Sale, Lehmann,
and Woodgate 2012). Hence, TLS polymerases provide the ability to tolerate the damage
and avoid replication failure (which can lead to DSBs and cell death) at the cost of
introducing more mutations. Translesion synthesis typically occurs during replication but
can also occur as a part of other repair mechanisms, such as cross-link repair when a
gap-filling synthesis across damaged DNA is required (Sale 2013).
Many of the TLS polymerases are interchangeable, however, they have di↵erent ef-
ficiency and error rates when replicating over di↵erent lesions. Defects in polymerase ⌘
(also termed XPV) leads to a xeroderma pigmentosum phenotype without the defects in
NER machinery itself, indicating that it is essential to tolerating UV damage, and cannot
be replaced by other polymerases (Masutani et al. 1999).
Of other TLS polymerases, polymerase  has a preference for correct synthesis over
G adducts and extends the synthesis from other lesions. REV1 is controlling the TLS
induction, polymerase ⇣ and ◆ can deal with a range of damaged bases but with an
increased error-rate. X-family TLS polymerase  , µ and   take part in BER and NHEJ,
and TLS polymerase ✓ is an important component of crosslink repair and double-strand
break repair (Sale 2013). In mammals, TLS polymerases ⌘, ◆ and REV1 play a crucial
role in somatic hypermutation (Zeng et al. 2001, Faili et al. 2002, Masuda et al. 2009).
Double-strand break repair
Double-strand breaks are typically the most lethal type of DNA damage and may
result in cell death. Consequently, there is more than one repair pathway that serves to
repair DSBs. Depending on the cell cycle phase and cell conditions (e.g. damage intensity
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Figure 1.2: A scheme of pathway choices for double-strand break repair. Adapted from
Kim, Hromas, and Lee 2013.
and repair enzyme availability), there are three mechanisms that can complete this task
(Figure 1.2).
Homologous recombination repair. The preferable pathway for DSB repair is
homologous recombination repair (HRR), which uses the sister chromatid as a template to
restore the information that may be lost around the double-strand break (Boulton 2010).
Typically, it is triggered when a DSB is detected in late S or G2-phase (Jackson 2002).
HRR is capable of accurately repairing the majority of DSBs. Moreover, recombination
repair is an important mechanism performing the crossing-over during meiosis (Jackson
2002).
There are currently four models of HRR: classical double-strand break repair (cDSBR),
synthesis-dependent strand annealing (SDSA), break-induced replication (BIR) and single-
strand annealing (SSA) (Li and Heyer 2008). All of them share the first essential steps
(Figure 1.3).
HRR starts with the MRN complex binding to the DNA on either side of the DSB,
tethering the ends and cleaving nucleotide links as well as signalling to recruit other repair
components. After that, 5’ ends are resected, and the double-stranded DNA is opened
by the helicases. The resulting single-stranded DNA is then cut by the exonucleases
and coated with RAD51 protein to protect it from endogenous damage. Then, a search
for a homologous DNA template is conducted by aligning the sister chromatid. Upon
finding one, the strand invasion begins and a displacement-loop is created, which results
in the formation of a heteroduplex. Then, a DNA polymerase is recruited to synthesise
the missing DNA, and the D-loop changes into a cross-shaped structure termed Holliday
Junction (Figure 1.3).
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Figure 1.3: A scheme of homologous recom-
bination repair steps and model choice.
In classical DSBR, the invasion will
happen for both strands at the same time
(two-end invasion), forming two Holliday
junctions. This mechanism is also re-
quired for meiosis to ensure the formation
of crossover products (Figure 1.3). In an-
other repair option, SDSA, only one strand
is synthesised using the homologous tem-
plate, after which it is displaced and an-
nealed, while the gap on the other strand
is filled by complementary DNA synthesis.
Thus, SDSA leads to non-crossover prod-
ucts only, but happens in both mitotic and
meiotic cells (McMahill, Sham, and Bishop
2007).
Break-induced replication is usually re-
cruited to repair DSBs created during the
fork collapse upon replication stress (Kra-
mara, Osia, and Malkova 2018). DSBs in
one of the two newly created dsDNA re-
gions of the replication fork are essentially one-sided (only the break in the old strand
needs to be repaired), hence a single-end invasion to the homologue is required: the bro-
ken end invades the homologous sequence, and unidirectional DNA synthesis is initiated
from the invasion site. This structure can replicate several hundred kbps after which
it separates. If needed, re-invasion and synthesis are triggered again until the repair is
complete. This type of repair can create genomic rearrangements and is typically avoided
by the cells unless it is necessary to restart replication (Deem et al. 2011).
If the break happened in a repetitive sequence, the resected ends can be repaired
by SSA (Figure 1.3). In this case no invasion is needed: direct repeats uncovered during
resection will be annealed together and XPF/ERCC1 will cleave the flapping strand ends.
As it only relies on connecting the repeats, SSA is the most mutagenic type of homologous
recombination repair (Bhargava, Onyango, and Stark 2016).
Non-homologous end-joining. If the HRR is not available or too slow, another
DSB repair pathway takes over: non-homologous end-joining (NHEJ). NHEJ is a cheap
yet mutagenic way of repairing DSBs as it simply processes and ligates the ends of a DNA
double helix (Figure 1.4). In diploid organisms, it typically occurs during early S or G0/1
phases when the homology donor is not nearby (Lieber 2010). In somatic non-dividing
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cells, NHEJ is the dominant DSBR repair pathway (Chakraborty et al. 2016).
Figure 1.4: A scheme of non-
homologous end-joining repair.
NHEJ requires the Ku70/80 complex, which forms
a subunit of DNA-dependent protein kinase (DNA-PK)
(Figure 1.4). This complex binds to DNA ends, bridg-
ing them and protecting from non-specific nucleases, and
triggers the assembly of NHEJ complex involving DNA-
PKs and a set of end-processing enzymes, which then
perform terminal end processing. Finally, once the blunt
ends are created, XRCC4/DNA ligase 4 complex ligates
DNA ends, and then the NHEJ complex dissolves (Davis
and Chen 2013).
If the overhanging DNA ends match exactly, this re-
pair process will not introduce mutations (Rodgers and
McVey 2016). NHEJ also shows high accuracy when re-
pairing the breaks detected by RNA polymerase II in
coding regions (Chakraborty et al. 2016). Otherwise, it can be mutagenic by introducing
translocations (if the ends from di↵erent breaks get ligated together) or small insertion-
s/deletions during the processing and ligation of DNA break ends.
Figure 1.5: A scheme of
microhomology-mediated end-
joining repair.
Alternative end-joining. In the absence of the
core components of NHEJ, or if their recruitment is de-
layed, a slower yet e cient alternative end-joining mech-
anism can operate in DSB repair (Figure 1.2) (Chang et
al. 2017). Alternative end-joining (a-EJ) pathway, also
known as microhomology-mediated end-joining (MMEJ)
or Pol ✓ mediated end-joining, was first identified as a
mechanism relying on the 2-20 bp long homologous se-
quences at either side of the break (Figure 1.5). Based
on the level of homology required for the repair, MMEJ
was put in between NHEJ, which processes the ends of a
break until they have 1-4 complementary bases, and SSA
which typically needs over 20 bp of homology (hence it
works well in repetitive regions) (Bhargava, Onyango,
and Stark 2016). HRR, in comparison, requires over 100
bp of homologous sequence to consider it a template for
repair (Lisby and Rothstein 2015).
In fact, a-EJ does not necessarily require microhomology, but MMEJ happens with
much higher frequency than microhomology-independent repair (Mansour, Rhein, and
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Dahm-Daphi 2010). Both, however, require the same basic steps to preform DSB repair
(Figure 1.5). DSB detection starts with the PARP1 protein binding to the exposed DNA
ends. Then the MRN complex along with the CtIP resection factor, BLM helicase, and
EXO1 exonuclease, perform end resection. The homologous regions on either side of the
break are annealed together (or single bases, if there is no microhomology), and flapping
ends are resected by XPF/ERCC1 factor. Finally, the gaps are filled by polymerase ✓, an
essential component of the pathway that can extend mismatched termini, and the DNA
is ligated by the ligation complex. MMEJ typically occurs in S-phase only (Seol, Shim,
and Lee 2018).
MMEJ plays a major role in DSB-induced mutagenesis: one of the homologous regions
and the sequence between them are always deleted (Schendel et al. 2016). MMEJ has also
been suggested to take part in the formation of chromosomal translocations and large-
scale rearrangements, as the breakpoints from chromosomal translocations in somatic cells
often have some degree of microhomology (Schimmel et al. 2017).
Crosslink repair
DNA crosslinking occurs when two non-pairing DNA bases form a covalent bond
between them. Typically, it happens via a reaction with a molecule capable of covalently
binding to two DNA bases at the same time (Noll, Mason, and Miller 2006).
DNA crosslinks may involve nucleotide on the same strand (intrastrand crosslinks), in
which case they are repaired by NER (O’Donovan et al. 1994), or bases on the opposite
strands (interstrand crosslinks, ICL). Interstrand crosslinks have a more serious e↵ect on
DNA structure, and can easily lead to double-strand breaks. Two mechanisms of ICL
repair have been observed in eukaryotes: recombination-dependent and recombination-
independent (Huang and Li 2013).
Recombination-independent, or mutagenic, interstrand crosslink repair mainly occurs
in G1 phase or in quiescent cells. It requires enzymes from multiple pathways. The
crosslink is recognised by NER enzyme XPC, and there is evidence that ICLs highly
a↵ecting the DNA structure can also be detected by MMR enzymes (Kato et al. 2017).
First, a gap is created in one of the strands by creating nicks on either side of the crosslink
(a process termed “unhooking”), leaving the crosslinked base attached to the intact strand.
The gap is then filled by a translesion synthesis polymerase, which can insert incorrect
bases. Then, the monoadduct on the other strand is removed by NER with a strand
incision and gap filling on the other strand. This can lead to mutations due to errors
made by a TLS polymerase on the first strand (Zheng et al. 2003). When abasic sites
occur as intermediates during ICL repair, BER enzymes cover them to protect from
reacting with other bases or proteins, and to avoid the formation of additional crosslinks.
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Figure 1.6: A scheme of the mechanisms repairing interstrand crosslinks. Adapted from
Huang and Li 2013.
Recombination ICL repair, also termed replication-dependent repair, happens in late
S or G2-phase when ICLs are detected by the replication fork stalling. According to the
current model (Hashimoto, Anai, and Hanada 2016), ICL causes stalling of two replication
forks on both sides of it. Similar to the first mechanism, NER structure-specific nucleases
unhook the ICL by making dual incisions on either side of the ICL on one strand, the
resulting gap filled by TLS polymerases that bypass the remaining lesion and connect
to the Okazaki fragments. The crosslinked oligonucleotides are then repaired by NER
factors. Finally, a DSB on the sister chromatid is repaired via a classical HRR pathway
using the restored duplex DNA as a template.
This complex mechanism is regulated by a set of proteins which were identified by
studying patients with a particular form of genetic bone marrow disease, the Fanconi
anaemia (FA) proteins (Lobitz and Velleuer 2006). The FA-mediated signalling is crucial
for the recruitment of incision factors and transition into HRR (Huang and Li 2013).
The disease that gave the name to the FA pathway was associated with bi-allelic
germline defects in these genes, which also included several HRR related genes such as
BRCA1/2, PALB2, RAD51C, XRCC2 and TLS component REV7 (Dong et al. 2015)
which are essential for successful crosslink repair. Individuals a↵ected by this disease very
often develop bone marrow failure, developmental abnormalities, and cancer (Lobitz and
Velleuer 2006).
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1.2 Mutational signatures
In the previous section, I introduced the types of DNA damage and repair, which
commonly occur in the cells and generate mutations. The genome of a cell contains
the mutational footprints of di↵erent genotoxic exposures experienced by the lineage.
Various mutational processes and repair mechanisms discussed in the sections above lead
to characteristic distributions of mutations. These are called mutational signatures. The
deconvolution of the mutational traces, or signatures, of individual processes can shed
light on potential sources of pathogenic mutations that led to cancerous transformation.
In this section, I will review the recent findings in the field of mutational signature analysis
and describe their clinical significance for cancer research.
1.2.1 Somatic mutations in cancer
Cancer is a set of diseases associated with the uncontrolled growth of cells. In the ma-
jority of cases, this increased proliferation rate stems from genetic alterations in cancer
genes, which activate oncogenes or knockout tumour suppressor genes (Stratton, Camp-
bell, and Futreal 2009). According to Armitage and Doll’s multistage theory of carcino-
genesis, there are typically around 6 mutational events that lead to the disease onset
(Armitage and Doll 1954).
Recent studies based on the whole-genome sequencing of a large number of tumours
demonstrated the prevalence of clonal expansions and ongoing evolutionary processes in
cancer (Greaves and Maley 2012). Somatic mutations aggregated in tumour cells can
shed light on the genomic history and evolution of the tumour (Nik-Zainal et al. 2012b,
Gerstung et al. 2018). This evolution may be gradual or punctuated by catastrophic
events such as chromothripsis (Forment, Kaidi, and Jackson 2012). Over the course of
cancer evolution, the mutation rate of all cells or di↵erent clones can change due to the
temporal activity of di↵erent mutational processes, or somatic disabilities in DNA repair
pathways occurring at di↵erent time points (Greaves and Maley 2012).
Mutations found in cancer cells may be either driver mutations if they alter the fitness
of the cell and provide it a selective advantage, or passengers if they do not a↵ect the fitness
but happen to be carried by the same cells which have acquired a beneficial mutation
(Stratton, Campbell, and Futreal 2009). The set of driver mutations is typically small
(Martincorena et al. 2017, Tomasetti et al. 2015). The majority of them tend to a↵ect
the genes essential for cell growth or damage-caused apoptosis such as tumour suppressor
gene p53 (Rivlin et al. 2011) or oncogene KRAS (Wang et al. 2015).
The collection of driver and passenger mutations is a consequence of the mutational
processes which were active in a given tumour. Hence, the overall distribution of mutations
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acquired at di↵erent times contains information about the mutagenic processes which
happened in the past. Unique spectra of mutations generated by di↵erent mutational
processes were termed mutational signatures. Analysing the mutational signatures of
the individual and interaction e↵ects of key elements of genome stability maintenance
and environmental exposures and finding them in the mutational spectra of a tumour
provides the means to trace back the causes of the disease and predict the outcomes of
chemo- or radiotherapy for individual cases (Poon et al. 2014).
Mutational signatures are not only applicable to cancer studies. Aggregation of germ
line data has allowed the examination of the distribution of mutations contributing to
human variation and genetic diseases (Chen, Fe´rec, and Cooper 2013). Additionally, the
introduction of high-depth sequencing opened the way to studying the processes creat-
ing somatic heterogeneity in healthy tissues (Behjati et al. 2014). Recent studies have
demonstrated a frequent and age-dependent presence of clones with driver mutations and
ongoing mutational processes in healthy tissues (Martincorena et al. 2015, Yadav, DeGre-
gori, and De 2016, Martincorena et al. 2018).
1.2.2 Signatures of mutational processes active in human cancer
Somatic mutations in cancer genomes are generated by multiple endogenous and ex-
ogenous processes with unknown timing and intensity. The genome of a tumour at the
time of diagnosis presents a superposition of these processes. Being able to deconvolve
the mutational spectra of di↵erent tumours into the mutational signatures would allow
inferring the processes which shaped these spectra (Figure 1.7). The recent explosion in
the amount of publicly available cancer sequencing data has made it possible to compu-
tationally identify and characterise the patterns of mutations present in human cancers
(Alexandrov et al. 2013b).
The decomposition of the mutational spectra into contributing factors currently has
several assumptions. Firstly, to be detected with confidence, each process should a↵ect
at least several samples. Secondly, the mutational spectra corresponding to these factors
are assumed to be constant across samples. Finally, di↵erent processes are thought to act
independently and contribute mutations in an additive manner. Under these assumptions,
one would expect that each of the mutational processes shaping cancer genomes would
correspond to a unique pattern of mutations, which can be identified from factor analysis
of many tumours.
The initial list of mutational signatures in cancer considered only single-base substi-
tutions (SBS) (Alexandrov et al. 2013b). The most recent version also inferred signatures
from dinucleotide variants (DNVs) and small indels (Alexandrov et al. 2018). According
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Figure 1.7: The concept of mutational signature analysis. Underlying mutational pro-
cesses P1, .., PS shape the mutational spectra of N samples, from which one extracts S
computational signatures and associates them to the mutagenic factors.
to the current state of the Catalogue Of Somatic Mutations In Cancer (COSMIC) project
(Forbes et al. 2015, Alexandrov et al. 2018), there are over 60 single-base substitution,
11 dinucleotide and 17 indel signatures as identified based on several thousand cancer
genomes and exomes (Weinstein et al. 2013, Campbell et al. 2017). These signatures are
largely defined by the relative frequency of di↵erent mutation types based on pyrimidine
reference and the local sequence context (adjacent 5’ and 3’ base for SBS, length of the
repeat for indels in repetitive regions).
It is important to note that these signatures may not be unique; they were extracted
from a large dataset of cancer genomes as one possible basis of the latent variable space,
and their linear combination may represent more meaningful signatures (e.g., as was
proven for signatures 1A, 1B and 5 in Alexandrov et al. 2015), especially as soon as more
data is added to the pool, increasing statistical power. In addition, signature identification
is further complicated by high interpersonal variability and the potential presence of
mutational signatures with similar mutation spectra (Baez-Ortega and Gori 2017). Most
importantly, the mutational signatures identified computationally do not necessarily have
a biologically relevant cause.
1.2.3 Methods for learning mutational signatures from muta-
tional spectra
The investigation of latent factors which induce mutations in cancer genomes has
gained much attention recently. Several methods have been developed for the de novo
extraction of mutational signatures, as well as for the decomposition of mutation spectra
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over a set of known signatures (or signature re-fitting).
Formulated in mathematical terms, the signature extraction task turns into a blind
source separation problem (Comon and Jutten 2010). Every sample i (out of N samples)
is characterised by a mutation spectrum yi, which is a set of counts for M di↵erent
mutation types, yi =
 
y1i , ..., y
M
i
 
, yki 2 (N [ {0}). Assume there are P mutational
processes sj defined by the probability distribution of acquiring mutation of a particular
class sj =
 
s1j , ..., s
M
j
 
, skj   0,
PM
k=1 s
k
j = 1. Then every spectrum can be approximated
(down to the noise) as a linear combination of processes:
yi =
PX
j=1
ejisj + ✏i, e
j
i   0
where eji , j = 1, ..., P are the exposures which quantify the contributions of mutational
processes to the sample i, and ✏i is the random noise added to the spectrum.
In matrix form, it can be represented as a matrix factorisation problem:
Y = E ⇥ ST + ✏, (1.1)
where Y is a N ⇥M matrix of mutation counts per sample, E – a N ⇥ P exposure
matrix, S – a M ⇥ P matrix of mutational signatures, and ✏ – a random error matrix.
Hence, signature extraction methods aim to find such non-negative exposure and signature
matrices that their product is close enough to the original count matrix under some feasible
assumptions for the noise and biological interpretation of the factors. There are several
machine learning and statistical techniques that can be applied to solve this task.
Non-negative matrix factorisation
The most common technique for mutational signature analysis is non-negative matrix
factorisation (NMF), which was initially introduced for extracting latent factors in image
analysis (Lee and Seung 1999). In contrast to other dimensionality reduction techniques,
such as principal or independent component analyses, NMF enforces non-negativity of
the components and their mixture coe cients yet makes no assumptions about orthogo-
nality or independence of the latent features. NMF has been successfully applied to mine
large biological data for patterns such as gene expression signatures (Brunet et al. 2004,
Devarajan 2008).
The initial NMF algorithm suggested for signature extraction in Alexandrov et al.
2013a aimed to minimise the Frobenius norm of the di↵erence between the real and
reconstructed count matrix. This was equivalent to assuming a normal distribution for
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the noise:
Y ⇠ N(E ⇥ ST ,  2),
(E, S) = argminE,S
 ||Y   E ⇥ ST ||F  2 ,
||Y   E ⇥ ST ||F =
vuutX
i,j
(yi,j  
PX
k=1
eki s
j
k)
2. (1.2)
An important drawback of NMF is the necessity to manually choose the most optimal
number of signatures, P , which is often chosen based on the stability of signatures (or
cophenetic distances between them) and the quality of reconstruction (Alexandrov et al.
2013a).
As Gaussian noise does not best describe the underlying variation in the data, several
successive methods (Alexandrov et al. 2018) switched to minimising Kullback-Leibler
divergence as an objective, which was equivalent to assuming a Poisson generative model
for the observed data:
Y ⇠ Poisson(E ⇥ ST ),
(E, S) = argminE,S
 
D(Y ||E ⇥ ST )  ,
D(Y ||E ⇥ ST ) =
X
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Recently, a penalised version of NMF was suggested to enforce the sparsity of the factors
(Ramazzotti et al. 2018) but the biological relevance of this assumption still has to be
determined.
Following the Bayesian NMF approach proposed by Cemgil 2009, another probabilistic
NMF model was developed by Fischer et al. 2013. They calculate E and S matrices using
an expectation-maximisation algorithm which explicitly assumes a Poisson distribution
for the mutation counts. The latent factors are assigned a Gamma prior, which essentially
corresponds to assuming negative-binomial distribution for the observed counts.
Other probabilistic interpretations of NMF were also suggested: bayesNMF (Kasar
et al. 2015) and SignatureAnalyzer (Alexandrov et al. 2018) use a Bayesian framework to
specify the priors on the matrix factors, and also apply the automatic relevance determi-
nation to automatically choose the best number of signatures. signeR (Rosales et al. 2016)
uses an empirical Bayes approach to NMF, takes into account the tumour-specific oppor-
tunity matrix and employs Markov Chain Monte-Carlo sampling to obtain the samples
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from posterior distributions of the factors.
Bayesian approaches and Dirichlet processes
Despite NMF being the most popular method for signature extraction, there are other
approaches based on the methods initially developed for natural language processing. The
most suitable of them is topic modeling, which aims to infer latent factors, or topics, of
each word in a set of documents drawn from the same vocabulary (Blei and La↵erty 2007).
Topic modeling for mutational signature analysis interprets observed mutational spectra
as documents, mutation types as vocabulary, and the signatures as topics.
Most topic modeling methods are based on Bayesian models such as latent Dirichlet
allocation (LDA) (Blei, Ng, and Jordan 2003). pmsignatures (Shiraishi et al. 2015), a
method which considers per-position mutation distributions rather than per-type, uses a
generalised LDA. A method based on Dirichlet processes was developed, which imposes a
prior on the number of signatures and uses hierarchical Dirichlet processes to model dif-
ferent numbers of signatures in di↵erent tissues and samples (Li et al. 2017b). To combine
signatures of di↵erent mutational classes, Funnell et al. 2019 created a correlated topic
model that extracted signatures from the base substitution counts as well as copy number
profiles, and used the correlation structure between them to better assign signatures to
samples. This approach can also be used to specify the e↵ect of clinical or genetic variance
on the exposures (Robinson, Sharan, and Leiserson 2019).
A recent comparison of performance across di↵erent de novo signature analysis meth-
ods suggested that probabilistic methods are superior over NMF-based ones in correctly
reconstructing signatures used to generate the simulated dataset (Omichessan, Severi,
and Perduca 2019).
Refitting approaches
Apart from searching for signatures, one may want to decompose a set of samples over
a known set of signatures. This task is usually referred to as refitting, as opposed to de
novo signature extraction. Some studies also point out that the exposure estimates are
more stable if they are obtained via a separate refitting procedure and not simultaneously
with signature extraction (Alexandrov et al. 2018).
Rosenthal et al. 2016 presented an iterative multiple linear regression approach to fit
signatures S to the sample matrix Y . This work was extended by Huang, Wojtowicz,
and Przytycka 2017 and Kru¨ger and Piro 2019 to ensure the optimality by the use of
quadratic programming and simulated annealing. In addition, non-negative least squares
can be used to solve this task (Blokzijl et al. 2018), as well as Bayesian inference (Gori
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and Baez-Ortega 2018) and hidden Markov models (Wojtowicz et al. 2019).
1.2.4 Associating signatures with their origins
Typically, the first and easiest approach to trace the causal factor behind a mutational
signature is visual investigation. Mutational properties of a number of genotoxic agents
have been well established, and a preference for a particular type of mutation in the
signature may be indicative of the underlying mutagenic process, such as in CpG>TpG
changes for spontaneous deamination of 5-meC or T>A mutations for aristolochic acid
exposure. Alternatively, a wider distribution of mutations may suggest a link to a more
complex genotoxin or an inactivation of a DNA repair pathway. However, mutational
spectrum can only suggest a set of possible candidates, and one still needs to establish
association between a factor and a signature, and then prove the causative role of this
factor.
As signature extraction is usually performed in an unsupervised manner, there is no
guarantee that the extracted signatures have a biological meaning. Based on the cancer
types where a signature occurs, particular factors are expected to be involved in the
mutagenesis, such as UV-light exposure in skin cancers or MMR deficiency in colorectal
cancers (Armstrong, Kricker, and English 1997, Bronner et al. 1994). Currently, the most
common approach to linking a signature with its underlying cause is to find a statistically
significant association between the exposure to this signature and a clinical, molecular or
demographic feature.
Thus, several correlation analyses were conducted that suggested associated muta-
tional mechanisms for about a half of the single-base substitution signatures found in
cancers (Table 1.2) (Helleday, Eshtad, and Nik-Zainal 2014, Alexandrov et al. 2018).
Two omnipresent signatures were associated with the age of the patient (Alexandrov et
al. 2015), and exposures to many carcinogens such as UV-light, smoking, aristolochic acid,
aflatoxin, haloalkanes, and chemotherapy drugs were correlated each with a respective sig-
nature (Table 1.2) (Poon et al. 2014). Recently, Zhivagui et al. 2019 identified a signature
present in many cancers types and potentially associated with exposure to acrylamide,
which was previously shown to cause cancer in mice.
Deficiencies of di↵erent DNA repair components were found to be correlated with in-
dividual signatures, sometimes more than one: 7 signatures were associated with MMR
deficiency, two of them being correlated with concurrent MMR and polymerase proof-
reading domain defects (Haradhvala et al. 2018). One of the most wide-spread mutational
processes characterised by two signatures of C>T and C>G mutations was found to be
associated with the activity of cytidine deaminases from the activation-induced cytidine
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deaminase (AID)/apolipoprotein B editing complex (APOBEC) family (Nik-Zainal et al.
2012a).
A strong correlation was observed between one of the base substitution signatures
frequently occurring in breast and pancreatic cancers and the defects in BRCA1/2 genes,
and generally with homologous recombination deficiency (Alexandrov et al. 2013b, Polak
et al. 2017, Riaz et al. 2017). Further analysis of the signatures composed of copy number
changes and structural variants revealed several signatures associated with HR deficiency
which correlated with di↵erent components being defective (Davies et al. 2017, Macin-
tyre et al. 2018, Funnell et al. 2019). This analysis suggested di↵erences in mutagenesis
between BRCA1 or BRCA2-associated HRD, and other types of HR deficiency.
Despite the methodological progress, many signatures are still lacking any indication
of their aetiology. About 30% of these signatures occurred in small proportions across
samples from di↵erent cancer types and were proposed to be stemming from sequencing
or variant calling artefacts (Alexandrov et al. 2018).
Some signatures showed associations only detectable in certain cancer types or patient
groups: significant correlation was observed for the contribution of signature SBS 5 and
defects in NER gene ERCC2 in bladder tumours of smoking patients (Kim et al. 2016).
Signature Potential cause Validation
SBS 1 ageing Alexandrov et al. 2015 Blokzijl et al. 2016
SBS 2/13 activity of APOBEC family of enzymes (Nik-
Zainal et al. 2012a)
Schumacher, Nissley,
and Harris 2005
SBS 3 biallelic BRCA1/2 defects (Alexandrov et al.
2013b, Polak et al. 2017, Riaz et al. 2017)
Zou et al. 2018
SBS 4 tobacco smoking Alexandrov et al. 2016 Kucab et al. 2019
SBS 5 clock-like Alexandrov et al. 2015, may be
associated with ERCC2 in tobacco-exposed
bladder cancers Kim et al. 2016
-
SBS 6, 14, 15,
20, 21, 26, 44
MMR deficiency (Alexandrov et al. 2013a,
Supek and Lehner 2015)
Drost et al. 2017, Zou
et al. 2018
SBS 7a/b/c/d UV-exposure (Alexandrov et al. 2013b, Hay-
ward et al. 2017)
Kucab et al. 2019
SBS 8 supposedly GG-NER deficiency Jager et al. 2019
SBS 9 activity of Pol ⌘ in somatic hypermutation
(Puente et al. 2011)
-
SBS 10a/b proofreading deficiency of Pol ✏ (Can-
cer Genome Atlas Network 2012, Cancer
Genome Atlas Research Network et al. 2013)
Shinbrot et al. 2014
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SBS 11 exposure to temozolomide (Alexandrov et al.
2013b)
-
SBS 14 concurrent MMR deficiency and Pol ✏ proof-
reading deficiency (Haradhvala et al. 2018)
-
SBS 16 supposedly associated with alcohol consump-
tion (Li et al. 2018)
-
SBS 17a/b possibly dTTP pool depletion mediated by
5-fluoracil or similar base analogue
Christensen et al. 2019
SBS 18 oxidative damage Drost et al. 2017, Zou
et al. 2018
SBS 20 concurrent MMR deficiency and Pol   proof-
reading deficiency (Haradhvala et al. 2018)
-
SBS 22 exposure to aristolochic acid (Poon et al.
2013)
Poon et al. 2013, Ku-
cab et al. 2019
SBS 24 exposure to aflatoxin (Poon et al. 2014) Huang et al. 2017a,
Kucab et al. 2019
SBS 29 tobacco chewing (International et al. 2013) -
SBS 30 BER deficiency due to NTHL1 inactivation Drost et al. 2017
SBS 31/35 prior chemotherapy with platinum agents
(Alexandrov et al. 2018)
Boot et al. 2018, Ku-
cab et al. 2019
SBS 32 prior treatment with azathioprine to induce
immunosuppression (Alexandrov et al. 2018)
-
SBS 36 BER deficiency due to MUTYH defects (Viel
et al. 2017)
Pilati et al. 2017
SBS 42 occupational exposure to haloalkanes
(Alexandrov et al. 2018)
Mimaki et al. 2016
SBS 84/85 activity of AID (Alexandrov et al. 2018) Pettersen et al. 2015
Table 1.2: Mutational signatures in cancer and their proposed aetiology.
1.2.5 Experimental validation
A correlation between a signature and a mutagenic factor is not su cient to establish
a causative relationship between them. Therefore, much attention turned to the exper-
imental validation of signatures in model systems, which involved both re-analysing the
existing genome-wide data on mutagenesis and conducting new experiments (Olivier et al.
2014).
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Several types of human-based systems were recently employed to validate the concept
of mutational signatures and confirm their aetiology. Zou et al. 2018 used immortalized
human near-haploid cell line HAP1 and CRISPR-Cas9 gene editing to produce detailed
profiles of several DNA repair knockouts including MMR, HRR and BER factors. The
sequencing of genetically manipulated stem-cell derived human organoids demonstrated
the presence of age-related signature and signatures associated with MMR and NER
deficiencies (Blokzijl et al. 2016, Drost et al. 2017, Jager et al. 2019). Further on, Kucab et
al. 2019 established the protocol for studying the accumulation of mutations in the clones
derived from human induced pluripotent stem cells (iPSCs), which allowed to describe the
mutational spectra of many environmental exposure agents such as UV-light, aristolochic
acid, and platinum-based drugs in iPS cells.
Many mutational processes were studied in cancer cell lines. The signatures of AID
and APOBEC were dissected using B-cell lymphoma cell lines (Pettersen et al. 2015). The
propagation of a large set of cancer cell lines allowed to distinguish between the processes
which were active in the past and hence are likely to be related to exogenous exposures
from those which are still on-going, such as DNA repair deficiencies, defects of POLE
proofreading domain, or endogenous damaging agents including reactive oxygen species
and over-active APOBEC enzymes (Petljak et al. 2019).
However, even the results from human-based model systems are not fully reflective of
the mutagenic activity that various agents have in the context of cancer. Many mutagens
require metabolic activation to obtain the reactive metabolite capable of damaging DNA
in the same way as in tumours (Guengerich 1992). Moreover, several experiments showed
high contamination by background mutational process which can mask weak mutational
patterns introduced by DNA repair deficiencies (Zou et al. 2018).
Apart from human cells, many other model systems were utilised to study signatures
(Segovia, Tam, and Stirling 2015). Multiple studies from bacteria (Maharjan and Ferenci
2014, Matsumura et al. 2018), yeast (Degtyareva et al. 2019, Larsen et al. 2017), nema-
todes (Meier et al. 2014, Meier et al. 2018, Huang et al. 2017a), murine models (Connor
et al. 2018, Dow et al. 2018) and other model systems such as chicken fibroblasts (Szikriszt
et al. 2016) generated a huge amount of data that reveals the mechanisms as well as the
distribution of damage of multiple genotoxic agents with respect to a model’s genome.
Many model organisms have the advantage of simplicity, lower costs and shorter time
scales compared to human-based systems. A study by Mimaki et al. 2016, which found
a mutational spectrum in cholangiocarcinomas, presumably associated with haloalkane ex-
posure, successfully used Salmonella typhimurium to validate this finding. Well-established
model systems, such as S. cerevisae and C. elegans, are equipped with large and consistent
libraries of knockouts and well-annotated genomes, which allows exploring the mutational
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response to mutagenic exposures across several genetic backgrounds (Meier et al. 2014),
as well as study a single process such as oxidative damage (Degtyareva et al. 2019) or
replication fork stalling in great detail (Larsen et al. 2017). Many studies of genome-wide
mutational distributions were conducted in mice, the most well-described model to study
the induction and development of cancer, helping to dissect the mutagenic contributions
of many mutagens (Nik-Zainal et al. 2016, Huang et al. 2017b), to explore the variability
of mutational landscapes in liver tumours (Connor et al. 2018, Dow et al. 2018), as well
as to describe the mutations and evolution of skin metastases (McCreery et al. 2015) and
KRAS-driven lung cancers (Westcott et al. 2015).
1.2.6 Clinical applications of mutational signatures
Apart from providing valuable insights in mutagenesis mechanisms, the utilisation of
mutational signatures in clinical research also provides a number of benefits.
Therapeutic biomarkers. Mutational signatures provide several types of clinically
relevant information (Ma et al. 2018). Experimentally confirmed links between signatures
and DNA repair deficiencies allow detecting these defects when the biomarkers or indi-
vidual gene analysis may fail to give the correct indication. The presence of a DNA repair
deficiency signature confirms the actual inability of the cell to repair the relevant dam-
age. Measures of DNA repair deficiencies can be exploited as an indicator of a patient’s
response to treatments such as chemotherapy (Hegi et al. 2005, Helleday et al. 2008),
immunotherapy (Le et al. 2017), or synthetic lethality approaches (Shaheen et al. 2011).
Cancer prevention. Many exogenous mutagenic exposures, including tobacco smok-
ing and UV-exposure, were shown to induce mutations and lead to cancer (Pfeifer 2010,
Armstrong, Kricker, and English 1997, Poon et al. 2014). Treatment with chemother-
apy drugs also generates specific traces of mutations (Szikriszt et al. 2016). Analysis of
signatures associated with environmental or lifestyle factors can be predictive of the ther-
apy outcome (Trucco et al. 2019) and indicative of the aetiology of cancer (Poon et al.
2014), which can help to improve both the e cacy of treatment and understanding of the
epidemiology of cancer.
Outcome prediction. Moreover, even if the precise causes of signatures are not
known, stratification of patients based on mutational signatures helps to predict the out-
comes as well as identify molecular subtypes of the disease. In gastric cancers, a signature
found in several molecular subtypes was found to be predictive of survival in one type
but not the others (Li et al. 2016), and signature analysis identified in esophageal cancer
identified subgroups of tumors with di↵erent aetiology (Secrier et al. 2016). In B-cell
lymphomas, analysis of clustered signatures yielded two signatures which could be used
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to classify the tumours by their cell of origin (Alkodsi et al. 2019).
However, despite the potential of mutational signatures to improve the treatment of
patients, several current limitations hold the medical oncology community from adopting
this tool. More cancer data and confirmation experiments are needed to define the univer-
sal signatures which can serve as a reference, more clinical trials are required to confirm
the utility and reliability of signatures as a response prediction indicator (Van Hoeck
et al. 2019). Most of all, the mutational signature analysis currently lacks a unified and
transparent methodology which would ensure the reproducibility and the best informative
interpretability of the signatures under consideration.
1.2.7 Limitations of current mutational signature analyses
The majority of currently existing factorisation-based approaches su↵er the drawback
of having to choose the number of signatures. All of them employ di↵erent heuristics
to identify the most suitable number of factors: quality of reconstruction, stability of
signatures, biologically relevant restrictions on the number of signatures per patient and
the number of mutations a signature should be contributing to a tumour.
The automatic relevance determination utilised by (Kasar et al. 2015) relies heavily on
the choice of priors for the matrices of signatures and exposures, which may also not be
representative of the underlying biology. Based on the NMF objective, a higher number
of factors tend to provide a better reconstruction. If the algorithm tends to choose the
strongest signals as factors, they will be stable and reproducible. Hence, even upon the
integration of these heuristics into the signature analysis, there is still a high chance to
derive an over-segmented set of signatures, mostly representative of the most mutated
samples in the dataset. Consequently, a careful assessment of the biological feasibility of
the extracted signals is essential.
Moreover, many mutational signature analyses focus on the distributions of single
nucleotide variants (SNVs). However, there are many other types of damage that may be
more representative of the mutational process. The challenge for analysing other types
of damage is the need to find an adequate classification which would yield biologically
feasible results.
Classification of copy-number changes by size and type turned out to be beneficial
for detecting the HR deficiency and distinguishing between the deactivation of BRCA1,
BRCA2 and other HR system defects (Nik-Zainal et al. 2016, Davies et al. 2017). Similar
analysis including the size of homology at breakpoints and correlations with SNV signa-
tures yielded signature based HRD determination in breast and ovarian cancers. A more
sophisticated classification of the copy number variants by many characteristics allowed
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to extract signatures highly predictive of the treatment outcome for high-grade ovarian
cancers (Macintyre et al. 2018). Finally, a thorough classification of all structural variants
detected in over 2,700 whole-genome sequenced cancers revealed a high contribution of
replication-dependent mutagenesis to the SV spectra in cancer (Li et al. 2017b).
Analysis of signatures of dinucleotide variants and small indels confirmed the presence
of several processes that were known to be involved in carcinogenesis, such as UV-induced
CC>TT mutations, PAH-associated CC>AA changes, and a high amount of indels in
repetitive regions occurring in MMR-deficient cancers (Alexandrov et al. 2018). The next
step in this regard would be to find a way of combining all types of variants and analysing
mutational signatures in the context of any mutational events.
Many previous studies have also suggested that mutations are not evenly distributed
across the genome. Some mutational and repair processes are transcription- or replication-
dependent, e.g. they could result from damage repaired by TC-NER, such as smoking-
induced mutations (Pleasance et al. 2010), or they could be the result of polymerase
errors (Reijns et al. 2015, Seplyarskiy et al. 2016). Hence the mutational signature may
have a strand bias: they can be more or less pronounced in template versus coding
strand, or in early versus late replicating regions (Morganella et al. 2016, Haradhvala
et al. 2016, Tomkova et al. 2018). Some processes such as UV-light exposure have more
specific genomic preferences: UV signature was shown to demonstrate di↵erent context
specificity in gene promoters compared to the rest of the genome (Fredriksson et al. 2017).
Besides, certain mutational processes, such as somatic hypermutation or AID/APOBEC
activity, can create distinct clusters of mutations (Supek and Lehner 2017, Roberts et al.
2012). Currently, strand biases or clustering of mutational signatures are investigated
post hoc, after extracting the signatures from mutation counts. However, incorporating
this information in the signature extraction has the potential to produce more biologically
relevant signatures.
Overall, the field of mutational signature analysis currently su↵ers from two main
drawbacks: the lack of generalised framework to assess performance which would allow
choosing the best method and making it a golden standard, and a large pool of unexplored
features of mutational processes that could refine the signature extraction and help to
produce signatures with more biological meaning.
1.3 Aims of this thesis
The field of mutagenesis has been extensively studied over the last century and can
nowadays provide an exceptionally detailed chemical and physical picture of individual
events damaging the DNA, as well as their repair. The introduction of mutational sig-
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natures allows us to take a broader look at the impact of DNA damaging agents on the
genome. This scale of investigation provides a quantitative and qualitative understanding
of the intensity and pathogenicity of genotoxic exposures and DNA repair deficiencies.
Analysis of mutational signatures in cancer can provide important information about
the potential causes and vulnerabilities. About a half of mutational signatures encoun-
tered in cancer studies have an association with a mutagenic process, nearly two-thirds of
them also have corresponding mutation spectra observed in model system experiments.
Yet a large amount of factors and variability in mutational signature analysis remains
unexplained, and requires further consideration.
Thus, the study I am describing in this thesis will contribute to these two aspects of the
mutational signature analysis: identifying signatures of the factors potentially implicated
in cancer and describing their mutational mechanisms, and explaining the variation in
mutational spectra by considering the interplay between DNA damage and repair which
may result in a dramatic change of mutational patterns in the genome. In this thesis, I
am aiming to fulfil the following tasks:
• create a detailed catalogue of a wide range of DNA repair deficiencies and genotoxin
exposures using a large mutagenesis screen conducted in C. elegans ;
• provide mechanistic insights into the interaction of mutagens, DNA repair factors,
and DNA;
• quantify the variability of experimental mutational signatures;
• compare the experimental mutational signatures to the ones observed in human
cancers;
• describe the diversity of interactions between DNA damage and DNA repair;
• quantify contributions of di↵erent factors shaping mutational signatures in the ex-
perimental model system;
• explore the range of such interactions detectable in cancer.
In chapter 2 I will describe the model system, introduce the data and point out the
most remarkable aspects which will be considered in greater detail in the following chap-
ters. I will also introduce the main computational tools used for the analysis of the
mutational spectra and distributions throughout the thesis.
Chapter 3 will present the analysis of mutational signatures and genomic properties
of the mutations induced via DNA repair deficiencies. It will include an overview of
mutation rates generated upon knockouts of di↵erent DNA repair factors, and a thorough
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analysis of variants acquired upon translesion synthesis and homologous recombination
deficiencies. Chapter 4 will focus on the signatures of mismatch repair deficiency and
present a comparison between the signatures extracted from gastrointestinal cancers and
C. elegans mutants. It will demonstrate the utility of model organism experiments in
cancer research, where many interacting processes are active at the same time, and a fully
unsupervised analysis is not su cient to dissect the individual factors.
Chapter 5 will consider signatures of 12 genotoxins compared to their human counter-
parts. Combining deficiencies and exposures will also allow me to explore the diversity of
DNA damage-repair interactions. I will show the most striking examples as well as review
the frequency and magnitude of such e↵ects in Chapter 6.
In Chapter 7, I will present an analysis of the DNA repair significance and its interac-
tions with genotoxic exposures in cancer exomes. As a tumour is a complex and evolving
structure, I will also present evolutionary considerations defining the scope of expected
e↵ects of the damage-repair interactions on cancer development and incidence.
Finally, in Chapter 8, I will summarise the findings and review the limitations of
the study described in the previous Chapters. Additionally, I will outline the future
perspectives and the directions of research that could further expand the understanding
of the antagonism between the DNA damage and repair, as well as its implications for
cancer and ageing.
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Chapter 2
Experimental and computational
methods to study mutagenesis in C.
elegans
2.1 Introduction
The first chapter of this thesis gave an overview of the history and current state of
knowledge of endogenous and exogenous mutagenesis and introduced mutational signa-
tures in the context of analysing somatic mutations in human cancer. Based on this vast
amount of knowledge, I will expand our understanding of mutational signatures, their
translatability across species, and their behaviour under di↵erent genetic conditions.
Mutational signatures have become a useful tool for oncological investigations, pro-
viding the means to uncover the functional causes of tumour development. Some of the
computationally extracted signatures were associated with the underlying processes, and
a small fraction was confirmed experimentally. However, there are several questions which
remain unclear:
1. How reliable are these associations? Are the relevant signatures directly linked to
the associated factor?
2. What are the origins of the remaining signatures?
3. How consistent is the signal across di↵erent organisms, tissues, and genetic back-
grounds?
To answer these questions, I will use a large experimental dataset and explore the
e↵ects of DNA repair deficiencies, genotoxic exposures, and their combination on the
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genome-wide distribution of mutations. Further, I will compare the results obtained
from C. elegans to the spectra observed in cancer, and develop the way to quantify the
variability in mutational signatures in response to genetic background and other factors.
In this chapter, I will introduce the mutagenesis screen performed in C. elegans and
describe the bioinformatics pipeline used to deliver the results from the sample stage to
mutational spectra, creating the basis for studying experimental signatures of di↵erent
factors contributing to mutagenesis.
Contributions
The experimental work on sample preparation was conducted at the University of
Dundee by Bettina Meier and colleagues. DNA sequencing, alignment and basic variant
calling for base substitutions and insertions/deletions were done by the Sanger Institute
facilities. Subsequent bioinformatics analyses such as filtering, classification and analyses
of mutational load and distributions as well as visualisations were performed by me.
All the data from this screen is available at the European Nucleotide Archive (Leinonen
et al. 2010) under accession numbers ERP000975 and ERP004086, and the code used for
these analyses is available under http://github.com/nvolkova. Di↵erent parts of these
analyses were published in Meier et al. 2018, Volkova et al. 2019, or are currently under
preparation to be submitted. The following chapters, which cover these analyses in more
detail, will also provide a detailed description of the contribution in respective studies.
2.2 C. elegans as an experimental system for muta-
genesis studies
In this study, we used C. elegans as a model organism to present a systematic screen of
mutational signatures induced by genotoxins and DNA repair deficiencies, with the same
setup as in Meier et al. 2014.
This organism is a suitable experimental model in many aspects: it is easy to manipu-
late, it has a well-annotated genome (Antoshechkin and Sternberg 2007) as well as a short
turnover time with a lifespan of approximately 3 days (Hope 1999). C. elegans genome
is small (approximately 100 Mbps) and has a high proportion of genome consisting of
functional elements (about 30%, compared to just 2% in humans; Hillier et al. 2005).
Importantly, DNA repair is conserved between human and C. elegans : 63% (75/118)
of the core DNA repair genes in humans have close orthologs in C. elegans (Shaye and
Greenwald 2011), and many other physiological processes are similar enough to use C.
elegans as an emulator of human pathology (Kaletta and Hengartner 2006). Moreover,
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it has a low background mutation rate of about 1.8 ⇥ 10 10 mutations per site per cell
division (Denver et al. 2009), which allows detecting even small changes in the rates of
mutation acquisition.
In this screen, we can take advantage of the self-fertilising, hermaphroditic reproduc-
tion of C. elegans. About 15 cell divisions are required to pass from one generation to
another, and both germ cells are coming from the same organism, thus creating a very
stable pattern of mutation propagation across generations.
Moreover, the genome size of just about 100 Mbps makes DNA sequencing at 40x cov-
erage cost e↵ective at approximately £100 per sample. Consequently, given the presence
of a well-established library of C. elegans DNA repair knockouts, we were able to perform
a large screen with several thousand samples using the same material and computational
resources as about 30 times smaller set of human cell line experiments.
2.2.1 Experimental design
The experimental design of the screen consisted of mutation accumulation and mu-
tagen exposure experiments (Figure 2.1). In the mutation accumulation experiments,
wild-type C. elegans and each of the 70 strains deficient for a particular DNA repair gene
were propagated for several generations to measure the mutations accumulated during
this period by subsequent whole-genome sequencing. In the mutagen exposure experi-
ments, wild-type worms or worms with knockouts of di↵erent DNA repair components
were exposed to di↵erent genotoxins, and their progeny was studied to analyse the range
of germline mutations acquired during the self-fertilising stage of the parental generation.
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Figure 2.1: Experimental design of the study. C. elegans of di↵erent genetic backgrounds
were propagated through several generations or exposed to metagenic agents. Their
progeny was then sequenced to obtain the spectra of acquired mutations.
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Mutation accumulation experiments
To mimic the mutation accumulation in somatic cells necessary for cancer development,
wild-type C. elegans and C. elegans introduced with DNA repair deficiencies were grown
through 20 or 40 generations, or for as many generations as possible (for the lines where the
DNA repair deficiency was too deleterious). The experimental setup allowed propagating
the clonal C. elegans lines, which in each generation passed through a single-cell bottleneck
provided by the zygote. To filter out the mutations present in the line before the start of
the experiment, the P0 (parental) or F1 (1st filial) generation were also sequenced. Each
experiment was performed in triplicates when possible, and three samples were sequenced
for each experiment.
List of genetic knockouts included genes representing all crucial DNA repair pathways:
we consider 6 genes responsible for translesion synthesis (TLS), 13 backgrounds associated
with single-strand break repair (SSBR) deficiency, 28 conditions associated with double-
strand breaks repair (DSBR) deficiency, 6 helicases with di↵erent additional properties,
7 DNA damage checkpoint genes and 5 genes related to damage-caused apoptosis (see
Table A.1, Appendix A). Due to the limitations discussed in Section 2.2, many of them
did not show any particular patterns of mutagenesis. However, several most striking cases
will be described in Chapter 3.
Mutagen exposure experiments
C. elegans were treated with DNA damaging agents at the late L4 and early adult
stages to target both male and female germ cells. Resulting zygotes provide a single-cell
bottleneck, where mutations are fixed before being clonally amplified during C. elegans
development and passed on to the next generation in a Mendelian ratio. Samples of
di↵erent genetic backgrounds, including wild-type, were treated with various genotoxins
in triplicates. The maximal exposure dose was chosen such that it would generate as many
mutations as possible without inducing severe mortality in the progeny (see Chapter 5
for more detail).
Panel of genotoxins used for mutagen exposure experiments consisted of substances
and exposures employed in cancer treatments: alkylating agents (dimethyl sulfate (DMS),
ethyl methanesulfonate (EMS), methyl methanesulfonate (MMS)), replication stalling
drugs (hydroxyurea (HU)), irradiations (gamma-irradiation (IR), X-rays (Xray) and sim-
ulated UV-B irradiation (UV)), agent creating bulky adducts (aflatoxin-B1, aristolochic
acid), and crosslinking agents (cisplatin, mechlorethamine and mitomycin C). The geno-
toxic agents, along with their signatures and mutagenesis features, are described in detail
in Chapter 5.
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In total, 915 experiments with 12 genotoxins and 70 di↵erent genetic conditions were
performed. DNA was extracted from the parent worm and the last filial generation of
these experiments, including 8 control experiments propagating wild-type C. elegans.
Samples obtained from the experiments were subjected to next-generation sequencing
using Illumina HiSeq short-read sequencing for the first 2027 samples, and 10x Genomics
short-read protocol for the rest of the samples.
2.2.2 Pre-processing of sequencing data
Raw sequencing data was aligned to the WBcel235 assembly of the N2 Bristol strain
reference genome using BWA (Li and Durbin 2009). Variant calling using a dedicated
normal sample was performed separately for single nucleotide variants, small indels and
large structural variants. The results have undergone a thorough filtering procedure to
exclude technical errors, sequencing artefacts, caller mistakes and germline variance.
In brief, individual SNVs and medium-size indels obtained using CaVEMan (Nik-
Zainal et al. 2012a) and PINDEL (Ye et al. 2009) variant callers, respectively, were sub-
jected to the following filters:
• Coverage control: total coverage of the variant site in both the test and control
samples should not exceed 150 reads or recede 15 reads;
• Absence of reads reporting the variant in the reference sample;
• VAF threshold: at least 20% of reads covering a site of interest in the test sample
support the variant;
• Variant coverage: at least 5 reads support the variant in the test sample;
• PCR error control: at least one read in the test sample reports the variant in each
direction;
• Indel filter for SNVs: should be no indel called at the same position (relevant for
homopolymer junctions);
• Repetitive region artefact control: if the variant falls into a repetitive region, the
regions should not be longer than 18 repeats;
Additionally, we implemented the deduplication procedure such that any variants
repeated in unrelated samples (i.e. those which are not descendants of each other) were
removed.
After filtering, SNVs for every sample were classified into 96 categories based on the
trinucleotide context and the type of base change. Multiple substitutions which were
found at adjacent sites in the same sample are classified as dinucleotide or multi-nucleotide
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variants, if their VAF is similar (di↵erence less than 5%). Indels were further classified
based on the type (deletions, insertions, and complex indels - or deletions-insertions (DI))
and size (1 bp, 2-5 bp, 5-50 bp, 50-400 bp). Small insertions and deletions are further
classified based on the local context: if the indel happened in repetitive sequence or not.
The structural variants were called using DELLY (Rausch et al. 2012) which extracts
breakpoints based on paired end and split read mapping. Filtering for the raw variant
calls included quality control (’PASS’ filter reflective of the mapping quality, and at least
10 reads reporting the variant in the test sample), absence of the variant in control, and
removal of artefacts/irrelevant events by removing all the events encountered in unre-
lated samples, or shared by a set of low-generation (0th or 1st generation) samples of the
same genotype. Variants in telomeric regions were further removed due to complexity of
resolving the repetitive structure or telomeric regions.
Structural variants were reported in the form of pairs of breakpoints, which were fur-
ther classified in line with Li et al. 2017b into the following categories: tandem duplications
(TD), deletions (DEL), inversions (INV), complex events (COMPLEX) - those with more
than two pairs of breakpoints, intrachromosomal translocations (INTCHR), interchro-
mosomal translocations (TRSL), and foldbacks (FOLDBACK) (when one inversion-like
breakpoint is present, i.e. polymerase is turning around and reversing the DNA without
turning back again).
The final distribution of variants among di↵erent classes after the filtering procedures
is shown in Figure 2.2.
Figure 2.2: Overall distribution of mutations across all samples after filtering. MNV:
multi-nucleotide variants, del - deletion, ins - insertion, SV - structural variants.
After performing quality control and variant calling, mutational spectra for each worm
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Figure 2.3: Number of observed mutations per replicate (grey dots) and experiment (av-
erage across replicates, colored dot) for base substitutions, indels and structural variants
across di↵erent experimental types. Horizontal lines indicate the medians across experi-
ments. Corresponds to Figure 1B from Volkova et al. 2019.
were obtained, including their base substitutions, insertions and deletions, and large-scale
structural variants. In total, we called 190, 388 variants, of which 152, 237 were single-base
changes, 1, 125 multi-nucleotide substitutions, 31, 702 indels and 2, 662 structural variants
(Figure 2.3).
Variant classification
Filtered variants were classified into 119 mutation classes: 96 single-base substitutions
classified by change and 5’ and 3’ base context, di- and multi-nucleotide variants (MNV),
6 types of deletions of di↵erent length and context, 2 types of complex indels di↵ering in
size, 6 types of insertions and 7 classes of structural variants.
Given the complementarity of base pairing, 6 possible base changes, namely C>T,
C>A, C>G and T>A, T>C and T>G can be defined. We included the local context of
these mutations in the form of their trinucleotide context describing the base upstream
and downstream from the mutation, leading to a spectrum of 96 types of single-base
substitutions. Several multi-nucleotide substitutions were also observed in the data. Upon
checking the variant allele frequency of the base substitutions involving adjacent sites, we
classified them as di- or multi-nucleotide variants (DNVs or MNVs) if the di↵erence in
VAF was less than 0.01.
Based on local characteristics, all the indels found in the data were classified by size:
single-base events, 2 to 5 base pairs, 5 to 50 bps, and medium-sized indels of 50 to 400
bps. Small events involving one or 2-5 bps were also classified based on their local context:
the sequence upstream and downstream from the indel was tested, and indels happening
in repetitive regions (homopolymers, di-, tri-, tetra- or pentapolymers) were classified in
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a separate category.
Structural variants were called in the form of breakpoints, which were clustered by
proximity and classified based on the set of breakpoints within the cluster into tandem
duplications, deletions, inversions, complex events, intrachromosomal translocations, in-
terchromosomal events, and strand foldbacks.
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Figure 2.4: Similarity map of all the experiments in the screen. Each circle corresponds to
a single experiment (average across three replicates), color reflects the mutagenic exposure,
and the size reflects the number of mutations.
2.2.3 Overview of the data
Thus, we have obtained 3,120 119-long mutational spectra from 915 experiments with
di↵erent genetic backgrounds and exposure doses. To obtain a panoramic overview of
the mutation spectra and their mutual similarity, we created a t-SNE plot of the samples
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where the distance between samples reflects how similar their spectra are to each other
(Figure 2.4). The similarity between the spectra was calculated via cosine similarity:
similarity(S1,S2) =
(< S1,S1 >)
(||S1|| · ||S2||)) ,
where < S1,S2 > is a scalar product of signature vectors, and ||S1|| =
P119
k=1 S
k
1 .
Clearly, the mutational spectrum of each sample was mostly defined by mutagenic ex-
posure. Samples with di↵erent genetic background exposed to the same mutagen clustered
together, indicating that the genetic background usually has only a moderate influence
on the spectrum. However, a number of exceptions to this trend were visible, which will
be further investigated in Chapters 3 and 6. Mismatch repair mutants (MMR) were sepa-
rated from the rest of the samples, and no exposure could overwhelm the MMR deficiency
spectra (Figure 2.4, top). Translesion synthesis (TLS) polymerase knockouts produced
spectra similar to each other regardless of the mutagenic exposures (Figure 2.4, left).
2.3 Extracting mutational signatures from experimen-
tal data
To utilise the controlled nature of the experiments, we used a mathematical model
describing the contributions of di↵erent factors to the mutational spectra of each sample.
We aimed to model the full mutational profile of a sample j as a function of its genetic
background and exposures. The natural assumption for mutation counts is a Poisson
generative model. In order to preserve the additive relationship between di↵erent factors,
we initially employed an additive Poisson model:
Y j = {Yi,j}mi=1
Y j ⇠ Poisson( j),
E[Y j] =  j = gj
 
Gj ⇥ STG
 
+ dj
 
M j ⇥ STM
 
,
where Yi,j was the number of mutations of type i in sample j (and Y j - a row vector of
mutation counts for samples j), gj reflected the number of generations that sample j was
propagated for (under the assumption that all mutations acquired in each generation are
passed to the next one), SG 2 Matm⇥p (R+ [ {0}) – signatures of DNA repair deficiencies,
SM 2 Matm⇥r (R+ [ {0}) – signatures of mutagens, dj 2 (R+ [ {0}) – the dose of the
mutagen for sample j, and the row vectors Gj 2 {0, 1}p and M j 2 {0, 1}r were indi-
cator vectors containing the information about the DNA repair knockouts and mutagen
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exposures in sample j (given that there are overall p knockouts and r mutagens).
If we concatenated the genetic and mutagenic signatures in one matrix, this model
could be reformulated to make similar to the NMF framework described in equation
1.3 with a fixed exposure matrix E. Hence, we had a computationally e cient way of
simultaneously estimating all parameters in this multivariate regression task.
However, a closer look at the residuals within replicates upon fitting a Poisson model
suggested the presence of overdispersion: residual deviance was significantly greater than
the residual degree of freedom (res.dev = 51697.44 whereas df = 42615, chi-squared p-
value < 0.001), therefore correct assessment of parameter variance required a model which
could account for the additional variance.
Figure 2.5: Per-experiment per-mutation type coe cient of variation (CV) to mean re-
lation (log scale). Red line corresponds to Poisson distribution, blue line corresponds
to maximum-likelihood fit using negative binomial distribution with the same dispersion
parameter for all experiments.
Hence, we decided to allow for additional variation in the data by adopting a negative
binomial distribution for the n⇥m matrix Y of observed counts:
Y ⇠ NegativeBinomial (µ, ) , (2.1)
where the overdispersion parameter   = 100 was chosen empirically based on the
estimates of overdispersion in the dataset (Figure 2.5).
2.3.1 Selecting the appropriate model
The naive model we utilised as the first approach assumed that the signatures of
genotoxins should be consistent across genetic backgrounds, and that the resulting profile
44
should be a linear combination of the signatures of genotoxins and DNA repair deficien-
cies. If this model was correct, it would be possible to fit the samples combining DNA
repair deficiency and genotoxin exposure using the signatures extracted from mutation
accumulation and wild-type exposure experiments. However, careful inspection of the
outliers demonstrated that the prediction was wrong across multiple experiments, sug-
gesting that additional interaction factors should be included to account for changes in
genotoxin-induced mutation rates compared to the wild-type experiments, as well as for
the complete change of mutational spectrum.
In order to be able to inspect and compare the degree of interaction between experi-
ments, we represented the mutational contribution of genotoxins in sample j as
dj
 
Mj ⇥ STM
 
exp
 
Wj ⇤ STI
 
,
where Wj 2 0, 1s is an indicator vector reflecting the presence or absence of genotype-
genotoxin combination, and STI 2 Matm⇥s (R) is a matrix of log-interaction e↵ects.
Due to a higher mutation burden in interaction samples compared to mutation ac-
cumulation samples, a straightforward estimation of parameters was prone to disbalance
between the values of the signatures of genetic backgrounds and interaction e↵ects due
to lower costs of wrongly predicting the outcomes for mutation accumulation samples
(Figure 2.6). Hence, we have applied restrictive priors on the matrices of signatures and
multiplicative interaction e↵ects to ensure that mutational signatures are mainly esti-
mated from the mutation accumulation and wild-type exposure experiments, while the
experiments combining di↵erent factors will only inform the interaction matrix.
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Figure 2.6: Schematic depiction of di↵erent models for extracting signatures and interac-
tion e↵ects from experimental data
Moreover, a hierarchical structure also simplifies identification of significant e↵ects by
degrading the task of signature comparison down to assessing whether the interaction
e↵ect is di↵erent from zero. In addition, it allows to control multiple confounding factors
including misannotation of initial generation number for exposure experiments, and vari-
ation in precise mutagen dosage between di↵erent batches of samples, as will be described
below (Section 2.3.2) when introducing the parameters of the full model.
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To assess the ability of the model to correctly predict the profiles for new data, we
performed 5-fold cross-validation (Mosteller and Tukey 1968) and estimated the recon-
struction error and Kullback-Leibler divergence between the predicted and observed values
for the test set (Figure 2.7). Introduction of interactions provides a great improvement
over the naive model, while adding the parameters controlling confounding factors helps
to perform better on the relevant subgroups of samples.
5−fold cross−validated RSS
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Figure 2.7: Residual sum of squares (RSS) (a) and average KL-divergence (b) estimated by
100 runs of 5-fold cross-validation in three models: without interactions, with genotype-
genotoxin interactions, and full hierarchical model.
2.3.2 Hierarchical model for dissecting the contributions of dif-
ferent factors
To quantify how much the signatures of genotoxins can change across di↵erent genetic
backgrounds, we created a hierarchical framework which allows small alterations to the
signature spectra for the samples with a combination of a knockout and exposure. The
framework we suggest is a hierarchical Bayesian model schematically depicted in Figure
2.8.
As before, let Y 2 Matn⇥m(N[{0}) be the matrix of mutation counts, which describes
the mutational spectra over m types of mutations for n samples. Let there also be p
di↵erent genetic backgrounds, r mutagenic exposures, and s combinations of DNA repair
knockouts and genotoxic exposures. Additionally, let G 2 Matn⇥p({0, 1}) be an indicator
matrix of genotypes across samples, M 2 Matn⇥r({0, 1}) – indicator matrix of exposures,
I 2 Matn⇥s({0, 1}) – an indicator matrix of interactions, and J 2 Matn⇥(s+r)({0, 1}) – an
indicator of experiments with interaction or any genotoxic exposure.
There are two main contributions to the expected value of the count matrix Y: ge-
netic contribution µG and mutagenic contribution µM , defined by the genotype and
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Figure 2.8: Graphical representation of the interaction model. Round circles denote the
stochastic components. Y is the observed set of counts.
mutagen indicator matrices G and M, respectively, and the signature matrices SG 2
Matm⇥p (R+ [ {0}) and SM 2 Matm⇥r (R+ [ {0}) that we aim to determine:
µG = G⇥ STG,µM =M⇥ STM . (2.2)
Interactions for µM
Since the mutagens were shown to be the major defining factor of the mutational
spectra (Figure 2.4), we first focused on the interaction e↵ects altering the appearance
of SM . To account for these interaction e↵ects, we introduced a multiplicative term
 I 2 Matn⇥m(R) which describes the change of mutagen signatures in the samples with
a combination of DNA repair knockout and mutagen exposure:
 I = exp
 
I⇥ STI
 
.
This term is composed of I, an indicator matrix of s interactions and their presence in
n samples, and SI ,SI 2 Matm⇥s(R) - a matrix of changes which DNA repair deficiencies
cause to the mutational spectra of the respective mutagen for each combination. As SI
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can be both positive and negative, both negative and positive e↵ects can be accounted
for. To allow for more flexibility in extreme values, we chose a Laplace prior on SI : for
each interaction j, S(j)I ⇠ Laplace(0,  2I,j), and all  2I,j ⇠  (1, 1) iid.
Essentially, each entry of  I represents a fold-change in a particular type of mutations
from the mutational spectrum of a mutagen caused by the interaction with the genetic
background. Thus, the total contribution of the mutagens in the model is described as
d(µM ·  I), where d is a vector of mutagen doses for all n samples, and the operator ·
means element-wise multiplication.
Interactions for µG
The genetic contribution, however, also carried several sources of variability. The
mutations contributed by the DNA repair deficiencies in the absence of any mutagenic
exposure are likely to result from endogenous damage, which would be consistent in both
the samples with and without additional exposures. Hence, we do not expect any negative
e↵ects on the mutational spectra generated by DNA repair defects. Consequently, we
introduced an additive adjustment tern ↵I 2 (R+ [ {0}).
First, the samples used in genotoxic exposure experiments may have slightly diverged
from the first filial generation F1. Hence, the term µG (Equation 2.2) would not correctly
describe the genetic contribution part in these samples. As the precise generation number
for these samples was not available, we described these additional generations in each
experiment with exposure by the vector aJ 2 (R+[{0})s+r, which means J⇥aJ additional
generations per sample. O↵sets aJ were modelled as log-normally distributed, aJ ⇠
logN(0, 0.5).
Moreover, we noticed that there are cases when the exposure causes a dose-dependent
amplification of the spectrum of the DNA repair deficiency rather than an original or
altered mutagen signatures, such as UV or MMS exposure of TLS polymerase knockouts.
This type of interaction was usually weak compared to the average amount of mutations
induced by a genotoxin, and could not be captured by  I e↵ects. Hence, we added a
term bI 2 (R+ [ {0})s which described the amplification of genotype spectrum caused by
an average dose of a mutagen in each of the s interactions. Across all samples, it would
mean additional µG (d(I ⇥ bI)) mutations of the mutagen-free spectrum. Rates bI were
also modelled as log-normal distributed random variables, bI ⇠ logN(0, 0.5).
Thus, the overall contribution of the genetic background can be described as:
µG (g + (J⇥ aJ) + d(I⇥ bI)) = µG (g +↵I) .
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Identifying signatures and interaction spectra
The model altogether aims to estimate the signature matrices SG and SM , the interac-
tion coe cients SI and the additional variation vectors aJ and bI based on the following
structure:
E[Y] = µG(g +↵I) + d(µM ·  I) =
= (G⇥ STG) (g + (J⇥ aJ) + d(I⇥ bI))+
+ d
 
(M⇥ STM) · exp (I⇥ STI )
 
.
(2.3)
The total number of parameters in this model (Equation 2.3) is comparable to the
number of observations, hence parameter fitting can lead to uncertain values due to
unidentifiability issues. To avoid it, we exploit the fact that we have a separate set
of mutation accumulation experiments without these additional variability factors, which
allows for shrinking the priors of SG by introducing a two-step fitting procedure. We first
estimate the posterior distributions for the signatures of DNA repair deficiencies, which
will, in turn, be used as priors for genotype contributions in interaction experiments. This
way, we both ensure the biological feasibility of these factors and incorporate the signals
from interaction experiments to better refine them.
Thus, in the first stage, the mutation counts Y⇤ for each of the mutation accumulation
samples are modeled by a negative binomial distribution
Y⇤ ⇠ NegativeBinomial(µ⇤,  = 100),
with an expectation
µ⇤ = g⇤ · (G⇤ ⇥ STG⇤).
Here the asterisk means that the respective entity was restricted to the samples from
mutation accumulation experiments. A log-normal prior SG⇤ ⇠ logN(0,  2G) iid with a
scalar variance  2G was used for quantifying S
⇤
G. In total, we used 451 samples from
mutation accumulation experiments with generation number higher than 1, and obtained
signatures for 70 genotypes (the rest of the knockouts did not have mutation accumulation
experiments).
In the main step, the prior for the signatures of genetic knockouts SG was defined as
SG ⇠  (shapeG⇤ , rateG⇤), where shapeG⇤ and rateG⇤ were fitted to the posterior draws
for SG⇤ .
Signatures of genotoxins contributed more mutations on average and exhibited less
variability. They were fitted simultaneously with the rest of the parameters using a
individual lognormal prior for each mutagen, S(j)M ⇠ logN
 
0,  2M,j
 
, where the variances
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 2M =
 
 2M,1, ...,  
2
M,r
 
had prior distributions  2M,j ⇠  (1, 1) iid.
Parameter estimation using Hamiltonian Monte-Carlo
●●●
●●
●● ●●
●
● ●●
●●
●
●
●●●●●●●
● ● ●
●
●●
●●
●
●●
● ●●
● ●●
●● ●
●●●
●● ●
● ●●
●●
●●●●●
●● ●
●●
● ●
●●●●
● ●●
●●
●
●●● ●●●
●
●
●
●●●
●
●●
● ●●
●●●
● ●●
●
●
●
●●●
● ●●
●● ●
● ●●
●● ●
●
● ●●
●●●● ●
● ●
●● ●
●●●
●
● ●
●●
●
●●
●●
●●●
●
●●●
●●●
●●●
●●● ●
●●
●
●● ●
●●●
●●
●● ●
●
● ●
● ●
● ●
●●●
●● ●
●
●●●
● ●
●
● ●
●●●
●● ●
●
● ●
●
● ●●
●
●●
●
●
● ●
●●
● ●
●
● ●
●●
●● ●
●
●
●●
●
●
●
●
● ●
●● ●
●● ●
●
● ●
●●
●●
●
● ●●
●●●
●
●
●●●
●
●
●
0 500 1000 1500
0
50
0
10
00
15
00
20
00
OBSERVED
PR
ED
IC
TE
D
Figure 2.9: Observed and predicted
mutation counts across all samples.
Defined as described above, the posterior dis-
tributions of di↵erent parameter groups are in-
tractable. This can be dealt with by using Markov
Chain Monte-Carlo methods which aim to estimate
the parameter of interest by randomly sampling
from a probability distribution, which is achieved by
constructing a Markov Chain that has the desired
distribution (in this case, intractable posterior) as
its equilibrium state. This way, we can obtain a
sample from the posterior distribution to calculate
point estimates as well as the variability of the pa-
rameters. Given the high dimensionality, we used
one of the most e cient sampling methods - Hamil-
tonian Monte Carlo sampling which is based on sam-
pling the derivatives of the target density function
to generate e cient transitions that span the target posterior distribution (Betancourt
and Girolami 2015, Neal and Others 2011).
The model was specified using R-package “greta” (Golding 2018), and the posteriors of
SG, SM , SI , aJ , bI and hyperparameters  2M ,  
2
I were estimated using Hamiltonian Monte
Carlo sampling. We used 2000 steps for warmup and 5000 steps over 4 chains to ensure
convergence. The point estimates for the parameters were taken as means of the samples
across all chains. These estimates yielded a good agreement between the observed and
predicted values of mutation counts (Figure 2.9).
2.3.3 Model for the simultaneous extraction of signatures and
interaction e↵ects for human data
We will also define a model for de novo signature extraction in the presence of addi-
tional factors that can alter the appearance of one of the signatures in a subset of samples.
Assume there are N samples, and their mutational spectra consisting of M types of mu-
tations are stored in a matrix Y 2 MatN⇥M(N [ {0}). Let X 2 MatN⇥K({0, 1}) be
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an indicator matrix of the K factors that can alter the spectrum of a mutational signa-
ture, where each column is a binary vector describing the presence of a factor across the
samples.
In a general mutation signature analysis framework described in Section 1.2, one seeks
to represent a matrix of mutation counts Y as a product of an exposure matrix E and a
signature matrix S under some assumptions about the nature of the noise (Equation 1.1).
We will again assume a negative binomial generative model:
Y ⇠ NegativeBinomial(µ, ),
µ = E⇥ ST .
For the analysis of human data, we will use   = 50 chosen based on variability esti-
mates across all cancer samples. Assume there are P signatures, S 2 MatM⇥P (R [ {0}).
To quantify how much a signature S(P ) changes in the samples with a particular factor,
we will decompose the expectation as follows:
µ = E P ⇥ S (P ) + (EP ⇥ S(P )) ·  F . (2.4)
The e↵ect  F is a matrix which defines how the signature S
(K) looks in each sample
depending on its composition of factors.  F can be represented as
 F = exp (X⇥ STX),
where SX 2 MatM⇥K(R) is a matrix of spectra of the interaction e↵ects per factor.
We assumed a uniform prior for E, E ⇠ Unif(0, R) where R is the maximal number of
mutations per sample in the dataset, and a normal prior for SX , SX ⇠ N(0, 0.5). This
model can use any sort of binary information to infer its e↵ects on the signature.
The posterior distributions for the signatures and the interaction e↵ects were estimated
using Hamiltonian Monte Carlo sampling (Neal and Others 2011) via R package ‘greta’
(Golding 2018). All models were run in 4 chains up to 1000 or 2000 warm-up and 1000
post-warm-up samples to ensure convergence. We run 4 chains of sampling and claimed
an e↵ect being real if it was consistently assigned to the same signature. The final number
of signatures was selected based on the convergence, similarity between signatures and
feasibility of e↵ect assignment, as the model tends to fluctuate or duplicate most variable
signals when the chosen number of dimensions is too high.
The e cacy of the method was demonstrated using a simulated dataset with 100
patients with at most 10000 mutations, 96 substitution types, 3 signatures (we took
COSMIC signatures 1, 17 and 4) and 1 factor a↵ecting the last signature in 20% of
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samples. In 100 trials we observed the reconstruction error and average similarity between
reconstructed signatures being the lowest and the similarity to the original signatures
being the highest for S = 3, the real number of signatures (Figure 2.10). The error in
e↵ect estimation did not di↵er between S = 2, 3, 4, but was generally low confirming
that the model is capable of simultaneously extracting correct mutational signatures and
estimating the e↵ects of additional factors on one of the signatures.
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Figure 2.10: Reconstruction error (a), e↵ect recovery error (b), average similarity between
extracted signatures (c), and the minimal similarity to the original signatures (d) for
di↵erent number of signatures in the simulated dataset with 3 underlying signatures with
1 factor.
2.4 Mutational signature comparison
2.4.1 Assessment of cosine similarity score as a measure of sim-
ilarity of mutational spectra
Cosine similarity is currently the most common measure of similarity between signa-
tures. If the two signatures are identical, the similarity between them is 1. However, it is
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not clear when to consider signatures dissimilar.
To find a threshold for ‘high’ similarity, we assessed the similarity distribution between
random uniformly generated ‘mutational profile’ vectors from the positive cone (Figure
2.11a). Its 95% quantile falls in 0.80, which we used further on as the cuto↵ under which
we can not call two signatures similar. Additionally, analysis of similarities within the
COSMIC cancer signature set (Alexandrov et al. 2013b) showed that only 3.4% of pairs
have a cosine similarity above this threshold (Figure 2.11b).
(a)
(b)
Figure 2.11: (a) Cosine similarity distribution for random vectors drawn uniformly from 0
to ymax (individual for every draw). The 0.95-quantile of this distribution is 0.80 indicated
by a red dashed line. (b) Frequency of cosine similarity scores for all pairwise signature
comparisons across the 30 COSMIC cancer signatures. 3% of signature pairs exhibited a
similarity higher than 0.80, a threshold indicated by a red dashed line. Corresponds to
Supplementary Figure 6A from Meier et al. 2018.
2.4.2 Comparing mutational signature across specie
Many DNA repair genes are conserved between C. elegans and humans; however,
performing a valid comparison between the mutational spectra and factor interactions in
these two systems is complicated by several factors, which require adjustment.
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A major di↵erence between C. elegans and Homo sapiens is their trinucleotide com-
position. The base frequencies of the C. elegans genome were skewed towards A and T,
especially in repetitive contexts ApApA and TpTpT, providing higher chances of T>N
changes in TpTpN context (Figure 2.12). The GC content of the C. elegans genome is
36% (Sequencing Consortium* 1998) which puts it close to the human genome with a
GC content of 41% (Piovesan et al. 2019), but far from the human exome that has 64%
of GCs (Lelieveld et al. 2015). Most of the currently available cancer data is coming
from whole-exome sequencing; hence, our main objective was to be able to compare the
signature observed from C. elegans to those found in human exomes.
Thus, to provide a meaningful comparison between C. elegans and cancer-derived
mutational signatures, the experimental signatures acquired from C. elegans were adjusted
to the human exome (or genome, if relevant) trinucleotide frequencies. The probabilities
for 96 base substitutions were multiplied by the ratio of respective trinucleotide counts
observed in the human exome (hg19, the counts pre-calculated in Rosenthal et al. 2016)
to those in the C. elegans reference genome (Figure 2.12).
Figure 2.12: Trinucleotide context comparison between C. elegans genome and H. sapiens
exome.
Apart from a 10-fold di↵erence in size, the architecture of the genome di↵ers sub-
stantially between C. elegans, which has about 27% of the genome contained in exons
(Sequencing Consortium* 1998), and the human genome with only about 1% of bases
coding for proteins (Gregory 2005). Hence, we can expect fewer mutations in worms, and
some of the observed spectra may be biased by such factors as transcription strand-specific
DNA damage or DNA repair. In addition, a complex metabolic activation of certain geno-
toxins can make their mutational footprint di↵erent in cells directly exposed to the agent
or indirectly exposed to its metabolites. The details of the metabolic activation of the
genotoxins used in the screen will be described in Chapter 5.
Lastly, one has to remember that cancer cells contain a historical record of mutagenic
exposures which may have changed over time. Consequently, they may have more factors
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contributing to the intensity of the observed mutational e↵ects, with unknown order
and duration, which creates much higher variability in the mutational spectra than can
potentially be observed in C. elegans within the same experiment.
2.5 Measuring other genetic features
2.5.1 Relationship to transcription and replication directional-
ity
To investigate the relationship between mutations in regions with di↵erent directions of
transcription, we created a map of transcription directionality using a list of all transcribed
genes along with the direction of transcription with respect to the reference (Lee et al.
2017) and classified every genetic region into 3 categories: as being transcribed in ‘+’ (e.g.
the coding strand being the reference strand) direction, being transcribed in ‘-’ direction,
or ambiguous (possibly transcribed in both directions). In total, 93% of coding regions
(which compose 67% of the C. elegans genome) were assigned a transcription direction.
The directionality of replication was determined using the Okazaki fragment sequenc-
ing from Pourkarimi, Bellush, and Whitehouse 2016. The fractions of Okazaki fragment
reads on the minus strand,
tlj =
tlj    tlj+
tlj  + t
l
j+
, j = 1, ..., 6, l = 1, ..., 1002685
were calculated for 100-bp bins. The bins where |meanj
 
tlj
  | > 2sdj  tlj  were assigned
a “+” (or called right-replicating) direction if meanj
 
tlj
 
> 0, or “-” (left-replicating
regions) if meanj
 
tlj
 
< 0. In total, we inferred the direction of replication for 45% of the
genome.
2.5.2 Analysis of clustered mutations
The clustering of mutations along the genome was assessed using the starting points
of all the base substitutions and indels across the samples of the same genotype and gen-
eration. Clustered status was assigned based on a hidden Markov model, which predicts
a series of M hidden states H = {Hm}Mm=1, Hm 2 {clust, not} (being in a cluster or not)
for all mutations within a sample based on the set of distances to the next mutation
D = {Dm}M 1m=1 , Dm 2 N (the last mutation in each chromosome is assumed to be fixed
in non-clustered state). The probability of a set of states given the observed distances
would then be calculated as
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P (H1:M , D1:M) = P (H1)P (D1|H1)
M 1Y
m=2
P (Hm|Hm 1)P (Dm|Hm) ,
where the transition probabilities
P (Hm = clust|Hm 1 = not) = 0.001,
P (Hm = not|Hm 1 = clust) = 0.1
and starting probabilities P (H1 = clust) = 0, P (H1 = not) = 1.
Each of the distances Dm can be considered as the number of nucleotides without
mutation before the mutation with index m. Then Dm|Hm can be considered as the
number of failures before the first success in a Bernoulli trial with a success probability
that depends on the state. Hence, the distances D given the states can be described by
geometric distribution. The density of mutations within a cluster was assumed to be at
least one mutation per 100 bases, and the mutations outside the clusters were assumed
to be uniformly distributed:
Dm|Hm = clust ⇠ Geom (p = 0.01) ,
Dm|Hm = not ⇠ Geom
✓
p =
1
mean(D)
◆
.
We used the Viterbi algorithm (Viterbi 1967) to infer the most likely set of states for
each sample.
2.6 Discussion
In this chapter, I introduced the dataset describing several hundred mutagenesis ex-
periments conducted on wild-type and DNA repair-deficient worms by mutation accu-
mulation over generations as well as by direct mutagen exposure. Having a system with
controlled exposures to di↵erent mutagenic factors allows us to describe the mutational
footprints of each factor, compare their relative contributions, and study the interaction
e↵ects between di↵erent groups of factors. The primary overview of the data suggested
that the mutagenic exposures have a higher impact on the mutational spectra in the
samples with a combination of DNA repair defect and genotoxic exposure.
We proposed a negative binomial regression framework to extract the contributions of
di↵erent mutagenic factors. This model can capture both the scale and the spectrum of
interaction-caused changes. Additionally, we proposed an algorithm for simultaneous de
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novo extraction of signatures and their mixing coe cients from cancer data along with the
e↵ects of additional variables on signature spectra. The applications of these frameworks
to real data will be demonstrated in Chapters 6 and 7, respectively. Methodologically,
this is the first analysis of mutagenesis experiments which considers interaction terms
between genetic and mutagenic factors.
Some limitations of the experimental approach have to be acknowledged. High fidelity
of replication, self-fertilising mode and a smaller non-coding fraction of the genome limit
the number of mutations that may be observed before the C. elegans lineage becomes
sterile or non-viable (Thompson et al. 2013). The call to overcome this negative selection
also limits the scale of events which may be observed: huge copy number rearrangements
or chromosomal alterations are less likely to be observed in mutation accumulation ex-
periments which involve germline propagation. Conversely, in human somatic cell line
expansion, acquired copy number changes are quite common (Abyzov et al. 2012, Mishra
and Whetstine 2016).
Nevertheless, this screen represents the first experimental dataset of this scale, cover-
ing the majority of DNA repair gene knockouts and exposures to several mutagens with
di↵erent mechanisms of DNA damage. Based on these data and inference models, we de-
scribed the mutational signatures of mutation accumulation across 70 lines with di↵erent
genetic backgrounds and quantified the mutagenic e↵ects of 12 genotoxins in the wild-type
and DNA repair-deficient conditions. These results will be structured in Chapters 3, 5
and 6.
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Chapter 3
Experimental signatures of DNA
repair deficiencies in C. elegans
3.1 Introduction
In the previous chapter, I introduced the mutagenesis screen and described the tools
and types of analysis used to produce an in-depth characterisation of experimental mu-
tational signatures.
DNA repair deficiencies have been long acknowledged as one of the main driving forces
in cancer. Many genetic conditions, which predispose to cancer, stem from mono- or bi-
allelic deficiency in di↵erent DNA repair pathways. Heterozygous defects in mismatch
repair machinery lead to Lynch syndrome which is associated with high rates of colorec-
tal cancer (Cancer Genome Atlas Network 2012), homologous recombination deficiency
conferred via mutations in BRCA1/2 genes yields high breast and ovarian cancer risks
(Antoniou et al. 2003), nucleotide excision repair defects can lead to xeroderma pigmen-
tosum, a syndrome with a tremendously elevated rate of skin cancers (Bradford et al.
2011).
Deactivation of a DNA repair pathway does not necessarily require a mutation. It may
be a consequence of hypermethylation, or alteration in the regulation of transcription, or
alteration of the post-translational modification process of a core component. Therefore,
sequencing of a relevant gene or transcription measurements are not always representa-
tive of the actual functionality of a DNA repair pathway. In such cases, identification of
a genome-wide signature of incorrect repair via this pathway is a more reliable way of
detecting a deficiency (Hollstein et al. 2017, Van Hoeck et al. 2019). However, our un-
derstanding of the mechanisms of DNA repair is not extensive enough to be able to link
every DNA repair deficiency to a pattern of genomic alterations. Research from geneti-
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cally manipulated model systems is therefore crucial to the understanding of mutational
consequences of DNA repair-related gene defects.
In this chapter, I will describe the quantitative characteristics and prospective mech-
anistic insights of the mutations introduced by DNA repair deficiencies in the C. elegans
genome.
Contributions
This work was conducted in collaboration with Bettina Meier and colleagues in Anton
Gartner’s group at the University of Dundee and Peter Campbell at the Sanger Institute.
All of the findings from this chapter will be included as a part of a manuscript under
preparation:
Meier, B., Volkova, N.V., Hong, Y., Wang, B., Gonzalez-Huici, V., Bertonlini, S.,
Boulton, S., Campbell, P.J., Gerstung, M. and Gartner, A. Systematic analysis of muta-
tional spectra associated with DNA repair deficiency in C. elegans mutation accumulation
lines.
For this manuscript, I performed variant calling and filtering, as well as visualisations,
analysis of clustering and local genomic features, and calculation of mutation rates and
mutational signatures of DNA repair deficiencies. BM performed the in-depth analysis of
structural variant breakpoints.
3.2 Mutation types and rates in wild-type and DNA
repair-deficient strains
To characterise the mutational signatures of DNA repair deficiencies in C. elegans, we
subjected 559 samples to mutation accumulation over 5 to 40 generations. In total, the
dataset contained 57 single and 10 double mutants, which covered most of the conserved
DNA repair and DNA damage response pathways (Table A.1).
We did not observe overtly elevated mutation rates in strains defective for nucleotide
excision repair (NER), base excision repair (BER), non-homologous DNA end-joining
(NHEJ) and apoptosis, consistent with a high level of redundancy of DNA repair path-
ways. Changes in mutagenesis were observed upon knockouts of translesion synthesis
polymerases, highly conserved genes involved in homologous recombination (HR), upon
depletion of mismatch repair machinery, and in double knockouts of HR-related and
apoptosis-related genes. All in all, this chapter will provide a global analysis of how
various DNA repair and DNA damage response pathways help to protect genome stabil-
ity from endogenous mutagenesis.
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3.2.1 Estimating mutation rates in mutation accumulation ex-
periments
Accumulation of mutations was achieved by passing the C. elegans lines through sev-
eral generations, introducing a single-cell bottleneck at each generation passage. We
assume that all mutations accumulated in a single cell are heterozygous; they have 25%
chance of being lost after propagation, 50% chance of remaining heterozygous, and 25%
chance of being fixed (becoming homozygous). Hence, in order to make the number of
mutations directly proportional to the number of generations, we adjusted the number of
generations as
eN =  (N) = NX
i=1
1
2i 1
+
1
4
N 1X
i=1
iX
j=1
1
2j 1
,
where eN denotes the adjusted generation number, and   is a function reflecting the
fraction of all accumulated mutations observed after N generations.
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Figure 3.1: Adjusted generation number ver-
sus the real one. Dashed line represents the
y = x/2 + 1 line.
We calculated the mutation rate as a
number of mutations of a particular type
accumulated in a wild-type or DNA repair-
deficient C. elegans line over one genera-
tion. Previously, we calculated a mutation
rate per base pair of ⇠ 1.0 ⇥ 10 9 muta-
tions per cell division for wild-type C. ele-
gans (Meier et al. 2014, Meier et al. 2018).
This corresponds to about one mutation in
the one hundred million base pair genome
within two C. elegans generations. For
comparison, in humans, analysing parent-
child trios yielded nearly 30 mutations oc-
curring from one generation to the next
(Conrad et al. 2011).
Using the generation adjustment de-
scribed above, we estimated the wild-type
mutation rate as approximately one heterozygous mutation per genome per generation
(0.95, SD = 0.05), which corresponds to about N/2 mutations after N generations as the
function  (N) becomes indistinguishable from N/2 + 1 for any N > 18 (Figure 3.1).
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3.2.2 Comparison of the mutation rates across genotypes
Di↵erent types of mutations, especially mutations of di↵erent scale, naturally have
di↵erent occurrence rates, which makes a comparison of the total mutation rates across
genetic backgrounds incorrect. Hence, we considered the rates of single-base substitutions,
indels of up to 400 base pairs, and structural variants per generation separately. Median
mutation rates across all genotypes were quite close to those in the wild-type: about 0.93
heterozygous substitutions (0.67, SD = 0.05 in wild-type), 0.33 indels (0.35, SD = 0.03
in wild-type) and 0.14 (0.12, SD = 0.03 in wild-type) structural variants per genome per
generation.
Comparing the mutation rates across 66 DNA repair-deficient backgrounds to the wild-
type (using a  2-test), we found that the substitutions rates for about half (53%) of all
strains were not significantly di↵erent from the wild-type, and for another 25%, the change
in mutation rate did not exceed 2-fold (Figure 3.2). Only 8 genotypes demonstrated
substitution rates higher than two mutations per genome per generation: a knockout
of double-strand break (DSB) repair regulator rtel-1, knockouts of stability maintenance
complex elements smc-5 and smc-6, knockouts of mismatch repair genes pms-2 andmlh-1,
and double knockouts brc-1; cep-1, mus-81; cep-1 and pole-4; pms-2.
One-quarter of genotypes showed indel rates di↵erent from that in the wild-type, of
which only 9 backgrounds (13%) exhibited at least a two-fold di↵erence (Figure 3.2).
Following our expectations, MMR-related knockouts pms-2, mlh-1 and pole-4; pms-2
demonstrated high rates of indels. Besides, the knockouts of TLS polymerases polh-1 and
rev-3, G-quadruplex resolving helicase dog-1 and the double knockouts brc-1; cep-1 and
mus-81; cep-1 also demonstrated elevated rates of indel acquisition.
In the structural variant rate comparison, only 20% of genotypes showed an SV rate
di↵erent from the wild-type. In particular, the mutants defective in helq-1, mus-81, slx-1,
mus-81; cep-1, smc-5, rtel-1 and smc-6 genes exhibited high SV rates (Figure 3.2). All
of these genes are associated with DSB repair or resolution of crosslinks.
3.3 Experimental mutational signatures and genomic
features
Upon analysing the mutational rates and signatures of DNA repair-deficient C. ele-
gans lines, several pathways demonstrated alteration in mutation rates: mismatch repair,
translesion synthesis mutants, lines defective in helicases which participate in crosslink
repair, and homologous recombination deficient mutants (especially in combination with
a knockout of an apoptosis-related gene). Below I will describe the most interesting spec-
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tra and investigate additional features of mutations accumulated in these lines. A full
list of all mutational signatures with indications of entries significantly di↵erent from the
wild-type can be found in Appendix B.
3.3.1 Mismatch repair deficiency yields high rates of indels and
single-base substitutions
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Figure 3.3: Experimental mutational signatures of mlh-1, pms-2 and pole-4; pms-2 defi-
ciencies along with their 95% credible intervals. Distribution of mutations is expressed in
numbers of mutations per generation.
Mismatch repair is one of the most crucial repair mechanisms, which dramatically
decreases the replication error rate by correcting the mismatches left by the replicative
polymerases ✏ and  .
In contrast to the wild-type, mlh-1 and pms-2 mutants carried an average of 1174 and
1191 unique mutations, respectively, of which 288 and 309 were base substitutions and
886 and 882 indels. This corresponded to acquiring about 26 base substitutions and 83
indels per generation, or a total of 7.10⇥ 10 8 (95% CI: 6.86⇥ 10 8 to 7.33⇥ 10 8) and
7.28⇥ 10 8 (95% CI: 7.10⇥ 10 8 to 7.48⇥ 10 8) mutations per base pair and cell division
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for mlh-1 and pms-2, respectively.
Interestingly, a double knockout of pms-2, an MMR component, and pole-4, accessory
subunit of the replicative polymerase epsilon, yielded a substantial increase in the base
substitution rate. The double pole-4; pms-2 mutants demonstrated a 2-fold increase
in total mutation rate over the single MMR mutants, reaching 1.51 ⇥ 10 7 (95% CI:
1.45⇥ 10 7 to 1.56⇥ 10 7) mutations per genome per division, leading to on average 101
base substitutions and 109 indels acquired per generation.
The main feature characterising the mutational spectra of MMR knockouts was a
high amount of single-base indels in repetitive regions (Figure 3.3), indicating the poly-
merase slippage as the primary mechanism of mutation acquisition upon MMR deficiency.
Presumably, additional defects in pole-4 lead to an increase in the error rate of the poly-
merase, which manifests via higher base substitution rate. The mutational patterns and
molecular mechanisms of MMR deficiency will be considered in more detail in the next
chapter (Chapter 4).
3.3.2 Defective translesion synthesis yields medium-sized dele-
tions
TLS polymerases are capable of replicating DNA across damaged bases. This synthesis
can lead to an error-free or an error-prone lesion bypass. C. elegans polh-1 (pol ⌘) and
rev-3 (catalytic subunit of pol ⇣) mutants displayed an increased level of deletions under
400 bps, especially those between 50 and 400 bps (Figure 3.4).
REV-1 protein serves as a sca↵old protein which recruits other TLS polymerases to the
damaged site. In the mutation rate comparison, rev-1 knockout displayed a more than
3-fold decrease in mutagenesis compared to wild-type, which is consistent with having
no TLS due to defective rev-1 function (Figure 3.2). The mutational signature of this
deficiency, however, was not di↵erent from the wild-type for any of the mutation classes.
Interestingly, only rev-1 (gk147834) demonstrated such behaviour, but not the other rev-1
knockout, rev-1 (gk924750).
Deletions associated with polh-1 and rev-3 deficiencies showed hallmarks of double-
strand break repair via alternative end-joining, which is mediated via polymerase ✓
(POLQ). The involvement of POLQ is marked by microhomology at the break junctions.
Additionally, there is evidence of polymerase slippage and re-priming at the junction, as
reported previously (Roerink, Schendel, and Tijsterman 2014). All in all, our data suggest
that POLH-1, REV-1 and REV-3 may prevent DNA breaks by reading across damage
bases. The failure to do so apparently leads to small deletions. Our results on pol ⌘/pol
⇣ defects and the evidence for repair by pol ✓ mirror the reports from the Tijesterman lab
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Figure 3.4: Mutational signatures of 4 TLS polymerase deficiencies, including two di↵erent
knockouts for polh-1 and rev-1. Brighter colors represent mutation contexts which are
di↵erent from the wild-type. Lines underneath denote mutation classes where the total
number of mutations within this class is di↵erent from the wild-type (FDR 10%).
(Roerink, Schendel, and Tijsterman 2014, Van Schendel et al. 2015).
3.3.3 Structural variation in DNA crosslink repair-deficient mu-
tants
Repairing DNA interstrand crosslinks (ICL) usually involves the so-called Fanconi
Anaemia (FA) pathway, which is required for sensing ICLs and for assembling various
repair factors. Severing an ICL leads to a single-strand break (SSB) in one strand, which
may be converted to a DSB and mended by HR repair if it persists until replication.
Finally, TLS polymerases are also involved as they need to read across the remaining
adduct on the other strand. In addition, the FA pathway is recruited to stalled replication
forks to prevent genome instability upon DNA replication stress (Lachaud et al. 2016).
There are six ICL repair mutants considered in the study. FCD-2 (Fancd1 in mam-
malian cells) is a sca↵old protein sensing the damage via ubiquitination upon ICL forma-
tion, and it is thought to be coordinating the assembly of the ICL repair complex.
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Figure 3.5: Experimental mutational signatures of helicase knockouts dog-1 and helq-1.
Brighter colors represent mutation contexts which are di↵erent from the wild-type. Lines
underneath denote mutation classes where the total number of mutations within this class
is di↵erent from the wild-type (FDR 10%).
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Figure 3.6: Distribution of mutations across
11 dog-1 mutants. Large symbols correspond
to the mutations which intersect with the
motifs prone to form G-quadruplexes.
FNCM-1 a helicase involved in DNA
damage recognition. Together with FNCI-
1, a component of an E3 ubiquitin lig-
ase complex, they are needed for FCD-
2 ubiquitination. FAN-1 is a structure-
specific nuclease involved in ICL repair,
but not epistatic to FCD-2 and FNCM-1.
DOG-1 is the C. elegans ortholog of the
mammalian FANCJ helicase implicated in
the resolution of DNA tertiary structures
formed by G-rich DNA stretches referred
to as G-quadruplexes, and HEL-Q is a con-
served helicase thought to act in parallel to
FCD-2.
Analysing the mutational signatures
present in the ICL repair mutants, we did
not find an overt deviation between fcd-2, fncm-1, fnci-1 and wild-type (Figure ??). How-
ever, dog-1 mutant strains showed a 3-fold increase in total mutation rates, and a distinct
mutational pattern with a shift towards deletions and deletion/insertions (complex indels)
in the range of 50-500 base pairs, as well as to larger SVs, predominantly deletions (Figure
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3.5).
Across 11 dog-1 deficient samples propagated for 20 generations, 81% of deletions
(17 out of 21) longer than 400 bp were overlapping with regions prone to generate G-
quadruplexes, as well as 78% (109 out of 139) of indels between 50 and 400 base-pair in
length (Figure 3.6). The density of such G-rich motifs in C. elegans genome was shown
to be about 0.89 per 1 kb (Marsico et al. 2019). Hence, our data suggest that the rate of
G-quadruplex formation in dog-1 deficient C.elegans is about 1 lesion per generation.
HELQ-1, a helicase previously named HEL-308, is thought to act in parallel to FancD2
in ICL repair. helq-1 mutants showed a high number of tandem duplications, which
ranged in size between 457 and 8089 bp with a median of 1270 bp (Figure 3.7a). The
breakpoints of these tandem duplications tended to be enriched within sequences with
inverted repeats. Of the 5 tandem duplications with breakpoints within an inverted
repeat accumulated across 3 helq-1 mutants after 40 generations, all occurred in right-
replicating regions, which suggests that they may be arising in a replication-dependent
manner due to secondary structures arising in single-stranded DNA.
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Figure 3.7: Distribution of (a) sizes of tandem duplications and (b) sizes of deletions
accumulated in mutation accumulation experiments per genotype. Only genotypes with
2 or more deletions/duplications are shown.
3.3.4 Evidence of alternative DSBR under homologous recom-
bination deficiency
Similar to mammalian cells, the repair of DSBs in C. elegans can occur via three
routes: error-free homologous recombination (HR) repair, error-prone non-homologous
end-joining (NHEJ), or alternative end-joining mostly comprised of the microhomology-
mediated end-joining (MMEJ). Hence, the knockouts of either of the two systems should
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Figure 3.8: Experimental mutational signature of the brc-1 knockout. Brighter colors
represent mutation contexts which are di↵erent from the wild-type. Lines underneath
denote mutation classes where the total number of mutations within this class is di↵erent
from the wild-type (FDR 10%).
produce mutational spectra indicative of the activity of an alternative pathway.
Knockouts of NHEJ and MMEJ. We first analysed cku-80 and lig-4 mutants
defective in NHEJ and polq-1 mutants defective for MMEJ (Figure ??). We did not
see any biologically relevant di↵erence in mutation rates for neither lig-4 or cku-80, nor
polq-1 mutants, which confirms that homologous recombination is capable of maintaining
genome integrity on its own, and does it in an error-free manner.
Deficiency in BRCA-1. In contrast, the brc-1 mutants showed an increased number
of mutations enriched with 5-50 bp pair deletions, as well as an increased SV rate (Figure
3.2). BRC-1 protein is involved in many stages of HRR and regulates several repair factors
(Boulton et al. 2004), and an absence of this protein turns o↵ the inter-sister recombina-
tion completely. Homologous recombination deficiency in C. elegans was associated with
elevated rates of base substitutions, which resembled a flat profile of substitutions found
in HR deficient human cancers (Polak et al. 2017, Riaz et al. 2017), deletions in the range
of 5-50 bp, and larger tandem duplications (Figure 3.8).
The tandem duplications accumulated in brc-1 mutants tended to have microhomol-
ogy at the breakpoints, indicative of active MMEJ repair. Tandem duplications ranged
in size between 1,601 bp and 500 kb, with a median of 11,913 bp, thus being longer
than the duplications observed in helq-1 mutants (Figure 3.7a). It also agrees with a
pattern of structural rearrangements associated with BRCA-1 loss in breast and ovarian
cancers (Nik-Zainal et al. 2016, Macintyre et al. 2018). In addition, brc-1 mutants accu-
mulated small deletions (Figure 3.7b) and base changes, which can also be a consequence
of mutagenic NHEJ.
End-processing and sister chromatid invasion. Once a DNA double-strand
break occurs, it has to be processed by a series of nucleases to generate single-stranded
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Figure 3.9: Experimental mutational signatures of the rfs-1 and rip-1 knockouts defi-
cient in essential HRR nucleases. Brighter colors represent mutation contexts which are
di↵erent from the wild-type. Lines underneath denote mutation classes where the total
number of mutations within this class is di↵erent from the wild-type (FDR 10%).
DNA tails. The knockouts of the essential nucleases in C. elegans, rad-51, mre-11, and
com-1 are sterile due to defects in meiotic recombination. We thus analysed strains
defective for the rad-51 paralog rfs-1, and a knockout of rip-1, which encodes an RFS-1
interacting protein. The RFS-1/RIP-1 complex is required to remodel presynaptic RAD-
51 containing filaments and to facilitate stand invasion (Taylor et al. 2015).
The strains with defective rfs-1 and rip-1 both showed a two-fold increase in mutage-
nesis (Figure 3.2). Mutational signatures of these knockouts both displayed an increased
number of small deletions (Figure 3.9). Apart from small and not biologically relevant
fluctuations (somewhat elevated level of SVs in rip-1 deficient strains), the mutational
spectra accumulated in the respective mutants were similar to each other and the signa-
ture of brc-1 deficiency, consistent with RFS-1/RIP-1 being an essential HRR factor as
well as BRC-1.
Cohesin complex and DNA stabilisation. Another complex involved in HR
is a ring-shaped cohesin complex considered to tether broken DNA strands with the
repair template on the sister chromatid to facilitate HR. Knockouts of smc-5 and smc-
6, which encode two components of this complex, both showed increased mutagenesis
and a distinct mutational pattern characterised by elevated levels of SVs, predominantly
deletions, tandem duplications and complex rearrangements (Figure 3.10). In line with
the high preponderance of SVs in these strains, they could not be propagated beyond 5
generations when they became sterile. The signatures of these knockouts di↵er from brc-1
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Figure 3.10: Experimental mutational signatures of the smc-5, smc-6, slx-1 and mus-
81 knockouts, deficient in the cohesin complex or Holliday Junction-resolving nucleases.
Brighter colors represent mutation contexts which are di↵erent from the wild-type. Lines
underneath denote mutation classes where the total number of mutations within this class
is di↵erent from the wild-type (FDR 10%).
signature through a high contribution of 10-kbps long deletions (Figure 3.7b). Given the
SMC’s role in stabilising the two sister chromatids, it is likely that the HRR is initiated,
but the D-loop falls apart prematurely due to the instability of the whole structure,
resulting in the loss of genetic material.
Holliday Junction resolution. Next, the invading strand has to capture the second
end of the double-strand break upon the D-loop extension. After this, the two DNA
double strands engaged in HR form cruciform four-way DNA intermediates referred to
as Holliday Junctions, which need to be resolved by DNA structure-specific nucleases
such as MUS81 and SLX1. C. elegans slx-1 and mus-81 mutants showed an identical
mutational spectrum, characterised by an increase in structural variant rates, especially
tandem duplications (similar to brc-1 ) and deletions with a median size of 7-8 kbps (Figure
3.7b, 3.7a, 3.10).
Helicases preventing wrong template choice. Another crucial factor of homol-
ogous recombination repair are helicases, enzymes that unwind double-stranded DNA.
They unwind the D-loop structures when the sequence of the invading strand does not
perfectly match the template strand, thus preventing recombination with homeologous
template sequences. To investigate the patterns induced by helicase defects, we anal-
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Figure 3.11: Experimental mutational signatures of the him-6, wrn-1, rcq-5 and rtel-
1 helicase knockouts. Brighter colors represent mutation contexts which are di↵erent
from the wild-type. Lines underneath denote mutation classes where the total number of
mutations within this class is di↵erent from the wild-type (FDR 10%).
ysed the 3 C. elegans RecQ helicases: him-6 - an ortholog of human Bloom syndrome
gene, wrn-1 - an ortholog of Werner’s syndrome gene, rcq-5 helicase, and also rtel-1, a
conserved helicase involved in genome stability and telomere maintenance. Consistent
with the similar function of these helicases, they showed spectra similar to each other.
The only noteworthy change was a high rate of tandem duplications in rtel-1 mutants,
which made its mutational signature more similar to brc-1 mutants (Figure 3.7a, 3.11).
RTEL-1 helicase di↵ers from other helicases in its ability to counteract recombination
and promote synthesis-dependent strand annealing (Uringa et al. 2010); the di↵erence
in mutational spectra likely reflects the pathogenicity of extensive recombination for the
repair of spontaneous DSBs.
Overall, our results recreate the mutational signatures of di↵erent kinds of homologous
recombination deficiency. The distribution of mutations and the presence of microho-
mologies indicate NHEJ and MMEJ, as well as a failed HRR, as the sources of mutations
observed upon propagation of HR deficient lines.
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Figure 3.12: Experimental mutational signatures of the brc-1; cep-1, and mus-81; cep-1
double knockouts. Brighter colors represent mutation contexts which are di↵erent from
the wild-type. Lines underneath denote mutation classes where the total number of
mutations within this class is di↵erent from the wild-type (FDR 10%).
3.3.5 Defects in DNA damage signalling exaggerate mutagenesis
upon HR deficiency
A cell’s reaction to DNA damage starts with damage signalling. Functioning DNA
damage checkpoints are required to delay cell cycle progression and facilitate DNA repair.
When the damage is excessive, DNA damage checkpoint can also trigger apoptosis to
remove abnormal and defective cells. In fact, the key human apoptosis regulator, TP53,
is mutated in more than half of cancers (Knijnenburg et al. 2018) which allows the cell
to accumulate deleterious mutations inducing fitness and metabolic changes.
Analysing mutants defective for atm-1, encoding for C. elegans ATM, a PI3-kinase
involved in detecting DSBs, we found a two-fold elevation of the level of structural variants,
but no specific change in SV type preference. Knockouts of cep-1, ced-3 and ced-4 showed
no e↵ect at all (Figure 3.2). cep-1 is the C. elegans TP53 homolog and is required for
DNA damage-induced apoptosis, while ced-3 and ced-4 encoding for a caspase and an
Apaf-1 like protein, respectively, are required for both DNA damage induced as well as
developmental apoptosis.
Observing distinctive patterns of mutations upon homologous recombination defi-
ciency, we wanted to see if they may be exaggerated by knocking o↵ DNA damage response
components. Double knockouts of apoptosis genes and him-6 helicase did not show any
extreme e↵ects beyond those induced by him-6 alone (Figure 3.2, ??). However, double
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knockouts of cep-1 gene with brc-1 and with mus-81 produced signatures di↵erent from
the spectra accumulated in the single mutants (Figure 3.12).
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Figure 3.13: Distribution of mutations across
10 mus-81; cep-1 double mutants.
Absence of CEP-1 exaggerated the mu-
tational spectra induced by brc-1 defi-
ciency, leading to a 2-fold increase in the
rate of base substitutions and small indels
compared to a single HRR mutant (Fig-
ures 3.2). Furthermore, a double knock-
out of mus-81 helicase and cep-1 apop-
tosis regulator boosted the mutation rate
about 10 times, creating a specific pat-
tern of T>N and multinucleotide substi-
tutions, small insertions, as well as large
tandem duplications and deletions (Figure
3.12). Interestingly, the hypermutant pro-
file reflected in the signature was present
in only one of the two independently cre-
ated strains, indicating that there may have been an additional factor triggering excessive
mutagenesis in these samples. Moreover, the contributing mutations were concentrated
in well-defined clusters (Figure 3.13).
3.3.6 Clustering of mutations across genotypes
Genomic clustering of mutations is a quite severe phenotype which would be selected
against in fully DNA repair and damage signalling proficient cells unless they are under
selective pressure for higher diversity such as in case of somatic hypermutation of im-
munoglobulins in immune cells (Chahwan et al. 2012). However, localised types of dam-
age, such as double-strand breaks, can produce clusters of mutations upon error-prone
repair. In addition, prolonged exposure of single-stranded DNA to the cell environment
during replication or transcription can lead to clusters of mutations, which are created via
repairing the damage incurred by antiviral protection mechanisms or secondary structure
formation (Chan and Gordenin 2015).
We investigated the numbers of clusters and proportions of clustered mutations across
genotypes and identified 7 backgrounds associated with an elevated rate of mutation
clusters (Figure 3.14). In line with the expectation, most of these were associated with
homologous recombination deficiency (brc-1, him-6, rip-1 and rfs-1 ), which leads to DSBs
being repaired by MMEJ or NHEJ pathways leaving clustered mutations close to the
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Figure 3.14: Numbers of clusters per generation for each genotype (left) and the fractions
of clustered mutations per genotype (right). Dotted line marks the wild-type level.
breakpoints.
mus-81; cep-1 double knockouts demonstrated the highest amount of clusters and
mutations within those clusters. As mentioned above, the clustering and hypermutation
occurred simultaneously and only in half of the samples, which indicates that there may
have been an additional mutational event leading to a leap in mutation rates and formation
of dense mutational clusters.
Another HR and apoptosis deficient mutant line, brc-1; cep-1, had on average 20%
of its mutations belonging to clusters which were arising a rate of 0.2 per sample per
generation. Similar to the mutational spectra, an additional cep-1 knockout seems to ex-
aggerate the features of a single brc-1 knockout, which also demonstrate cluster formation
covering on average 10% of mutations. Thus, at least for HR deficiency conferred via brc-1
knockout, the additional cep-1 knockout allows for tolerating more mutations and more
intensive clustering of these mutations. Benefits of such combinations for mutagenesis
can be detected in cancers as well: breast cancers with germline BRCA1/BRCA2 defects
were shown to be enriched with somatic TP53 mutations compared to sporadic tumours
(Greenblatt et al. 2001).
An unexpected background in this list is the agt-2 knockout. AGT-2 is one of the
two predicted DNA alkyl-guanine alkyl-transferases in C. elegans, enzymes performing
direct damage reversal upon alkylation of guanines. Mutational clusters were detected
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in several independent samples and came together with a modest 2-fold increase in the
base substitution rate (Figure 3.2). One of the possible explanations may be the ability of
O6-alkylguanine to serve as a template for a TLS polymerase acting at a site of localised
damage, leading to C>T changes on the opposite strand.
3.4 Discussion
In this chapter, I catalogued the mutational characteristics of DNA repair deficiencies
across several DNA repair-related pathways in C. elegans. High-resolution characterisa-
tion of mutation rates, mutational signatures and local features provided insights into
mechanisms of mutation acquisition. We described the process of deletion accumulation
in GC-rich sequences for dog-1 mutants, and replication-associated aggregation of tan-
dem duplications in repetitive regions for helq-1 helicase mutants. Moreover, our data
suggested that localisation of mutational clusters in any other genomic region is a highly
deleterious trait which would normally lead to cell death upon apoptosis induction.
The absence of significant mutagenic e↵ects for the majority of genotypes indicates a
high level of redundancy among di↵erent DNA repair pathways, which means that it may
require the combined deficiency of multiple DNA repair pathways to trigger excessive
mutagenesis. Equally, a latent defect in DNA replication integrity might only become
apparent in conjunction with a DNA repair deficiency. Indeed, the increased mutation
burden detected in the pole-4 ; pms-2 double mutant while no increased mutation rate
is observed in pole-4 alone suggested a latent role of pole-4. Similarly, double knockouts
of HR repair and apoptosis-related genes, brc-1 ; cep-1 and mus-81 ; cep-1 reveal the
aggregation of clustered mutations upon alternative end-joining repair of DSBs which is
only visible in cells lacking the apoptosis regulators.
However, when we do observe an e↵ect di↵erent from that in the wild-type, we often
do not know where these mutational spectra come from. It is clear that the damage which
produces mutations upon an absence of mismatch repair is incurred by the polymerases
which incorporate wrong or damaged bases; for other DNA repair pathways, not directly
liked to replication, it is much harder to infer the original damaging agent. There are
many processes which can cause chemical or mechanical damage to the cells without any
exposure to exogenous mutagens: segregation, cell movement, replication-transcription
collisions, meiosis, mechanical stress.
In the next chapter, I will study the mutational signatures of mismatch repair defi-
ciency in more detail, and show the usability of C. elegans research to understanding the
aetiology of mutations in human cancers.
76
Chapter 4
Comparison of mutational signatures
of mismatch repair deficiency in C.
elegans and human gastrointestinal
cancers
4.1 Introduction
In the previous chapter, I showed that many types of DNA repair deficiency could alter
spontaneous mutation rates and generate specific mutational patterns. In particular, the
mutants with defective mismatch repair have drawn our attention as they had the most
well-defined mutational spectra and the highest amount of mutations across the genotypes.
One of the initial questions that this study aimed to answer was whether the muta-
tional signatures are consistent across species, and how well the signatures obtained from
model systems could explain the mutations observed in cancer. As MMR deficiency is also
a well-known carcinogenesis factor (Hsieh and Yamane 2008), the MMR mutants were the
best candidates to explore the translational potential of C. elegans derived signatures.
Moreover, mismatch repair deficiency has been associated with more than one muta-
tional signatures (Alexandrov et al. 2013b, Alexandrov et al. 2018). Adding the informa-
tion from a model organism, where mutagenesis was performed in a completely controlled
environment, may help to disentangle the relationship between these di↵erent mutational
spectra and the underlying mutational processes.
In this chapter, I will present a comparison of MMR deficiency between C. elegans
and human cancer data, and study the composition and origins of mutations observed in
MMR deficient cancers.
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Contributions
The following work was published in co-authorship with Bettina Meier and colleagues:
Meier, B., Volkova, N.V., Hong, Y., Schofield, P., Campbell, P.J., Gerstung, M., and
Gartner, A. 2018. Mutational signatures of DNA mismatch repair deficiency in C. elegans
and human cancers. Genome Research 28, 666-675.
For this project, AG, MG and PJC have conceived the study, BM and PS prepared
the C. elegans data, and BM and YH and suggested initial filtering, mutation rate anal-
ysis and homopolymer analysis. I extracted the mutational signatures from experimental
data, derived the final estimates for indels per homopolymer, and preformed the com-
parative study in human cancers (including signature analysis, association with indels
and search for interaction factors). Compared to the publication, this chapter focuses on
the comparison between C. elegans and cancer, and includes an additional adjustment
of single-base indels when comparing mutational signatures of MMR deficiency between
species. All the scientific results, as well as figures and figure captions, were published in
Meier et al. 2018.
4.2 Mismatch repair deficiency in cancer
Mismatch repair (MMR) was one of the first DNA repair pathways to be associated
with cancer predisposition: mutations in MMR genes were associated with hereditary
non-polyposis colorectal cancer (HNPCC), also referred to as Lynch Syndrome, at the
beginning of 20th century (Fishel et al. 1994, Bronner et al. 1994, Nicolaides et al. 1994,
Papadopoulos et al. 1994, Miyaki et al. 1997). Defects in MMR related genes were found to
be the cause of more severe conditions leading to high rates of gastrointestinal, endometrial
and brain cancers: biallelic mismatch repair deficiency syndrome (bMMRD) (Durno et
al. 2015), Muir-Torre syndrome and Turcot’s syndrome (Lawes, SenGupta, and Boulos
2003).
Several cancer types have a high frequency of MMR deficiency (Figure 4.1), especially
so uterine, stomach and colorectal cancers (Cortes-Ciriano et al. 2017). Among sporadic
colorectal and gastric cancers, about 15% harbour MMR defects (Funkhouser et al. 2012,
Cancer Genome Atlas Research Network 2014a). This number is higher in uterine cancers
(up to 33% (Hecht and Mutter 2006)) but much lower in other cancer types (Cortes-
Ciriano et al. 2017, Bonneville et al. 2017).
MMR deficiency in humans (as well as many model organisms) mainly manifests via
contraction and expansion of repetitive regions called microsatellite instability or short
tandem repeats, which would normally be repaired by MMR machinery (Denver et al.
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2004, Hanford et al. 1998, Lujan, Clark, and Kunkel 2015). As discussed in the Introduc-
tion, three mechanisms ensure the fidelity of replication. Selectivity towards the correct
nucleotide and 3’-5’ exonuclease ability of the main replicative polymerases prevents some
of the errors. However, the misincorporation rate is still at the order of 10 5 potentially
leading to thousands of mismatches genome-wide turning into mutations during the next
round of replication (Kunkel and Bebenek 2000).
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Figure 4.1: Number of tumours per can-
cer type in TCGA with experimentally
identified or predicted microsatellite in-
stability (MSI). MSS - microsatellite sta-
ble, NA - data not available. Based on
the data from Lee et al. 2015 and Cortes-
Ciriano et al. 2017.
In healthy human cells, postreplicative mis-
match repair repairs these mismatches on the
newly synthesised strands, reducing the result-
ing mutation rate down to about 10 10 corre-
sponding to 1 mutation per cell division (Bern-
stein et al. 2013). Upon a knockout of an
MMR gene, the mutation rate can increase
up to 100-1000 fold (Simpson 1997, Zou et al.
2018). The fold-change in cancer is more mod-
erate as cancers generally have a higher muta-
tion rate: MMR proficient colorectal adenocar-
cinomas have an average point mutation rate
of ⇠4 mutations per Mb, whereas in MMR-
deficient colorectal cancers it is 10 times higher
and reaches 40-50 mutations per Mb (Cancer
Genome Atlas Research Network 2012).
Before the spread of high-throughput se-
quencing, the detection of mismatch repair deficiency was performed based on measuring
the number of repeats in five selected microsatellites and comparing them between the tu-
mour and normal samples (Boland et al. 1998, Laghi, Bianchi, and Malesci 2008). Cancer
predisposition used to be identified by detecting specific single-nucleotide polymorphisms
in MMR genes (Buhard et al. 2006). Following the aggregation of sequencing data, a num-
ber of computational methods were developed that classify the samples based on di↵erent
data types (whole genome, whole exome, or targeted sequencing) and characteristics of
cancer samples: mutational burden, number of indels in repetitive regions, and density of
mutations in particular microsatellites (Cortes-Ciriano et al. 2017, Niu et al. 2014, Bon-
neville et al. 2017, Huang et al. 2015, Nowak et al. 2017). Another typical marker used in
the clinic is the epigenetic silencing of MLH1, which was found to be common in cancers
with sporadic MMR deficiency and is easier to reliably detect via immunohistochemistry
(Herman et al. 1998, Boissie`re-Michot et al. 2016).
Identification of functional MMR deficiency in tumours is important for making deci-
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sions about treatment and prognosis. It has been associated with better clinical outcome
(Lee et al. 2002) and better response to immunotherapy (Dudley et al. 2016, Le et al.
2015, Kelderman, Schumacher, and Kvistborg 2015).
4.3 Mutational spectra of mismatch repair deficiency
in C. elegans
Compared to human, the C. elegans genome does not encode obvious MutL-  and  
sub-units (PMS1 and MLH3 homologs, respectively), while the homologs for MutL-↵ sub-
units MLH1 and PMS2 can be readily identified using homology searches. We studied
two knockouts lines, mlh-1 and pms-2 mutants.
(a) (b)
Figure 4.2: The numbers of single-base substitutions (a) and indels (b) in the samples
with mlh-1 or pms-2 knockouts of di↵erent generations.
4.3.1 Mutation types and rates in MMR mutants
The mutational spectra of the two knockouts were primarily defined by C>A, C>T,
T>C substitutions as well as single-base deletions and insertions (Figure 4.2, 4.3). A
similar prevalence of T>C and C>T transitions was previously reported in S. cerevisiae
msh2 mutants and in MMR defective human cancer lines (Alexandrov et al. 2013b, Lujan
et al. 2014, Supek and Lehner 2015). Analysing these base substitutions within their 5’
and 3’ sequence context, we found no enrichment of distinct 5’ and 3’ bases associated
with T>C transitions prominent in mlh-1 and pms-2 single mutants. In contrast, T>A
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transversions occurred with increased frequency in an ATT context, C>T transitions in
a GCN context, and C>A transversions in an NCT context (Figure 4.3).
Analysis of the broader sequence context of T>A transversions in an ATT context re-
vealed that > 90% of substitutions occurred in homopolymer sequences; the majority (>
75%) in the context of two adjoining A and T homopolymers. Similarly, an increased fre-
quency of base substitution at the junction of adjacent repeats has recently been reported
in S. cerevisiae MMR mutants, giving rise to the speculation that such base substitutions
may be generated by double slippage events (Lang, Parsons, and Gammie 2013). To
further analyse base changes, we visually searched for base changes occurring in repeat
sequences. We found several examples in which one or several base substitutions had oc-
curred that converted a repeat sequence such that it became identical to flanking repeats
consistent with polymerase slippage across an entire repeat. Such mechanisms could lead
to the equalization of microsatellite repeats - a phenomenon referred to as microsatellite
purification (Harr, Zangerl, and Schlo¨tterer 2000).
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Figure 4.3: Spectra of base substitutions in mlh-1, pms-2 and pole-4; pms-2 knockout
lines of di↵erent generations, along with their 95% confidence interval. Corresponds to
Figure 1A,B in Meier et al. 2018.
The genome-wide mutation rates observed in the absence of C. elegans MutL-↵ pro-
teins MLH-1 and PMS-2 agree with mutation rates previously determined for C. elegans
MutS and S. cerevisiae MMR mutants (Strand et al. 1993, Yang et al. 1999, Degtyareva
et al. 2002, Tijsterman, Pothof, and Plasterk 2002, Denver et al. 2005). The mutational
signatures extracted from the two knockouts were remarkably similar (cosine similarity
of 0.97, Figure 3.3). However, similar experiments in mammalian cells (Yao et al. 1999,
Baross-Francis et al. 2001) demonstrated di↵erence in mutation rates and spectra for
cells deficient in MLH1 or PMS2, which suggests that the inactivation of the MutL-↵
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heterodimer in C. elegans is su cient to yield a fully penetrant MMR deficient pheno-
type. This observations is consistent with the absence of any PMS1 MutL-  and MLH3
MutL-  homologs in the C. elegans genome.
4.3.2 Interaction between MMR and pol "
(a) (b)
Figure 4.4: The numbers of single-base substitutions (a) and indels (b) in the samples with
pms-2 single or pole-4; pms-2 double knockouts of di↵erent generations. Corresponds to
Figure 1C,D in Meier et al. 2018.
Mismatch repair ought to repair the errors left by a replicative polymerase. Deficiencies
in human polymerase epsilon and polymerase delta were previously reported as driver
events in hypermutated brain cancers, as well as colorectal and endometrial cancers (Shlien
et al. 2015, Shinbrot et al. 2014). Given that the null alleles of the human and C. elegans
leading strand polymerase Pol " catalytic subunit, POLE and pole-1, respectively, are
essential for viability, we focused our analysis on a non-essential C. elegans Pol " subunit,
termed POLE-4. Dbp3p, the S. cerevisiae POLE-4 ortholog, was shown to be implicated
in the stabilization of POLE with the primer-template DNA complex (Aksenova et al.
2010).
pole-4; pms-2 mutants could not be readily propagated beyond the F10 generation,
hence we compared them to wild-type, pms-2, and pole-4 mutant strains which were also
grown for 10 generations. pms-2 mutant strains carried an average of 145 base substitution
and 527 indels over 10 generations, roughly half the number we observed in the F20
generation (Figure 4.4). In comparison, the number of single-base substitutions and
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indels was increased 4.4 fold and 1.4 fold in pole-4; pms-2 double mutants, respectively
(Figure 4.4).
In contrast to mlh-1 and pms-2 mutants, pole-4 single knockout lines exhibited muta-
tion rates and profiles not significantly di↵erent from the wild-type - a finding which was
confirmed by propagating pole-4 propagated over 40 generations (Figure 3.2). However,
the double pole-4; pms-2 mutants demonstrated a 2-fold increase in total mutation rate
over the single MMR mutants.
The fact that pole-4; pms-2 mutants could not be grown beyond F10 suggests that
a mutation burden higher than 500-700 single-base substitutions in conjunction with
the 700-800 indels might be incompatible with organismal reproduction. These numbers
are in line with our inability to propagate mlh-1 and pms-2 single mutant lines for 40
generations. The multiplicative e↵ect on mutation burden detected in pole-4; pms-2
double mutants alongside with unchanged mutation rate for pole-4 alone suggests that
replication errors occur at increased frequency in the absence of C. elegans pole-4 but are
e↵ectively repaired by MMR.
Our finding that pole-4 mutants do not show increased mutation rates is surprising
given that the deletion of the budding yeast POLE-4 homolog Dpb3 leads to increased
mutation rates comparable to the proof-reading deficient pol2-4 allele of the Pol " catalytic
subunit (Aksenova et al. 2010, Lujan et al. 2012). Increased mutation rates have also been
reported for proof-reading defective POLE Pol " catalytic subunit in mice and human
cells, and in humans, such mutations are associated with an increased predisposition to
colorectal cancer (Albertson et al. 2009, Palles et al. 2013).
While we could not define mutational patterns specifically associated with pole-4 loss
due to the low number of mutations, the profile of pole-4; pms-2 double mutants di↵ered
from mismatch repair single mutants. Most strikingly, in addition to C>T transitions in
a GCN context, T>C transitions were generated with higher frequency accounting for >
50% of all base changes (Figure 4.3). Interestingly, T>C substitutions were underrep-
resented in the context of a flanking 5’ cytosine. Notably, T>C changes not embedded
in a clearly defined sequence context have also been reported for MMR-deficient tumour
samples containing mutations in the lagging strand polymerase Pol   (Shlien et al. 2015),
but not in S. cerevisiae and human tumours with a combined MMR and Pol " deficiency
(Lujan et al. 2014, Shlien et al. 2015)
4.3.3 Indels in homopolymeric sequences
The mutational spectra in mlh-1 and pms-2 single and pole-4; pms-2 double mutants
were mostly composed of small insertions/deletions (indels) (Figures 4.2, 4.4). Mismatch
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repair is known to manifest via microsatellite instability expressed as expansion or con-
traction of highly repetitive regions, which led is to investigate the local context of indels
in these mutants.
To assess the likelihood of these mutations falling into repetitive regions by chance, we
calculated the total numbers of homopolymers, di- and tri-nucleotide runs encoded in the
C. elegans genome, defined here as repetitive DNA regions with a consecutive number of
identical bases or repeated sequence of n   4 were identified from the reference genome
WBcel235.74 using repeat search. As a result, we identified 3.433.785 homopolymers, with
the longest homopolymer being comprised of 35 Ts in the C. elegans genome (Figure 4.5).
In addition, we found 25,156 dinucleotide repeats and 7,615 trinucleotide repeats. In total,
homopolymers covered about 16% of the C. elegans genome, similar to humans (16.3% as
calculated on hg19). The fraction of genome covered by repetitive sequences composed of
2-6 bp repeats was overall less than 1%; hence, we focussed our analysis on homopolymeric
regions.
Figure 4.5: Distribution of homopolymer repeats encoded in the C. elegans genome by
length and DNA base shown in log10 scale (left panel) and the relative percentage of A,
C, G and T homopolymers in the genome (right panel). Corresponds to Figure 2A in
Meier et al. 2018.
Overlaying the indels with a map of homopolymers showed that the absolute majority
of indels in single and double mutant backgrounds, 90% of which were 1-bp insertions
or deletions, occurred in homopolymer runs (Figures 3.3, 4.6). 2 bp indels accounted on
Figure 4.6: An example of sequence context of a single- and double-base indels in MMR
deficient C. elegans mutants. Corresponds to Figure 1F in Meier et al. 2018.
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average for 5.5-8.6% of all indels (Figure 4.2), and a↵ected homopolymer runs as well as
dinucleotide repeat sequences at a similar frequency. Similar results were also reported
for MMR defective S. cerevisiae strains, human iPS cells and human organoids (Lujan,
Clark, and Kunkel 2015, Zou et al. 2018, Drost et al. 2017).
Trinucleotide repeat instability has been associated with a number of neurodegen-
erative disorders, such as fragile X syndrome, Huntington’s disease and Spinocerebellar
Ataxias (Brouwer, Willemsen, and Oostra 2009). Based on our analysis, trinucleotide
repeat sequences are present in the C. elegans genome at > 400 fold lower frequency than
homopolymer runs. Across F20 and F10 generation samples of mlh-1 and pms-2 mu-
tants, we observed between 3 to 7 trinucleotide indels per 10 generations predominantly
in homopolymer sequences precluding estimation of mutation rates for these lesions.
Given the high number of indels arising in homopolymer repeats, we aimed to investi-
gate the correlation between the frequency of indels and the length of the homopolymer
in which they occurred. 47% of genomic homopolymers in C. elegans were comprised of
As, 47% of Ts and 3% each accounted for Gs and Cs. A and T homopolymer frequen-
cies decreased continuously with increasing homopolymer length; C and G homopolymer
frequencies decreased up to homopolymer lengths of 8 bp, followed by roughly consis-
tent numbers for homopolymers of 8-17 bp length and decreasing frequencies with longer
homopolymers (Figure 4.5).
Although we identified slightly higher overall numbers of homopolymer runs in the
genome, this base specific size distribution is consistent with previous reports (Denver et
al. 2004). An average of ⇠ 0.5 1-bp indels arising in homopolymer sequences was observed
in 101 wild-type lines of di↵erent generations, indicating the frequency with which such
events might occur in wild-type or as amplification artefacts during sequencing.
Small indels in repetitive sequences could be generated as polymerase errors during
bridge amplification or sequencing, leading to possible sequencing artefacts. Across a
total of 101 wild-type samples of di↵erent generations, 7,433 1-bp indels were observed
on average prior to post-processing. Of these, 7,109 1-bp indels on average occurred
in homopolymer runs. Following filtering, we observed on average 0.5 out of 0.54 1-bp
indels arising in homopolymers per sample, with the majority of indels being removed
when filtering for quality and frequency of mutant reads. Thus, 1-bp indels likely arising
during PCR amplification or sequencing seem to be e ciently removed using our filtering
procedure.
Plotting the frequency of all 1-bp indels observed in MMR deficient backgrounds in
relation to the length of the homopolymer in which they occur, we found that the likeli-
hood of indels increased with homopolymer length of up to 9-10 base pairs, and trailed
o↵ in longer homopolymers. Given that the frequency of homopolymer tracts decreases
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with length, we normalised for homopolymer number (Figure 4.7a). These results are
consistent with observations in budding yeast (Lang, Parsons, and Gammie 2013).
To assess the variability of the frequency estimation, we applied a generalised additive
model (GAM) with a spline term which supported a rapid increase for homopolymers
up to length 9 followed by a drop or plateau in indel frequency for longer homopolymer
with decreasing confidence (Figure 4.7b). The lack of statistical power precludes firm
conclusions about indel frequencies in homopolymers > 13 bp based on low numbers of
long homopolymers in the genome and too few observed indel events (Figure 4.7).
In summary, our data suggest that replicative polymerase slippage occurs more fre-
quently with increasing homopolymer length, with a peak for homopolymers of 10-11
nucleotides, followed by reduced slippage frequency in slightly longer homopolymers. A
similar frequency distribution has been reported for human MLH-1KO organoids (Drost
et al. 2017).
(a)
(b)
Figure 4.7: (a) Average number of 1-bp indels in homopolymer runs for di↵erent mutant
lines adjusted for homopolymer length. (b) GAM fit for the ratio of 1bp indels normalised
to the frequency of homopolymers (HPs) in the genome, best fit denoted by red line along
with its 95% CI. The grey dots and grey bars indicate the average frequency and the 95%
confidence intervals, respectively. Corresponds to Figures 2B-C in Meier et al. 2018.
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4.4 Mutational processes shaping gastrointestinal tu-
mours
4.4.1 De novo extraction of mutational signatures
The 2013 COSMIC v.2 mutational signature catalogue (Alexandrov et al. 2015, Forbes
et al. 2015) contained 5 signatures associated with mismatch repair: 6, 15, 20, 21 and 26.
It might indicate that mismatch repair deficiency contributes to mutagenesis via multi-
ple mechanisms at the same time, but these signatures seemed to be uncorrelated across
cancer types (Alexandrov et al. 2015). In order to gain insights into the aetiology of these
signatures, we studied the mutational signatures of stomach and colorectal adenocarci-
nomas. Apart from having a high frequency of MMR deficiency, these two cancer types
stem from similar tissues yet carry di↵erent mutational signatures associated with MMR
deficiency (Alexandrov et al. 2013b).
The datasets acquired from ICGC (http://icgc.org) contained single nucleotide
(SNV) and small indel variant calls from 215 and 289 donors, respectively. According to
the TCGA Clinical Explorer (Lee et al. 2015), 40/215 and 63/289 samples were labelled
as microsatellite instable-high (MSI-H), which we considered as an indicator of MMR
deficiency. The samples labelled as microsatellite instable-low (MSI-L) or microsatellite
stable (MSS) were considered MMR proficient. Comparison of the mutational spectra
averaged across all MMR deficient samples within COAD and STAD datasets showed high
similarity between the two cancer types, in contravention with the presence of di↵erent
signatures in these cancers as determined by COSMIC analysis. The cosine similarity
between them reached 0.98, with the main source of variability being the contribution
of CpG>TpG (Figure 4.8). Based on this results, we hypothesised that the underlying
signature of MMR deficiency in these two cancer types should be the same, but there may
be di↵erent interacting processes present in these datasets that confine the mutational
signature analysis.
In order to analyse the signatures of mismatch repair deficiency active in these cancer
types, we performed an unsupervised signature extraction via non-negative matrix fac-
torisation similar to that initially proposed by Alexandrov in Alexandrov et al. 2013b.
However, the initial procedure was performed using Frobenius norm as the loss functions
minimised during the optimisation, which did not take into account the discrete nature of
mutation count data. Hence, we applied Brunet NMF with Kullback-Leibler divergence as
an objective Brunet et al. 2004, which is equivalent to an additive Poisson model. Given
the high prevalence of indels observed in C. elegans data, we also included single-base
insertions and deletions to the count matrix used for signature extraction.
87
Figure 4.8: Averaged per-substitution type per-context variability of mutation spectra
from MSI samples in COAD (top) and STAD (bottom) datasets. The averaged spectra
look extremely similar (0.99 similarity between the per-type per-context means) with most
of the variability coming from di↵erent fractions of C>T transitions in NCG contexts.
Corresponds to Supplementary Figure 5C in Meier et al. 2018.
Figure 4.9: AIC and RSS for detecting the number of signatures in COAD/STAD dataset.
Corresponds to Supplementary Figure 3A in Meier et al. 2018.
The number of signatures was chosen based on the saturation of both the Akaike
Information Criterion (AIC) (Akaike 1992) and the residual sum of squares (RSS). The
AIC is calculated as
AIC = 2k · (n+N)  2 logL,
where the first term reflects the number of parameters (k is the number of dimensions, n
is the number of signatures, N is the number of samples), and L denotes the maximised
model likelihood. AIC penalises the As the L would naturally increase with the addition
of parameters, we performed signature extraction for di↵erent ranks and chose the one
where AIC and also RSS decrease slows down to avoid oversegmentation (Figure 4.9).
4.4.2 Aetiology of extracted signatures
Based on this metric, we extracted 8 mutational signatures from the combined STAD
and COAD dataset (Figure 4.10). Many of these signatures matched to one or more
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COSMIC signatures, validating these results.
Figure 4.10: Mutational signatures including base substitutions and 1-bp indels derived
from the combined COAD-US and STAD-US data sets. Corresponds to Figure 3B in
Meier et al. 2018.
For three signatures out of eight, the fraction of mutations assigned to these signatures
was significantly higher in MMR-deficient cancers compared to proficient ones: for MMR-
1 (one-tailed t-test p-value = 4.7 · 10 55), MMR-2 (p-value = 1.1 · 10 11) and MMR-
3 (p-value = 6.0 · 10 12) (Figure 4.11). Of these, MMR-1 mostly resembled signature
20, MMR-2 - signature 15, and MMR-3 - signatures 21 and 26. Interestingly, only one
signature, MMR-1, carried all the indel information, which indicates that the profile of
base substitutions defined by this signatures is likely to be the typical distribution of
mutations stemming from replicative errors. This signature also showed high accuracy in
classification of MMR deficiency (AUC - the probability of a random MSI sample having
higher MMR-1 contribution than a random MSS sample - of 0.985).
Additional signatures identified in the tumour samples were characteristic of defects
in the proofreading domain of replicative polymerase " (“POLE”) (Alexandrov et al.
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2013b, Shinbrot et al. 2014). A signature characterised by C>T mutations in a CpG base
context, which is most likely to result from 5-meC deamination (Alexandrov et al. 2015),
was referred to as “Clock-1 (5meC)”. Signature “Clock 2” was present in the majority of
samples and likely reflected the background mutation rates (similar to COSMIC signature
5). “17-like” is a signature predominantly found in stomach cancers and highly similar to
COSMIC signature 17 (Alexandrov et al. 2013b), which was suggested to be associated
with some mutagenic exposure based on its transcriptional strand asymmetry (Tomkova
et al. 2018), and was recently found to closely resemble mutational spectrum of 5-fluoracil
treatment that depletes the pool of thymine triphosphates (Christensen et al. 2019).
Figure 4.11: Relative contribution of MMR-
1, MMR-2, and MMR-3 signatures to cancer
samples clinically classified as MSI or MSS.
Box plot with outliers shown as individual
filled circles. Corresponds to Figure 3C in
Meier et al. 2018.
Finally, we also identified a signature
predominantly consisting of T>A muta-
tions at CpG sites. This type of mu-
tations was present in high fraction in a
limited number of samples (all of which
were coming from the same sequencing cen-
tre), which indicated an artefactual nature
of this signature. Indeed, comparing the
base substitutions from the samples car-
rying over 50% of mutations assigned this
signature to the set of SNPs prevalent in
the human population (based on the db-
SNP database Sherry et al. 2001) showed
a high overlap: the mutational burden of
these samples consisted, on average, of 76%
(IQR 76-85%) SNPs, whereas for the rest of samples this number was much lower (18%,
with IQR 0-40%). In addition to that, we compared the ratio of coding and non-coding
SNPs (The 1000 Genomes Project Consortium 2015 ) and identified a much lower ratio of
non-synonymous to synonymous changes (0.8 with IQR of 0.68-0.88) across these samples
than expected for cancer variants (higher than 1, Ding et al. 2008), suggesting a germline
nature of these variants. Hence, this signature was referred to as “SNP” and considered
as an artefact.
By plotting a map of similarities between mutational spectra of all samples using
a t-SNE representation (Maaten and Hinton 2008), we have observed some distinctive
grouping of samples (Figure 4.12). A small yet well-defined cluster was formed by the
samples whose mutational spectra were defined by POLE signature (brown). Samples
dominated by Clock-2, 17-like or SNP signature tended to be located towards di↵erent
ends of the map (blue, pink and grey, respectively).
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Figure 4.12: Two-dimensional representation of the mutational spectra composition across
cancer samples. The size of each circle reflects the mutation burden. MSI samples are
highlighted by a bold, black outline. The color of segments reflects the signature compo-
sition. Corresponds to Figure 3A in Meier et al. 2018.
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The majority of MSI samples (circles with a black rim) concentrated in one cluster.
These samples carried diverse combinations of signatures MMR-1-3 and Clock-1, but
overall this group was mostly defined by the presence of the MMR-1 signature (green),
while the MMR-2 (purple) and MMR-3 (orange) signatures occurred in a small number
of tumours with high mutation burden. Moreover, the samples with the highest number
of mutations were in fact largely described by a single signature, possibly reflecting the
tendency of NMF to extract signatures from the most extreme cases first and then fit
other samples as a linear combination of these basis vectors.
4.4.3 Mismatch repair and its interactions with other processes
Individual signatures often represent the most extreme ends of the mutational spec-
trum; a typical tumour, however, is usually represented by a linear combination of multiple
processes. Given the di↵erent substrate specificities of MutS-↵ and MutS- , MMR-2 and
MMR-3 might reflect mutations arising by inactivation of unique subunits within these
heterodimers. However, investigating MMR gene mutations and methylation status in
these tumour samples, we observed few cases of MSH6, MSH3, PMS1 and MLH2 inacti-
vation, which often occurred in combination with inactivation of other MMR genes, but
did not correlate with the presence of any of the mutational signatures of interest.
In addition to the MMR-1-3 signatures, MSI samples were also partially composed
by signature Clock-1. The Clock-1 signature closely resembled COSMIC signature 1,
which was associated with 5-methyl-cytosine deamination and found to be correlated
with the age at the time of diagnosis across a range of cancer types (Alexandrov et al.
2013b,Alexandrov et al. 2015). Given that there was no di↵erence in the average age
between MMR deficient and proficient groups of samples, this signature should be con-
tributing a similar amount of mutations across these two groups. Since the average muta-
tional burden in MMR deficient samples is higher, relative contribution of Clock-1 to these
samples should be lower. However, we observed no change in the relative contribution,
and a 10-fold increase (one-tailed t-test p-value = 4.3 · 10 22) in the absolute number of
mutations assigned to Clock-1 in MMR deficient samples compared to proficient, similarly
to signatures directly associated with MMR status (Figure 4.13).
This relationship indicates that MMR deficiency increased the rate of mutations re-
sulting from spontaneous cytosine deamination. 5-methylcytosine can deaminate directly
to thymine and form a G:T mismatch. A number of studies have previously suggested
that mismatch repair can also detect and repair such mismatches as well as some alkylated
and oxidised nucleotides outside of the context of replication (Bellacosa 2001, Tricarico
et al. 2015b, Grin and Ishchenko 2016), performing so-called non-canonical mismatch
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Figure 4.13: Fold-change in the average number of mutations assigned to di↵erent sig-
natures in MSI samples compared to MSS samples. As expected, the number of POLE-
related mutations is higher in MSS samples as all POLE-deficient tumours are MSS. Apart
from MMR signatures, Clock-1 signature also contributes over 10 times more mutations
to MSI samples than to MSS. Corresponds to Figure 3E in Meier et al. 2018.
repair. Typically, deamination-caused G:T mismatches in non-dividing cells would be
processed by the base excision repair pathway. Notably, two of the COSMIC signatures
associated with MMR deficiency, signatures 6 and 20, are very similar (cosine similarity
0.97) and only di↵er in the contribution of C>T mutations in NCG context, which may
be reflecting a mixture between MMR mutational footprint and acceleration of cytosine
deamination-caused transitions.
4.4.4 Deletions and insertions in repetitive sequences
The distribution of 1-bp indels extracted alongside with the base substitution profile
for signature MMR-1 favours all of the bases equally (Figure 4.10), however in C. elegans
we observed a huge shift towards indels of A and T. Mainly, this is due to a di↵erence in
homopolymer composition between the two systems: homopolymers in C. elegans genome
mostly consist of poly-A and poly-T stretches (Figure 4.5), whereas the human exome
features equal amounts of homopolymers formed by either base (Figure 4.14). In total,
the human exome contained 976,390 homopolymer stretches between 4 and 43 bases in
length, with A/T homopolymers contributing only about 55% or all homopolymers. For
comparison, the C. elegans genome (with a length of 100 Mbps, approximately 3 times
larger than the human exome) contained 3,433,785 homopolymers of which 94% were A/T
stretches.
When adjusted for the di↵erence in the available span of homopolymers, the frequen-
cies of indels of A and T in C. elegans mlh-1 and pms-2 knockouts were still about 4
times higher than those of G and C (Figure 4.17). This indicates intrinsic di↵erences in
the processing of deletions and insertions of single bases.
Overall, 82% (25,093 out of 30,561) indels in the human dataset were single-base indels,
and the majority of these occured in homopolymer runs: 69-72% of 1-bp indels/sample
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Figure 4.14: Distribution of homopolymeric sequences in the human exome. Corresponds
to Supplementary Figure 4A in Meier et al. 2018.
in the COAD dataset and 91-93% 1-bp indels/sample for STAD (Figure 4.15).
The total amount of indels per homopolymers relative to the number of homopolymers
in human data was much lower than that in C. elegans, hence, analysing the frequencies of
indels per homopolymers of di↵erent length did not yield stable results for homopolymers
longer than 9 bases.
(a)
(b)
Figure 4.15: Indels in (blue) and outside (red) of homopolymeric regions per sample in
(a) COAD and (b) STAD dataset. Corresponds to Figure 4B in Meier et al. 2018.
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4.5 C. elegans experimental MMR deficiency signa-
tures correspond to signature MMR-1 in cancers
MMR mutant experiments in C. elegans allowed us to extract the mutational signa-
tures of mlh-1, pms-2 and pole-4; pms-2 mutants. Having this data, we aimed to check
how comparable these signatures are to the one active in cancer genomes. Using the
trinucleotide frequency correction introduced in Chapter 2, we brought the C. elegans
signatures into accordance with the human exome (using the counts from Rosenthal et al.
2016) (Figure 4.16). Indel fractions were adjusted using the ratios between the numbers
of homopolymers built by respective bases in the C. elegans genome and in the human
exome.
Figure 4.16: Original and humanised versions of C. elegans experimental signatures of
mlh-1, pms-2 and pole-4; pms-2 knockouts. Corresponds to Figure 4A in Meier et al.
2018.
Of the three human MMRD-associated de novo signatures, only MMR-1 displayed
similarity to the C. elegans MMR substitution patterns with cosine similarities of 0.84
and 0.81 to pms-2 and mlh-1 signatures, respectively (Table 4.1, Figure 4.17). Most of
the discrepancy between the C. elegans MMR deficiency spectra and MMR-1 was coming
from di↵erent levels of CpG>TpG mutations and change in frequency of ATT>AAT
mutations.
C. elegans is lacking 5-methyl-cytosine (Greer et al. 2015). Hence, there is no spon-
taneous deamination, which explains much lower levels of C>T mutations at CpG sites.
As 5-meC deamination appears to constitute a distinct mutational process, which is ex-
acerbated by MMRD, it is likely that these mutation types define residual mutations
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mlh-1 pms-2 pole-4;
pms-2
Clock 1 0.18 0.17 0.15
Clock 2 0.36 0.32 0.30
POLE 0.19 0.21 0.15
17-like 0.23 0.21 0.13
MMR-1 0.81 0.85 0.63
MMR-2 0.36 0.43 0.42
MMR-3 0.62 0.56 0.75
SNP 0.52 0.47 0.55
Table 4.1: Cosine similarity values for the comparison between humanised C. elegans
derived MMR signatures and human de novo signatures (adjusted to human whole-exome
trinucleotide frequencies).
Figure 4.17: Signature MMR-1 and humanised mutational signatures of MMR deficiency
in C. elegans.
rates which could not be attributed exactly by NMF. If these contexts were excluded,
MMR-1 would show similarities of 0.92 to pms-2 knockout signature, and 0.90 to mlh-1
knockout signature. The human exome and the C. elegans genome also have a di↵erent
composition of homopolymer types. The amount of poly-A and poly-T in the C. elegans
genome is more than 6 times higher despite a comparable size (30 Mbps of the human
exome, and 100 Mbps of the worm genome). Consequnently, the probability of more than
one indel per homopolymer or of clashes between A-homopolymers and T-homopolymers
is higher. Detection of indels at such positions is di cult since a read alignment with
mismatches would be preferred over alignment with multiple gaps, and many indels in
homopolymers are likely to be misinterpreted as a base substitution at the end of the
respective homopolymer.
Having multiple experimental replicates allowed us to measure the variability of exper-
imental signatures in C. elegans. In order to assess the variability of cancer-derived signa-
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tures, we performed signature extraction for each jack-knife (leave-one-out) bootstrapped
sample of the COAD/STAD dataset. Due to the presence of correlated processes (such as
MMR deficiency and 5-meC deamination), computational signature decomposition may
be unstable and produce di↵erent signatures. Hence, to quantify the corresponding change
in similarity between the MMRD signatures, we calculated the cosine similarities between
a random draw from 95% confidence intervals of C. elegans signatures and a randomly
selected jack-knife draw from the MMR-1 signature (selected as the solution closest to
the original MMR-1 signature in each subsample) (Figure 4.18).
Figure 4.18: Distribution of similarities be-
tween humanised mlh-1 signature (top) or
pms-2 signature (bottom) and human de
novo signature MMR-1 with and without
NCG>NTGmutations. Corresponds to Sup-
plementary Figure 6 in Meier et al. 2018.
Stability assessment of the similarity
between C. elegans and human signatures
shows that the similarity between human-
ised MMRD patterns and MMR-1 sig-
natures varies substantially (inter-quantile
range (IQR) of 0.66 to 0.76 for mlh-1 and
0.70 to 0.80 for pms-2, respectively). Con-
sistent with the assumption that dissection
of MMRD and 5-meC deamination signa-
tures may introduce additional variance,
we observed that the range of similarity
values shrinks as soon as we exclude C>T
at CpG sites (IQR of 0.87-0.90 and 0.90-
0.92, respectively) (Figure 4.18, red dashed
line - the similarity for point estimates).
These results support our conclusion about
the signature MMR-1 being the closest re-
flection of the real MMRD signature con-
sisting of mutations generated by the errors of replicative polymerases.
None of the human signatures showed notable similarity to the pole-4; pms-2 muta-
tion pattern. It may be because the dataset did not contain a sample with comparable
concurrent defects of POLE4 and PMS2, or due to actual di↵erences in the e ciency and
proofreading abilities between human and C. elegans polymerase ", however this question
will require further investigation.
4.6 Discussion
In this chapter, I characterised the mutational signatures of mismatch repair deficiency
across colorectal and stomach cancers and compared those to the mutational landscapes
97
associated with MutL MMR deficiency in C. elegans. MMR deficiency was of special
interest as it led to the highest number of mutations and the most distinctive phenotype
compared to other DNA repair deficiencies in our screen, surpassed only by that of the
pole-4 ; pms-2 double mutants, which exhibited 2-3 fold higher mutation rates. In addition
to high substitution burden, MMR deficiency was associated with a high number of small
indels in repetitive regions in both C. elegans and human cancers, consistent with the
concept of polymerase slippage on homopolymer stretches, which should normally be
repaired by the MMR system.
Out of the signatures we found to be associated with microsatellite instability in cancer
cells, only one signature (MMR-1) was shown to be related to the experimental signatures
of MMR deficiency found in C. elegans mlh-1 and pms-2 mutants. Taking into account
the controlled nature of the C. elegans experiment, we postulated that MMR-1 might in
fact reflect the underlying “basal” mutational process of DNA replication errors repaired
by MMR conserved between species. Consistent with this, we find that MMR-1 showed
high correlation with MSI status, and performed well in tumour classification (P-value
4.7 · 10 55 , AUC 0.985) into mismatch repair-deficient and proficient. Similarly, another
study using human MLH1 /  organoid cells identified a mutational profile similar to
that of MMR-1 (Drost et al. 2017).
The distribution of signature contributions indicated mixed origins of the other two
MSI-associated signatures which tend to be concentrated in the most hypermutated sam-
ples. These signatures might be caused by a defect in another DNA repair gene, which
led to an amplification of damage by replicative polymerases, or to a defect in replicative
polymerase itself which contributed to the change of error profile, similar to pole-4 ; pms-2
double mutants in C. elegans experiments or COSMIC signature 14, which was found to
be associated with a concurrent loss of MMR and POLE proofreading ability (Haradhvala
et al. 2018).
A particular value of comparison between C. elegans experiments and human data
was coming from the absence of 5-cytosine methylation in C. elegans, which allowed us to
extract an MMRD signature free from confounders. The most common MMRD signature
found in cancer datasets, MMR-1, included an additional contribution of unrepaired 5-
meC deaminations leading to C>T changes coming from the secondary role of MMR
machinery in detecting and repairing the mismatches they cause. This part of human
MMRD spectrum varies significantly depending on the age, tissue type and activity of
other processes, which can cause ambiguities in unsupervised signature extraction. Any
other human model would be prone to a similar issue. Due to the absence of such processes
in C. elegans MMR knockouts, we could extract and compare the basic spectrum of
mutations induced by MMR deficiency, which can be useful both for studying the error
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profile of replicative polymerases and for diagnostics of MMR across individuals.
The similarity of the MMRD signatures across species also confirmed that the func-
tionality and context-specific error rates of DNA polymerases " and   are well conserved
between human and C. elegans. In this and previous chapters, I demonstrated how dif-
ferent DNA repair deficiencies are manifested in C. elegans genome, and confirmed the
applicability of these insights to cancer data. The DNA repair deficiency, however, does
not create damage on its own, the associated mutations have to result from another pro-
cess which causes damage to the DNA. In the next chapter, I will consider a range of DNA
damaging agents and study their mutational signatures in C. elegans and in humans.
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Chapter 5
Experimental signatures of
genotoxin exposures
5.1 Introduction
In the previous chapter, I demonstrated the ability of the C. elegans experimental
screen to inform the mutational signature analysis in MMR deficient gastrointestinal
cancers. DNA repair deficiencies were found to be a driving force in many cancers. Still, it
is worth remembering that compromised DNA repair is not mutagenic by itself, but rather
exacerbates the mutagenicity of endogenous or exogenous DNA damaging processes. In
case of mismatch repair deficiency, it is the infidelity of DNA replication that causes most
of the mutations observed in MMR deficient tumours. Many cancers have been associated
with prolonged exposure to exogenous mutagens such as tobacco (Gandini et al. 2008),
UV-light (Armstrong, Kricker, and English 1997) and ionising radiation (Shah, Sachs,
and Wilson 2012, Health and Services 2016), which increases the probability of acquiring
oncogenic mutations.
In tumours, exposures to genotoxins typically occur very early in the tumour devel-
opment timeline (Stratton, Campbell, and Futreal 2009). Consequently, the mutations
produced by these exposures are shared by a large number of tumour cells, and their spec-
trum creates a strong signal. The presence of a signature associated with a mutagenic
exposure can serve as a molecular confirmation of the exposure, enhancing the epidemi-
ological studies, or reveal previously unknown carcinogens (Helleday et al. 2008). This
information can be important for cancer prevention: according to statistics on already
identified carcinogens, lifestyle factors and infectious agents, about 40% of cancer could
have been prevented by reducing or eliminating risk factors (Vineis and Wild 2014).
Apart from the potential causes, mutational signatures of genotoxins can also indicate
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the origin of a tumour. Detection of cancer drug-associated signature in secondary tu-
mours can help to distinguish between relapses and a de novo disease (Van Hoeck et al.
2019). Similarly, the presence of a signature associated with a mutagen that only a↵ects
one tissue or organ in a non-typical tumour – e.g. finding mutations induced by UV-light,
which mostly a↵ects the skin, in a lung tumour – strongly suggests a metastatic nature
of such tumour (Liu et al. 2017b).
Studying genome-wide distributions of mutations induced by various genotoxins also
provides insights into the mechanisms and specificities of their interaction with the DNA.
Analysis of genome-wide signatures of mutations induced by di↵erent polycyclic aromatic
hydrocarbons (PAHs) provided the basis to infer the diol-epoxide pathway of metabolic
activation as the most likely (Kucab et al. 2019).
In this chapter, I will present a comprehensive analysis of mutation rates across di↵er-
ent kinds of genotoxins, and consider the mechanistic details of mutation acquisition upon
these exposures. To underline the significance of the signatures obtained in model systems
to cancer research, I will compare the experimental signatures derived from C. elegans
screen to mutational spectra observed in experiments conducted in di↵erent organisms
and those detected in human cancers.
Contributions
As discussed in Chapter 2, the data was generated by Bettina Meier and colleagues
from Anton Gartner’s group at the University of Dundee. All downstream bioinformatics
analyses were performed by me. A brief overview of the signatures of genotoxins and
their comparison to mutational signatures of genotoxins in human cells and cancer was
submitted for publication as a part of Volkova et al. 2019.
5.2 Experimental signatures of mutagenesis upon geno-
toxin exposure
To enrich the understanding of mutagenesis induced by di↵erent kinds of genotoxins,
we exposed both wild-type and DNA repair-deficient C. elegans to 12 mutagenic agents.
The genotoxins used in the screen were chosen such that a wide range of DNA damage
could be observed. The list of mutagens we studied includes irradiations, alkylating
agents, crosslinkers and agents inducing bulky adducts.
In particular, we investigated the mutational signatures of UV-light by using a source of
simulated UV-B radiation, as well as the spectra resulting from exposures to aflatoxin-B1,
a naturally occurring mycotoxin produced by certain species of fungi capable of inducing
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liver cancers (Kew 2013), and aristolochic acid – a phytochemical associated with kidney
damage and elevated rates of urothelial cancers (Arlt, Stiborova, and Schmeiser 2002).
We included several genotoxins used for chemotherapy treatment such as cisplatin, hy-
droxyurea (also known as hydroxycarbamide), Mitomycin C, and both  - and X-rays to
study the mutational properties of ionising radiation. In addition, we enhanced the screen
using three mutagenic substances commonly used in genetics: monofunctional alkylating
agents ethyl methanesulfonate (EMS), dimethyl sulfate (DMS) and methyl methanesul-
fonate (MMS).
Apart from inducing a diverse and robust range of mutations, the mutagen exposure
should still allow producing viable progeny, which will be used to collect DNA for se-
quencing. Hence, the exposure dose had to be adjusted not to cause severe mortality in
C. elegans. Consequently, the genomic DNA of the adult progeny derived from single
fertilised eggs was sequenced. To ensure that the progeny was able to reach the three-day
adulthood stage, the highest dose for each exposure experiment was chosen such that no
more 25% reduction in the viability of embryos occurred.
5.2.1 Signatures of alkylating agents
In its simplest form, DNA adducts are methyl or ethyl groups, and three common
agents of alkylation are methyl methanesulfonate (MMS) and dimethylsulfonate (DMS),
both leading to methylation, and ethyl methanesulfonate (EMS), leading to ethylation of
DNA bases. Generally, these alkylating agents are not considered to be environmental
contaminants. However, there have been reports of accidental EMS contamination of
Viracept – film-coated tablets used as an antiviral medication (Gerber and Toelle 2009),
and evidence of occupational DMS exposure in the chemical industry, where the reagent
is being used to alkylate organic substrates (Rippey and Stallwood 2005).
EMS
The substance that yielded the highest number of mutations was EMS – a monofunc-
tional alkylating agent with a chemical formula C3H8SO3 (Figure 5.1a). EMS is one of
the most commonly employed mutagens for randomly introducing mutations into genomes
during genetic screens. It was shown to be mutagenic in many systems from viruses to
mammalian cells, including T4 bacteriophages, D. melanogaster, and C. elegans, where it
was used to perform unbiased genetic screens (Hartman et al. 2014, Huang 1981, Drabløs
et al. 2004).
EMS mostly alkylates guanines at the O6 position leading to the formation of O6-
alkylguanines (Figure 5.1b). Due to an alkyl group on the oxygen atom, O6-alkylguanine
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Figure 5.1: EMS mutagenesis. (a) Chemical structure of EMS molecule. (b) Modification
of guanine upon EMS exposure turns it into a O6-ethylguanine, which can pair with
thymine, leading to G:C>A:T mutations. Adapted from Klug and Cummings 2006. (c)
Experimental mutational signature of EMS in C. elegans.
does not form a triple bond with cytosine and is prone to be paired with thymine, which
can result in C:G>T:A transition (Brookes and Lawley 1961). Many of these mutations,
when occurring in coding regions, generate premature stop codons, leading to strong
loss-of-function mutations (Flibotte et al. 2010). This base modification was previously
described to account for 2-3% of ethylation upon EMS treatment. O6-alkylguanines are
typically repaired by direct repair enzymes, namely the O6-alkylguanine alkyltransferases
(AGT1 in C. elegans or MGMT in humans), which remove the alkyl group without altering
the base.
The rest of the damage incurred by EMS are non-mutagenic lesions such as N7-
alkylguanine, which does not directly lead to mutagenesis as it does not a↵ect guanine to
cytosine base pairing. However, N7-alkylation makes guanine more prone to depurination,
creating additional AP-sites (Boysen et al. 2009).
In agreement with other model systems, EMS mostly caused base substitutions in wild-
type C. elegans. On average, exposure with 10 mM of EMS led to about 230 mutations
per genome in the progeny, most of which were C>T transitions with a small preference
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for TpCpC and TpCpT contexts (Figure 5.1c).
MMS and DMS
In contrast to EMS, exposure to alkylating agents MMS and DMS yielded a di↵erent
mutational spectrum. MMS is a monofunctional alkylating agent with a chemical for-
mula C2H6O3S (Figure 5.2a). While having a di↵erent chemical structure (Figure 5.2a,
C2H6O4S), DMS causes the same kinds of DNA damage as MMS (Figure 5.2b). DMS is
a highly mutagenic methylating agent widely used in the chemical industry.
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Figure 5.2: DMS and MMS mutagenesis. (a) Chemical structure of MMS (top) and DMS
(bottom) molecule. (b) Most common modifications of DNA bases upon DMS/MMS ex-
posure: N3-methyladenine, N7-methylguanine, O6-methylguanine. Adapted from Chadt
et al. 2008. (c) Experimental mutational signatures of MMS and DMS in C. elegans.
Both MMS and DMS a↵ect DNA by methylating their bases. Up to 82% of MMS-
induced adducts are expected to be N7-meG (which is not mutagenic), accompanied by
11% of N3-meA, which lead to T>N mutations and a small amount (0.6%) of O6-meG
(Wyatt and Pittman 2006). The rest of damage is comprised of less impactful adducts
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(N1-meA, N7-meA, N1-meG, N3-meG, N3-meC, O2-meC, N3-meT, O2-meT, and O4-
meT). The distribution of DMS damage is similar but not identical: it typically introduces
N7-meG in about 61.5% of cases, N3-meA in 38.2%, and O6-meG in the remaining 0.3%
of cases (Chadt et al. 2008).
In C. elegans, both agents caused nearly identical mutation spectra (with cosine sim-
ilarity of 0.98) characterised by T>A and T>C substitutions (Figure 5.2c). Evidence
suggests that the T>A and T>C changes might result from an error-prone bypass of
N3-methyladenine, a lesion associated with stalling of replicative polymerases (Fronza
and Gold 2004). As described above, the rare alkylation of O6 in guanines is equally
mutagenic due to O6-methylguanine being able to mispair with thymidine (Brookes and
Lawley 1961).
Interestingly, the ratio of the damage probabilities is di↵erent from the observed mu-
tation ratio: for both MMS and DMS, 85% of the damage consisted of T>N changes,
whereas based on the reported frequencies of the meA and meG adducts, it should have
been 95% for MMS and over 99% for DMS. This indicates a di↵erence in repair e cacy of
di↵erent bases: seemingly, the probability of correctly bypassing N3-meA is higher than
the probability of repairing O6-meG before it causes a C>T mutation during replication.
On average, MMS caused 218 mutations per 1 mM per genome, while DMS demon-
strated a lower rate of only 26 mutations per median unit dose 0.1 µM (Figure 5.2c),
implying a di↵erent reactivity of introducing DNA methylation, lower rates of cellular
uptake, or higher rate of metabolism.
5.2.2 Agents introducing bulky DNA adducts
Various genotoxic substances can generate highly reactive intermediates upon metaboli-
sation. These molecules are capable of covalently bonding to the DNA resulting in bulky
adducts to the nucleotides, which can distort the spatial conformation of the double
helix. Such damage is typically repaired by the nucleotide excision repair system, and
unrepaired adducts can lead to base substitutions as a result of error-prone bypass, but
also replication stalling (Minca and Kowalski 2010).
Aflatoxin B1
Aflatoxin B1, a mycotoxin produced by a fungus Aspergillus flavus, has been associated
with the development of liver cancers in populations such as Sub-Saharan and South
African, or South-East Asian where the food is often stored in hot and humid conditions
and may be contaminated with aflatoxin (Kew 2013).
Aflatoxin B1 requires metabolic activation: an active form of this substance, exo-
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AFB1-8,9-epoxide, can bind to the N7 position of guanine residues forming 8,9-dihydro-
8-(N7-guanyl)-9-hydroxyaflatoxin-B1 guanosine adducts (AFB1-N7-dG, Figure 5.3a). If
left unrepaired, these adducts can undergo spontaneous depurination, which would usually
cause a G:C>A:T change if unrepaired, or rearrange to an open-ring AFB1-formamidopy-
rimidine (AFB1-FAPY) adduct leading to G:C>T:A transversions upon replication due
to error-prone bypass by polymerase ⇣ (Lin et al. 2014), each causing characteristic peaks
in the base substitution spectrum (Figure 5.3b). If the translesion synthesis is delayed, a
stalled replication fork can result in single- or double-strand breaks, generating medium-
size deletions via polymerase ✓ mediated end-joining (Roerink, Schendel, and Tijsterman
2014, Larsen et al. 2017).
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Figure 5.3: Aflatoxin-related mutagenesis. (a) A scheme of aflatoxin modification: afla-
toxin is metabolised to epoxide, which creates AFB1-N7-dG lesions; they can further
undergo depurination and cause a G>A change, or transform into AFB1-FAPY causing
a G>T mutation. (b) Experimental mutational signatures of aflatoxin B1 in C. elegans.
Aflatoxin has been shown to cause similar kinds of DNA damage and mutations in
C. elegans cells as well as other model systems (Leung et al. 2010, Meier et al. 2014,
Huang et al. 2017a), indicating conserved metabolic activation and repair patterns in
humans, mice and C. elegans. Bulky adducts created by aflatoxin-B1 led to a mutational
spectrum consisting mostly of C>A and C>T mutations in agreement with its adducts
being concentrated on guanines (Figure 5.3b), with a small fraction of 50-400 bp long
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deletions. Treatment with 1 µM of aflatoxin caused on average 4 mutations in wild-type
C. elegans.
Some properties of aflatoxin mutagenesis across DNA repair mutants were already
studied in Meier et al. 2014.
Aristolochic acid
Aristolochic acid (AA) is a natural nitro-compound associated with Balkan Endemic
Nephropathy, a chronic renal disease frequently leading to upper urothelial cancer (Arlt,
Stiborova, and Schmeiser 2002, Poon et al. 2015), and also hepatocellular carcinomas (Ng
et al. 2017). AAs, the most abundant of which is AAI (Figure 5.4a), are phytochemicals
produced by Aristolochia clematitis, the European birthwort, a weed growing in wheat
fields leading to the contamination of baking flour. Other members of Aristolochia family
are commonly used in traditional Chinese medicine (Tian-Shung et al. 2005).
(a)
C>A C>G C>T T>A T>C T>G MNV Deletions Complex indels Insertions
Structural
 Variants
0
1
2
3
Nu
m
be
r o
f m
ut
at
ion
s
Effects for AristolochicAcid, 18.1 mutations on average per 10 muM
2 
bp
ov
er
 2
 b
p
1 
bp
 (i
n 
re
pe
at
s)
1 
bp
 (n
on
−r
e p
.)
2−
5 
bp
 (i
n 
re
pe
at
s)
2−
5 
bp
 (n
on
−r
ep
.)
6−
50
 b
p
ov
er
 5
0 
bp
1−
49
 b
p
50
−4
00
 b
p
1 
bp
 (i
n 
re
pe
at
s)
1 
bp
 (n
on
−r
e p
.)
2−
5 
bp
 (i
n 
re
pe
at
s)
2−
5 
bp
 (n
on
−r
ep
.)
6−
50
 b
p
ov
er
 5
0 
bp
T a
nd
em
 d
up
.
De
let
ion
s
In
ve
rs
ion
s
Co
m
ple
x e
ve
nt
s
Tr
an
slo
ca
tio
ns
In
te
rc
h r
. e
ve
nt
sACGT
A C G T3’ base
5’ base ACGTACGTACGT ACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGT
Fo
ldb
ac
ks
(b)
Figure 5.4: Aristolochic acid-induced mutagenesis. (a) Chemical structure of AA-I and
its reactive metabolite aristolactam, which can cause adducts to purines. Adapted from
Sidorenko et al. 2012. (b) Experimental mutational signatures of aristolochic acid I in C.
elegans.
Upon metabolisation, AA is enzymatically reduced to form several carcinogenic in-
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termediates. Among others, it produces aristolactam which forms adducts on the exo-
cyclic amino groups of deoxyguanosine and deoxyadenosine, dG-AAI and dA-AAI (Pfau,
Schmeiser, and Wiessler 1990, Figure 5.4a). Of these, adenine adducts are 5 to 10 times
more abundant than the guanine ones and also more mutagenic: both of them mostly
lead to a misincorporation of an adenine (Attaluri et al. 2009). dA-AA causes A:T>T:A
changes, which are usually repaired by TC-NER and are more persistent in untranscribed
regions (Sidorenko et al. 2012). This profile was first measured by base changes in the
p53 locus of urothelial cancers associated with AA and more recently was confirmed by
next-generation sequencing on a genome-wide scale (Poon et al. 2013, Poon et al. 2015).
Mutational signature of aristolochic acid (AA) exposure in C. elegans showed a char-
acteristic T>A substitution spectrum with a low amount of C>N changes, which was
about 5 times lower than the amount of T>N substitutions in agreement with the re-
ported frequencies of dA and dG adducts, indicating similar mutagenicity of each lesion.
In addition, we observed a high prevalence of 50-400 bp long deletions and complex in-
dels (Figure 5.4b), which are likely to arise due to MMEJ repair of double-strand breaks
(DSBs) caused by a delayed or failed translesion synthesis similar to aflatoxin-induced
mutation spectra. On average, exposure with 10 µM of AA led to approximately 10
mutations per C. elegans genome.
5.2.3 Crosslinking agents
Cisplatin
Cisplatin (Figure 5.5a) is a widely used chemotherapy drug, mostly due to its crosslink-
ing properties, which stall replication and lead to apoptosis of cycling cells in which the
damage cannot be repaired su ciently fast. Cisplatin molecules can create intra- and
inter-strand crosslinks between N7 positions of purines, as well as platinum mono-adducts
or DNA-protein crosslinks (Figure 5.5b). Over 90% of the lesions induced by cisplatin are
intra-strand crosslinks: on average, two-thirds of them are GpG crosslinks, one-quarter –
ApG lesions, and the rest are GpNpG crosslinks (Cohen and Lippard 2001).
Intra-strand crosslinks and DNA-protein crosslinks are usually repaired by the NER
and Fanconi Anaemia pathways, whereas monoadducts can also be repaired by BER.
Hence, most of the mutagenesis induced by genotoxin is caused by polymerase ⇣-dependent
translesion synthesis over the intrastrand crosslinks, which leads to single-base and dinu-
cleotide substitutions (Noll, Mason, and Miller 2006).
In C. elegans, cisplatin exposure induced C>A transversions in a CpCpC and CpCpG
context as well as deletions and structural variants (Figure 5.5b, Boot et al. 2018, Meier
and Gartner 2014). A high number of dinucleotide substitutions at the sites of intrastrand
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Figure 5.5: Cisplatin mutagenesis. (a) Chemical structure of cisplatin molecule. (b) Dam-
age types caused by cisplatin. Adapted from Rabik and Dolan 2007. (c) Experimental
mutational signature of cisplatin in C. elegans.
crosslinks were observed, mostly of CT>AC and TG>GT types (Figure 5.6), consistent
with previous reports (Meier et al. 2014). In cisplatin-treated cancer cell lines, equal
amounts of CC>AD (where D stands for A, G or T) and CT>AM (M = A,C) dinu-
cleotide substitutions were observed (Boot et al. 2018), potentially indicating di↵erent
repair capacities for GpG and ApG crosslinks in C. elegans and human cell lines. How-
ever, some reports suggest that CC>AA (GG>TT) mutations are wide-spread across
cancers, correlate with the age of diagnosis and can arise in normal human cells (Alexan-
drov et al. 2018). Interestingly, the computationally derived DNV signature found to be
associated with treatment with platinum drugs in cancers was on two-thirds comprised of
CT>AA, and one-third of CT>AC, indicating that when the damage occurs in the same
dinucleotide, the repair can be di↵erent (Alexandrov et al. 2018).
In addition, we observed a high proportion of deletions between 2 and 50 bp in size
and occasional large deletions in the mutational spectrum generated by cisplatin exposure
in C. elegans (Figure 5.5c). These are likely to stem from the homology-directed repair
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Figure 5.6: Distributions of dinucleotide substitutions for mitomycin C, UV, cisplatin and
radiation exposures.
of interstrand crosslinks (Jonnalagadda, Matsuguchi, and Engelward 2005).
Mechlorethamine
Mechlorethamine, or chlormethine, is an analogue of mustard gas. It is a bi-functional
alkylating agent capable of introducing interstrand DNA crosslinks by reacting with N7
end of two guanines from opposite strands. Due to its crosslinking abilities, mechlorethamine
is used as a chemotherapy drug for the treatment of Hodgkin lymphomas (Engert, Wolf,
and Diehl 1999).
Similar to cisplatin, mechlorethamine (Figure 5.7a, C5H11Cl2N) can create crosslinks,
especially interstrand crosslinks between guanines in CpGpN and GpCpN contexts, and
monofunctional adenine and guanine adducts (Povirk and Shuker 1994). Nucleotide exci-
sion repair e ciently removes the adducts, but is not as e cient in resolving interstrand
crosslinks: if not repaired, interstrand crosslinks will be repaired by homologous recombi-
nation repair which can result in a loss of genetic information (Jonnalagadda, Matsuguchi,
and Engelward 2005).
Consistent with previous reports (Wijen, Nivard, and Vogel 2000, Meier et al. 2014),
10 mM of mechlorethamine caused on average 15 mutations in wild-type C. elegans, most
of which were small deletions between 2 and 50 bp in length (Figure 5.7c). Similar to
cisplatin, they can be caused by the homology-directed repair of interstrand crosslinks,
which was shown to have a higher chance of deletions and insertions compared to the HR
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repair of spontaneous DSBs (Jonnalagadda, Matsuguchi, and Engelward 2005).
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Figure 5.7: Mechlorethamine and mitomycin mutagenesis. (a) Chemical structure of
mechlorethamine molecule. (b) Chemical structure of mitomycin C molecule. (c) Exper-
imental mutational signatures of mechlorethamine and mytomycin C in C. elegans.
Mitomycin C
Another crosslinking drug used in chemotherapy, mitomycin C, demonstrated a muta-
tional spectrum almost exclusively defined by dinucleotide substitutions (Figure 5.7c). Its
main mechanism of action mostly introduces N7-guanine adducts and crosslinks between
guanine residues of 5’-CpG-3’ sequences through the minor groove of DNA. Previously,
mitomycin C was shown to cause deletions containing CpG dinucleotides in C. elegans
(Tam, Chu, and Rose 2016), however, our experiments did not yield a high number of
deletions.
Crosslinks between the neighbouring guanines which are on the same strand are prone
to result in dinucleotide substitutions due to error-prone bypass during replication (Noll,
Mason, and Miller 2006). In wild-type C. elegans, 1 mM of mitomycin C yielded about 33
mutations (Figure 5.7c), with a high prevalence of CC>AA and CC>AG changes (Figure
5.6).
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5.2.4 Electomagnetic radiation
Highly energetic electromagnetic radiation interacts with the atoms in the DNA and
other molecules in the cell, introducing DNA damage and inducing oxidative damage.
The severity and proportions of damage caused by electromagnetic waves vary depending
on the wavelength. Therefore UV (  = 10-400 nm), X- (0.01-10 nm) and gamma (  <
0.01 nm) are potent mutagens and known carcinogens.
UV
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Figure 5.8: UV mutagenesis. (a) Types of UV exposures and DNA damage. (b) Experi-
mental mutational signatures of simulated UV-B radiation in C. elegans.
Sunlight exposure is one of the most common cancer risk factors. About 3% of the
solar irradiation at ground level covers the UV spectrum ranging from 400 nm (UVA)
over 315 nm (UVB) to 280-100 nm (UVC; Figure 5.8a). Interaction of UV-light with
DNA causes direct damage consisting of pyrimidine dimers (CPDs) and 6-4 pyrimidone
photoproducts (6-4PPs). Whole-genome assessment of UV damage distribution in yeast
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reported over 70% of CPDs occurring at TpT dinucleotides, followed by TpC and CpT
(about 12% each), with only 5% occurring at CpCs, whereas 6-4PPs were, in contrast,
enriched at CpTs, with the rest almost equally divided between TpT and CpC (Bryan
et al. 2014). In humans, CPDs occur 3 to 5 times more frequently than 6-4PPs (Cadet
and Douki 2018).
Typically, the lesions classified as direct damage are repaired by nucleotide excision
repair, or replicated over by translesion synthesis polymerases. Polymerases ⌘ can bypass
CPDs and tends to insert an adenine opposite a damaged base (Matsuda et al. 2001),
thus generating the characteristic C>T and CC>TT mutations while correctly bypassing
the most abundant TpT dimers (Ikehata and Ono 2011). 6-4PP is a more helix-distorting
lesion, and requires a joint e↵ort of two or more TLS polymerases: polymerases ⌘ or ◆ can
insert the first base, which for pol ⌘ is often a G opposite a 3’ T (Johnson et al. 2001),
and polymerase ⇣ extends to the second base (Yoon, Prakash, and Prakash 2010), which
can potentially generate a T>C mutation.
Additionally, UV can cause indirect damage (or ’dark’ UV damage) by inducing re-
active oxygen species, single-strand breaks (SSBs) and depurination of bases leading to
abasic sites (Rastogi et al. 2010, Figure 5.8a).
Exposure to simulated UV-B radiation in C. elegans experiments showed characteris-
tic C>T transitions in a YpTpH context (Y=C/T; H=A/C/T), and also an unexpected
prevalence of T>A transversions in a TpTpA context and T>C transitions in TpTpN con-
text (Figure 5.8b). As we used only UV-B for this experiment, we expected more 6-4PPs
to be generated (Cadet and Douki 2018). 6-4PPs in C. elegans are also repaired slower
than in humans (Hartman et al. 1989), and have a higher chance to remain unrepaired
until cell division. Hence, a high fraction of T>C mutations can be stemming from the
error-prone bypass of 6-4PPs by polymerase ⌘. These changes were further exaggerated
in NER deficient mutants (which will be discussed in detail in the next chapter).
In addition, a large fraction of UV-generated mutations across all genotypes were
dinucleotide substitutions, in particular, CC>TT/AT (Figure 5.6), similar to the UV-
associated DNV spectrum inferred from cancers (Alexandrov et al. 2018). In total, UV-B
exposure with the energy of 100 J/m2 led to approximately 8 mutations per genome.
Moreover, C>T mutations (but not T>C) induced by UV exposure demonstrated
a transcriptional strand bias, with 10% more C>T mutations happening on the cod-
ing strand compared to the template strand, similar to the bias calculated for the UV-
associated signature in melanomas (Alexandrov et al. 2013b). This confirms the high
contribution of transcription-coupled NER to the repair of UV-induced CPDs.
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Ionising radiation
X-rays and   irradiation are potent mutagens, which are also frequently used in cancer
treatment due to their DNA damaging properties. The ability to direct the exposure using
irradiating machines allows focusing the maximal energy of the irradiation precisely at
the tumour site while minimising the exposure for healthy tissues. The energy of X- and
 -rays is su cient to ionise atoms in a cell, inducing oxidative damage, and to introduce
single- and double-strand breaks (SSBs, DSBs) in the DNA, which can result in single
and dinucleotide substitutions, but also deletions and structural variants (Willers, Dahm-
Daphi, and Powell 2004).
Both X-rays and  -rays are electromagnetic waves composed of high-energy photons,
but stems from di↵erent sources:   irradiation is emitted when a radioactive substance
undergoes decay whereas X-rays are generated by the device that excites electrons (Baskar
et al. 2012). Beta-irradiation, or electron beams, are also used in cancer therapy. Elec-
tron beams have higher LET (linear energy transfer) and stronger biological e↵ects than
photons, but are also more expensive in use, and are typically applied in treatment of
radioresistant tumours (Baskar et al. 2012).
(a)
C>A C>G C>T T>A T>C T>G MNV Deletions Complex indels Insertions
Structural
 Variants
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
Nu
m
be
r o
f m
ut
at
ion
s
Effects for Gamma and X−rays, 51.5 and 10.7 mutations on average per 100 Gy
Gamma-rays
X-rays
2 
bp
ov
er
 2
 b
p
1 
bp
 (i
n 
re
pe
at
s)
1 
bp
 (n
on
−r
e p
.)
2−
5 
bp
 (i
n 
re
pe
at
s)
2−
5 
bp
 (n
on
−r
ep
.)
6−
50
 b
p
ov
er
 5
0 
bp
1−
49
 b
p
50
−4
00
 b
p
1 
bp
 (i
n 
re
pe
at
s)
1 
bp
 (n
on
−r
e p
.)
2−
5 
bp
 (i
n 
re
pe
at
s)
2−
5 
bp
 (n
on
−r
ep
.)
6−
50
 b
p
ov
er
 5
0 
bp
T a
nd
em
 d
up
.
De
let
ion
s
In
ve
rs
ion
s
Co
m
ple
x e
ve
nt
s
Tr
an
slo
ca
tio
ns
In
te
rc
h r
. e
ve
nt
sACGT
A C G T3’ base
5’ base ACGTACGTACGT ACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGTACGT
A C G T
ACGTACGTACGT
Fo
ldb
ac
ks
(b)
Figure 5.9: Ionising radiation-caused mutagenesis. (a) Damage inflicted by ionising radia-
tion: direct damage on the DNA backbone causing SSBs and DSBs, and indirect damage
via production of free radicals and reactive oxygen species (ROS). (b) Experimental mu-
tational signatures of   and X-ray irradiation in C. elegans.
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An irradiation dose of 2 Gy can cause up to 3000 lesions in a mammalian cell including
1000 SSBs and only 50 DSBs, the rest being base modifications occurring through the
activity of reactive species induced by radiation (Figure 5.9a, Lomax, Folkes, and O’Neill
2013). However, a very small fraction of this damage turns into mutations in healthy cells:
exposing mice to 3 Gy of X-rays did not induce elevated numbers of single-nucleotide vari-
ants (SNVs), but led to 14 copy number variants (CNVs) compared to just one detected
in the untreated control (Russell and Kelly 1982).
In C. elegans experiments, Cs-137 was used as a source of  -rays and, to a lesser
degree,  -rays. It induced lethality but not a huge mutational burden in many samples,
which indicates the high impact of the DSBs and indirect IR e↵ects – i.e. the induction
of oxidative stress – on cell’s ability to propagate. On average, Cs-137 exposure led to
about 52 mutations per 100 Gy per genome, whereas X-ray yielded 11 mutations per 100
Gy.
The overall distribution of mutations was relatively uniform across all SNV types,
without any particular influence of 5’ and 3’ nucleotides flanking the detected SNVs
(Figure 5.9b). Gamma-irradiation but not X-rays also induced a high amount of CC>AA
and TC>AA dinucleotide variants (Figure 5.6). These mutations may be arising via
guanine intrastrand crosslinks of adjacent bases which can occur at an increased rate
upon oxidation stress and irradiation (Cadet et al. 2014). In addition, we observed a
high number of deletions, mostly in the spectrum from 1 to 50 bp upon IR exposure
but also some longer deletions (Figure 5.9b). This resembles the mutational footprint of
BRCA-1/2 deficiency and indicates the NHEJ repair acting on double-strand breaks.
5.2.5 Replication stalling agents – hydroxyurea
Hydroxyurea (Figure 5.10a) is a chemical agent and an inhibitor of the ribonucleotide
reductase (RNR) enzyme. As a consequence, no new dNTPs are produced from ribonu-
cleotides. In a dividing cell, it stalls replication forks and ultimately leads to cell cycle
arrest when dNTP pool size is below the critical threshold of about 20% necessary for
replication (Koc¸ et al. 2004). Stalled replication forks can also collapse into a double-
strand break (Figure 5.10b).
As HU does not incur any direct damage to the DNA structure, the mutational signa-
ture we observed was unstable, with likely peaks in N[C>A]A and C[C>T]N substitutions
which may suggest a particular e ciency of HU in depleting dGTPs. HU only yielded
about 1.5 mutations per 1 mM of the agent. Other studies of chemical mutagenesis by
HU also did not show a clear mutation pattern under normal conditions (Szikriszt et al.
2016).
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Figure 5.10: Hydroxyurea mutagenesis. (a) Structure of HU molecule. (b) Mechanism of
HU-induced depletion of dNTP and replication stalling. Adapted from (c) Experimental
mutational signatures of hydroxyurea exposure in C. elegans.
5.3 Cross-species comparison
Using the adjustment procedure described in Chapter 2, we assessed the comparability
of experimental mutational signatures of di↵erent genotoxins in C. elegans and human
cells (as per Kucab et al. 2019) as well as the similarity between experimental signatures
and computational mutational signatures extracted from cancer genomes (Alexandrov et
al. 2018).
The signature of EMS in worms was strikingly similar (0.90) to the cancer-derived
computational signature SBS11 associated with temozolomide treatment. However, it
turned out to be di↵erent from the temozolomide signature in iPS cell lines (Figure 5.11a).
This may be due to cell type-specific metabolic activation of the mutagen: mutational
spectrum observed upon EMS exposure in Salmonella typhimurium was nearly identical
to the one we saw in C. elegans (Matsumura et al. 2018).
UV-B exposure in worms showed a mutation spectrum dominated by C>T, which was
similar to that in cell line experiments and cancer, albeit with an additional fraction of
T>C mutations (Figure 5.11b). As discussed above, the discrepancy can be coming from
the di↵erence in UV exposure sources: we used a UV-B source, whereas Kucab et al. 2019
used a mixture of 90% UV-A and 10% UV-B similar to actual UV spectrum contained in
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the sunlight.
(a)
(b)
Figure 5.11: Experimental signatures of (a) EMS and (b) UV exposures in C. elegans
(top) and human iPS cells (middle), and cancer signatures (a) SBS11 and (b) SBS7a
(bottom).
The signature of aflatoxin-B1 was similar to the computationally extracted signature
SBS24 (similarity 0.8) but di↵erent compared to the experimental one (0.62) (Figure
5.12a). Similarly, aristolochic acid signatures were consistent between both experimental
systems and cancer, with cosine similarities of 0.91 and 0.90, respectively (Figure 5.12b).
As there was no experimental data available for gamma-irradiation in human cells, we
considered an averaged spectrum of 12 radiotherapy-associated secondary malignancies
from Behjati et al. 2016, which showed a high similarity to the C. elegans Cs-137 induced
base substitution signature. The spectrum of indels associated with this exposure also
agreed with the prevalence of small indels found in Behjati et al. 2016. Compared to
computationally derived cancer signatures, IR exposure spectrum was most similar to
SBS40 (Figure 5.12d), which is found across all cancer types (Alexandrov et al. 2018). It
suggests that the SBS40, as well as the IR spectra, are generated by error-prone repair
of DSBs. Interestingly, the spectrum of IR-induced mutations observed in C. elegans was
di↵erent from an IR signature found in a pooled analysis of human and mouse radiation-
induced malignancies (Davidson et al. 2017), which was mostly characterised by C>A,T
mutations.
Signature of cisplatin treatment in C. elegans consisted almost exclusively of C>A
mutations being di↵erent from the one identified in human iPS cells, which was shifted
towards C>T contribution. Mutational spectra observed upon cisplatin treatment in
chicken fibroblasts, however, had a similar preference for C>A mutations (Szikriszt et al.
2016). Multiple studies of cisplatin-treated cancers suggested that cisplatin treatment
yields both C>A and C>T mutations (Boot et al. 2018, Liu et al. 2017a), which also
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(a) (b)
(c) (d)
Figure 5.12: Experimental signatures of (a) aflatoxin-B1, (b) aristolochic acid, (c) cisplatin
and (d)  -rays and X-rays exposures in C. elegans (top) and (a)-(c) human iPS cells or (d)
average mutational spectrum of radiation-associated secondary malignancies from Behjati
et al. 2016 (middle), and corresponding COSMIC cancer signature (a) SBS24, (b) SBS22,
(c) SBS31 and SBS35 and (d) SBS40 (bottom).
confirms the link between signatures SBS31/35 and platinum-based agent treatment.
Exposures to mechlorethamine and DMS exhibited di↵erent mutational spectra in the
two model systems (Figure 5.13).
No counterparts from human data were found for HU, Mitomycin C, and MMS.
Thus, we observed C. elegans signatures matching the ones in derived from cancer
samples for half of the genotoxins tested. This similarity reflects the fact that the majority
of DNA repair pathways are highly conserved among eukaryotes, but also that DNA repair
capacity and genotoxin metabolism may di↵er moderately between nematodes, human cell
lines, and cancer cells. Human cell lines were, in fact, no better model system for cancer:
some of the experimental signatures derived from human cells, such as signatures of
aflatoxin (Figure 5.12a) and temozolomide (Figure 5.11a), were further away from cancer
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(a) (b)
Figure 5.13: Experimental signatures of (a) mechlorethamine and (b) DMS exposures in
C. elegans (top) and human iPS cells (bottom).
signatures than C. elegans ones.
At a mean cosine similarity of 0.63 (range 0.20-0.84), these experimental signatures
generally displayed a good, although not perfect level of similarity with their human
experimental counterparts and also with computationally derived cancer signatures with
the same suspected origins (Figure 5.14).
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elegans.
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5.4 Discussion
In this chapter, I introduced the genotoxins used in the screen and demonstrated
the signatures generated by these substances upon exposure in wild-type C. elegans.
Experimental signatures of mutagens with di↵erent mechanisms of mutagenicity were
described on a genome-wide scale, demonstrating how di↵erent mechanisms of interaction
with DNA generate di↵erent spectra of mutations.
Many of the genotoxins used in mutagenesis experiments can yield a high amount of
lesions, yet result in a small number of mutations if those lesions are not mutagenic or can
be e ciently repaired. Alkylating agents EMS and MMS produce more alkylated bases
than mutations. The distribution of these mutations also does not necessarily reflect the
distribution of damage as some DNA damage can be repaired faster or better than other,
such as UV-induced pyrimidine dimers at di↵erent dinucleotide contexts. Hence, these
di↵erences can indicate di↵erential mutagenic potency, such as TLS-mediated mispairing
during replication, or di↵erential repair, as in the case of mechlorethamine.
In addition, I compared the experimental signatures in C. elegans to those derived
from human iPS cell line and cancers. Spectra of aristolochic acid and ionising radiation
were well conserved, whereas other agents such as cisplatin and mechlorethamine showed
diverging distributions of mutations. Interestingly, signatures associated with aflatoxin
and temozolomide exposures in cancers were more similar to the spectra obtained in the
corresponding C. elegans experiments than human cell lines. This overview confirmed that
C. elegans is a good model to study the mechanisms of mutagenesis due to its simplicity,
but the limited capacity of cross-species comparison revealed several limitations of this
model system.
As discussed before, one of the drawbacks of C. elegans is its low tolerance to muta-
tions due to the high proportion of coding genome and, consequently, high probability
of deleterious mutations. It limited the maximal dose which could be applied to obtain
mutations, which was compensated by multiple replicates which were pulled together to
infer the experimental mutational signatures.
A general challenge to the studies of mutagenesis in model systems are the di↵erences
in the metabolism of di↵erent genotoxins. Multiple alkylating agents showed a di↵erent
mutational spectrum in human cells compared to C. elegans probably indicating di↵erent
reactive compounds and corresponding damage mechanisms, but the agreement between
the iPSCs and actual cancers was also limited (Kucab et al. 2019). The discrepancies in
mutational spectra across model systems can provide information about the complexity
of metabolic processing of genotoxic substances.
Divergent mutational spectra arising in response to the same genotoxin can also in-
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dicate di↵erent DNA repair pathways acting upon the inflicted DNA damage. Among
these, a wider range of translesion synthesis polymerases in humans compared to ne-
matodes could lead to a di↵erent error-prone repair of the same lesions: for instance,
polymerase ◆ can perform mutagenic bypass of UV-lesions in humans but is absent in C.
elegans (Knobel and Marti 2011). Hence, it is important to remember that a genotoxin
only suggests a set of DNA lesions, but the observed mutational spectrum is ultimately
shaped by the activity of DNA repair and tolerance mechanisms.
A more systematic assessment of the rates and genetic determinants of DNA lesions
in relation to the resulting mutation spectra could shed more light on the mutagenicity
and repair e ciency of di↵erent DNA damage. To address the latter aspect, namely the
e ciency of DNA repair and its potential to alter the mutagenic properties of genotoxins,
we analysed the mutational spectra generated by the same agents across a range of DNA
repair-deficient backgrounds. In the next chapter, I will study the relationship between
DNA damage and repair in more detail, present a model for quantification of the mu-
tagenic contribution of genotypes and genotoxins, and demonstrate the frequency and
magnitude of interaction e↵ects across a range of combinations between DNA damage
deficiencies and DNA damage types.
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Chapter 6
Interactions between DNA damage
and repair
6.1 Introduction
In the previous chapters, I described the genome-wide mutational signatures of DNA
repair deficiencies and genotoxin exposures in C. elegans. Mutations observed upon se-
quencing typically arise in a two-step manner: it starts with damage to the DNA, and
it is the repair or replication over a lesion which leads to mutation. Given this double-
sided nature of mutation acquisition, it seems reasonable to assume that changes in the
DNA repair component availability may a↵ect the mutational signatures of exogenous or
endogenous mutagenic agents.
In this chapter, I will quantify and describe the contributions of di↵erent factors and
their interactions to the mutational spectra of samples with combined DNA repair defi-
ciency and mutagen exposure. I will also show that the interplay between DNA repair and
damage is common and can alter the signature of the mutagen due to a switch of DNA
repair pathway that acts on the damage, and present a summary of interaction e↵ects
along with the most striking examples. This chapter will further stress the fact that the
strongest mutational signals – which would be the first ones to be picked up by conven-
tional unsupervised factor analysis methods – usually result from non-linear interactions
of di↵erent factors, and should not be considered as caused by a single independent factor.
Contributions
The findings described in this chapter were submitted for publication as a part of the
following manuscript:
Volkova, N.V., Meier, B., Gonza´lez-Huici, V., Bertolini, S., Gonzalez, S., Abascal,
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F., Martincorena, I., Campbell, P.J., Gartner, A. and Gerstung, M. (2019). Mutational
signatures are jointly shaped by DNA damage and repair. bioRxiv, 686295.
This chapter represents a reformulation of the first part of the manuscript, which
focuses on the DNA damage-repair interactions in the C. elegans experimental data. The
manuscript was restructured to highlight the methodological innovation as follows: section
6.2 provides a novel introduction presenting the interaction concept, and section 6.3 is
almost identical to the one in the manuscript and describes the most striking examples
and a summary of the frequency and magnitude of the damage-repair interactions across
the mutagenesis screen.
This work was conducted in collaboration with Bettina Meier and colleagues from
Anton Gartner’s research group at the University of Dundee, and Inigo Martincorena’s
and Peter Campbell’s groups at the Sanger Institute. All of the analyses described below
were performed by me.
6.2 Interplay between DNA repair and DNA damage
The genetic material of a cell is constantly being attacked by various types of damag-
ing processes. Replicative errors induce mismatches or contraction/expansion of repetitive
regions, which result in mutations in one of the daughter cells. Replication-transcription
collapses can lead to replication fork collapse and rearrangements of DNA. Reactive species
within the cell react with di↵erent nucleotides and DNA backbone, inducing base mod-
ifications and strand breaks. The presence of additional mutagenic processes, such as
exposures to environmental genotoxins, further amplifies the number of lesions that cell’s
DNA repair machinery has to deal with.
Many types of DNA lesions can be processed by multiple DNA repair pathways. The
redundancy of DNA repair ensures persistence of replication and survival of the organism.
However, di↵erent DNA repair pathways may have di↵erent accuracy and e cacy when
repairing the same damage, which means that the mutational footprint left by the same
damaging agents will not be the same when di↵erent DNA repair components act upon
it.
For example, exposure to benzo-[a]-pyrene, one of the main components of tobacco
smoke (Phillips 2002), leads to the formation of bulky adducts on guanines (Li et al.
2017a). Typically, these adducts would be excised and correctly replaced with a G by
nucleotide excision repair (Hess et al. 1997). However, if the lesion persists until the
replication, it can be replicated over with translesion synthesis polymerases (Rechkoblit et
al. 2002), which may result in a G>A mutation in one of the daughter cells. Alternatively,
if left unrepaired, BaP-adducts can cause double-strand breaks by altering the spatial
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Figure 6.1: The concept of damage-repair interaction. The precise type of mutation
observed depends on the repair available. BP - Benzo-[a]-pyrene adduct.
structure of the DNA around the adduct (Tung et al. 2014). Both cases lead to di↵erent
variants, caused by the same genotoxin. Hence, we suggest that the DNA repair status
can alter the mutational signature of a mutagen.
This implies that there are at least two unknowns that contribute to a mutational spec-
trum. This dichotomy holds not only for exogenous mutagens but also for any cellular
process which can introduce DNA damage. The e↵ects of such interactions are exemplified
by cancers with combined MMR deficiency and defects in exonuclease domain of replica-
tive polymerase ✏, which display a profoundly di↵erent spectrum compared to samples
with the same POLE deficiency but intact MMR (Haradhvala et al. 2018).
Measuring such interaction requires knowledge of the nature of DNA damage and the
cell’s repair capacity. We, therefore, conducted a large combinatorial mutagenesis screen,
which allowed us to deconvolve the contributions of genotoxic processes and DNA repair
machinery to the samples where a knockout and an exposure were combined. Experiments
combining genotoxin exposure and DNA repair deficiency show signs of altered mutage-
nesis, signified by either higher or lower rates of mutations as well as altered mutation
spectra. These interactions highlight how DNA lesions arising from the same genotoxin
are mended by a number of DNA repair pathways, often specific towards a particular type
of DNA damage and therefore changing mutation spectra usually in subtle but sometimes
also dramatic ways.
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6.3 Quantifying interaction e↵ects in a controlled ex-
perimental model
The controlled nature of the mutagenesis screen allowed us to take a step further
towards dissecting the contributions of DNA repair and DNA damage to the mutational
spectra of C. elegans samples.
The experimental setup provided us with the full information about the absolute
dosage of each genotoxin and the duration of the exposure to cell-intrinsic mutagenic
processes for each sample. With this data, it was possible to go beyond the recognition
of recurrent patterns and quantify the actual amount of change introduced by each inter-
action. Hence, our analysis could capture both amplifications and reductions of existing
signatures as well as transformations of genotoxin-induced signatures. This is unlike the
conventional signature analysis, which can only model additive e↵ects because additional
factors are assumed to be solely able to add mutations; however, the data from our ex-
periments indicated that mutagenesis could also be reduced.
In order to fulfil this task while maintaining interpretability of all model components,
we developed a hierarchical Bayesian model which adapts a range of the possible changes
and noise sources in the data, discussed in Chapter 2.
6.4 Alteration of mutagen profiles in C. elegans ex-
periments
Upon quantifying the interaction e↵ects, we confirmed a number of known cases of
the interplay between DNA damage and repair, for which we now o↵ered a genome-wide
spectrum estimation, as well as identified previously understudied combinations.
6.4.1 Alkylating agents and corresponding repair enzymes
Among all of the interaction experiments, the highest number of mutations was ob-
served for the knockout of TLS polymerase polk-1 under exposure to alkylating agent
MMS. Deficiency of polymerase  increases the total mutation rate 17x to approximately
3,800 mutations/mM/generation (Figure 6.2a). This increase also coincides with a dis-
tinct change in the mutational spectrum with a prominent peak of T>A transversions in
a TpTpT context (Figure 6.2a, central panel).
Quantifying these changes relative to the wild-type mutation spectrum and accounting
for possible genotoxin-independent e↵ects of polymerase  deficiency revealed that the rate
of T>M mutations is approximately 10-100x higher, especially in TpTpN and CpTpN
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(a)
(b)
Figure 6.2: Mutations introduced per unit of MMS in wild-type (top panel) and in (a)
polk-1 or (b) agt-1 deficient mutants (central panel), along with the fold-change per
mutation type (bottom) and the total numbers of mutations in response to di↵erent doses
(right panel). Corresponds to Figure 3A/B in Volkova et al. 2019.
contexts (Figure 6.2a, bottom). These figures indicate that 90-99% of MMS-induced
mutations are avoided by Pol  driven TLS. T>M mutagenesis is likely to be caused by
N3-methyladenosine, which is considered to represent the largest proportion of mutagenic
adducts, stalls replicative polymerases, and is mended by several TLS polymerases (Yoon
et al. 2017). Our data indicate that TLS in the polk-1 mutant, contrary to the wild-type,
N3-meA bypass had to be achieved by other, error-prone TLS polymerases, resulting in
largely increased T>M mutagenesis.
A further mutagenic DNA modification induced by MMS is O6-methylguanine, which
leads to G:T mispairing resulting in C>T transitions. In wild-type experiments, MMS in-
duced less than 10 C>T mutations/mM. Combining MMS exposure with alkyl-transferase
agt-1 deficiency, however, increases C>T mutations by a factor of 12, while leaving the
rate of T>M mutations unchanged (Figure 6.2b). This demonstrates that AGT-1 specif-
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ically reverses most O6-methyl-guanine adducts, thus acting as the functional C.elegans
ortholog of the human O6-methylguanine DNA methyltransferase MGMT.
A similar change of the mutation spectrum was observed for DNA ethylation by EMS.
Upon exposure in polk-1 deficient samples, EMS signature demonstrated a 10x increase
in T>M mutations (Figure 6.3a), whereas in agt-1 mutants it only showed a 1.5-fold
increase in C>T mutations (Figure 6.3b). These changes in the signatures suggest that
the adenine alkylation damage inflicted by MMS and EMS is normally bypassed via
POLK-1 mediated TLS, and that AGT-1 e ciently repairs guanine methylation, but is
less e cient in repairing guanine ethylation, which is consistent with the reports in E.
coli (Taira et al. 2013).
(a)
(b)
Figure 6.3: (a) Mutations introduced per unit of EMS in (a) wild-type (top panel) and
in polk-1 deficient mutants (central panel), or in (b) agt-1 deficient mutants (top panel),
along with the fold-change per mutation type (bottom) and total numbers of mutation
in response to di↵erent doses of mutagen (right panel). Corresponds to Supplementary
Figure 4 in Volkova et al. 2019.
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6.4.2 Translesion synthesis deficiency decreases the number of
observed mutations
Knockouts of two other translesion synthesis polymerases, POLH-1 and REV-3, led to
a severe inability of the cell to replicate over multiple sorts of lesions. As demonstrated
in Chapter 3, the mutation accumulation patterns for these knockouts in the absence of
exogenous genotoxicity were characterised by deletions in the range of 50-400 bp, thought
to arise via the formation of DNA double-strand breaks and polq-1 mediated repair.
Error-prone TLS is a key mechanism to overcome UV-induced DNA damage such as
cyclobutane pyrimidine dimers, which stall replication polymerases. Exposure of TLS
polymerase ⌘ and ⇣ mutants, the latter one in particular, led to a distinctive reduction in
the amount of observed substitution: upon UV exposure, rev-3 mutant showed a 1.5-fold
reduction in substitutions and 4-fold increase in deletions > 50 bp (Figure 6.4a).
MMS exposure in rev-3 mutants caused severe lethality, making the mutants unable
to bear the doses higher than the lowest one used in the wild-type experiments (50 µM
of MMS), which led to a very small and variable number of substitutions. Projecting the
values of mutation burden observed at low mutagen concentrations to those used for the
wild-type samples, we expect a 20% reduction in the number of substitutions and a 5-fold
increase in the number of indels (Figure 6.4b). This supports the concept of TLS bypass
protecting the genome from more severe mutation - such as deletions - at the cost of
increased error rate and consequently elevated base substitution rate (Yoon et al. 2019).
6.4.3 Nucleotide excision repair deficiency exacerbates the ef-
fects of mutagens
In contrast to the above examples where repair deficiency leads to both increase in
mutagenesis but also to alteration of mutational spectra, the knockouts of the NER genes
xpf-1 and xpc-1 increased the rate of UV-B induced mutagenesis by factors of 10 and 35,
respectively. The fold-change appears to be relatively uniform across the entire mutation
spectrum, indicating that NER is involved in repairing the large majority of UV-B damage
of di↵erent types, including both single- and multinucleotide lesions (Figure 6.5a).
Interestingly, xpf-1 and xpc-1 knockouts also uniformly increased the mutation burden
due to alkylation by a factor of 2, indicating that alkylation damage is eventually repaired
by NER (Appendix B). Similarly, both xpf-1 and xpc-1 knockouts also showed a two-fold
increase in mutations after aristolochic acid, demonstrating that NER repairs both small
and bulky adducts (Figure 6.5). Against previous reports on the lack of recognition of
the aristolactam adducts by global genome NER (Sidorenko et al. 2012), xpc-1 mutants
in our screen showed an increase in mutations upon aristolochic acid exposure, especially
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(a)
(b)
Figure 6.4: Mutations introduced per unit of (a) UV irradiation and (b) MMS in wild-type
(top panel) and in rev-3 deficient mutants (central panel), along with the fold-change per
mutation type (bottom) and the total numbers of mutations in response to di↵erent doses
(right panel). Corresponds to Figure 3C and Supplementary Figure 4 in Volkova et al.
2019.
deletions in the range of 50-400 bps (Figure B), similar to that in xpf-1 mutants deficient
in both NER modalities. This may be a consequence of the experimental setup, in which
C. elegans has to survive the embryonic development stage, when GG-NER is more active
than in adult stages (Lans and Vermeulen 2011).
A strong change in the mutational spectrum was also observed upon irradiation of xpa-
1 deficient mutants with  -rays (Figure 6.5c). We observed a 1.5-fold increase in C>T,A
base changes and indels, as well as a 3-fold increase in DNVs. XPA is a NER factor
involved in damage recognition for both TC-NER and GG-NER, which also serves as a
sca↵old to assemble the excision complex. Similar e↵ects were observed in other NER
mutants, but to a lesser degree (Appendix B). It is likely that these proteins enhance
the damage detection and repair capacity of DSB repair (Zhang, Rohde, and Wu 2009),
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(b)
(c)
Figure 6.5: Mutations introduced per unit of (a) UV-irradiation, (b) aristolochic acid
exposure or (c)  -irradiation in wild-type (top panel) and in (a) xpc-1, (b) xpf-1 and (c)
xpa-1 deficient mutants (central panel), along with the fold-change per mutation type
(bottom) and total numbers of mutations in response to di↵erent doses of mutagen (right
panel). Corresponds to Figure 3D and Supplementary Figure 4 in Volkova et al. 2019.
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and an absence of XPA can increase the amount of unrepaired SSBs and intrastrand
crosslinks, which result in DNVs, and mutagenic DSB repair generating base substitutions
and deletions.
6.5 Widespread and potent damage-repair interac-
tions in C. elegans screen
These examples of genotoxin-repair interactions are not uncommon: in total, 72/196
(37%, at FDR of 10%) of combinations displayed an interaction between DNA repair
status and genotoxin treatment, involving 9 out of 11 genotoxins which had interaction
experiments (Figure 6.6). Conversely, more than a half of combinations produced muta-
tion spectra which could be fully described as the superposition of the wild-type genotoxin
signature and that of the DNA repair deficiency background, indicating that the two pro-
cesses acted independently. Usually, genotoxin-repair interactions increase the numbers of
mutations obtained for a given dose of mutagen, leaving the mutational spectrum mostly
unchanged; others have a profound impact on mutational spectra (Figure 6.7).
Figure 6.6: Fold changes in base substitution rates between the e↵ects of mutagen expo-
sure in the wild-type and under di↵erent DNA repair-deficient conditions. Each bar marks
a 95% confidence interval for the fold-change of the base substitution rate. Dark bars de-
note the combinations with a fold-change significantly di↵erent from 1. Corresponds to
Figure 4A in Volkova et al. 2019.
The emergence of distinct mutational spectra depending on DNA repair status reflects
how multiple repair enzymes and pathways contribute to mending damaged DNA as in
the case of DNA alkylation. If DNA repair is predominantly achieved by one pathway
such as by NER for UVB damage and bulky DNA adducts, the number of mutations is
increased, but the signature tends to remain unchanged.
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Figure 6.7: Cosine distances between the mutational signatures of mutagens in the wild-
type and under di↵erent DNA repair-deficient conditions. Each bar marks a 95% confi-
dence interval for the distance between the signatures. Dark bars denote the combinations
with a mean distance higher than 0.2 (the threshold was chosen based on the simulations,
Appendix ??). Corresponds to Figure 4B in Volkova et al. 2019.
Figure 6.8: Contributions of di↵er-
ent factors across all interaction ex-
periments. Corresponds to Figure
4C in Volkova et al. 2019.
To illustrate the overall magnitude of these in-
teraction e↵ects, we estimate that of the 141,004
mutations we observed upon treatment with geno-
toxins in DNA repair-deficient strains 23% of muta-
tions were attributed to the endogenous mutagenic-
ity of DNA repair deficiency genotypes independent
of genotoxic exposure, and 62% of mutations would
be attributed to genotoxic exposures independent
of the genetic background. Of these, 2% were not
observed due to negative interactions of genotoxins
and DNA repair deficiency, such as UVB exposure
of TLS knockout strains, and 17% of mutations were
added because of the positive interactions, which in-
creased mutagenicity (Figure 6.8).
6.6 Discussion
In this chapter, I presented a way of quantify-
ing the degree of interaction between genetic and
mutagenic factors in controlled experiments on C.
elegans, and performed a comparison of e↵ects across 196 combinations of repair com-
ponents and damaging agents which showed the diversity and abundance of significant
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interaction e↵ects which may be both positive and negative. I also demonstrated how
these interactions might increase or decrease the total burden, and alter the signature of
the mutagenic agent as well as intensify the signature of genetic factors, which in total
was observed in 37% of experiments.
The mode of interaction detected for a mutagen in a DNA repair-deficient environment
indicates the relationship between the lesions introduced by the damaging agent and the
repair pathway. Observing a change of the spectrum, as in the case of alkylating agents
and polk-1 and agt-1 knockouts suggests that divergent repair pathways are involved in
repairing di↵erent lesions introduced by the same genotoxin. When either repair compo-
nent is knocked out, a distinct part of the mutation spectrum changes, indicating those
lesions which would otherwise be repaired by the given repair pathway. Conversely, a
change in exposure only indicates that the inactivated DNA repair component is either
contributing to repair of all the lesions introduced by a damaging agent, as in case of UV
exposure and NER deficient mutants or participates in the damage response pathway.
Overall, this analysis shows that the signatures of many mutagenic processes are not
necessarily constant, and may vary in di↵erent ways. As multiple and only partially over-
lapping repair pathways are mending genotoxic lesions, the resulting mutation spectrum
may change depending on the activity of each component in a given cell. It opens the
way for considering DNA repair status as a factor in signature decomposition as it may
alter the appearance of latent components or introduce additional ones.
Studying the e↵ects of DNA repair deficiencies on the mutagenic exposures also pro-
vides insights into the mechanisms of repair and specificity of the damage. We observed
a shift in context preference of mutational signature of MMS exposure upon polk-1 de-
ficiency, leading to a peak in T[T>A]T mutations. It raises the question of whether it
is due to MMS preferentially introducing damage in this context, or due to POLK-1 be-
ing able to replicate over a lesion in this context much more accurately than other TLS
polymerases?
The screen above only considers mutations, i.e. results of repair-damage interplay;
combined with the analysis of unrepaired damage, which may be detected with direct
damage detection methods based on fluorescence or spectrometry (Sykora et al. 2018,
Figueroa-Gonza´lez and Pe´rez-Plasencia 2017), it could provide a comprehensive and quan-
titative picture of mechanisms of damage and repair of the genomic DNA. Techniques
sensitive to any kind of damage, however, can only provide the intensity of damage but
not its precise genomic location. More specific methods designed to detect a particu-
lar type of lesions are being developed including XR-seq for UV-induced CPD detection
(Hu et al. 2015) and AP-seq for oxidative damage detection (Poetsch, Boulton, and Lus-
combe 2018), as well as computational methods for damaged base detection in Nanopore
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sequencing (Liu et al. 2019, Georgieva et al. 2019).
The pervasive existence of mutagen-repair interactions raised the question to which
extent similar phenomena can be observed in human cancers. In the next chapter, I
will explore the range of repair-damage interaction in human cancers by modifying the
signature extraction model and incorporating additional information about DNA repair
status of the samples.
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Chapter 7
Interplay between DNA damage and
repair in cancer
7.1 Introduction
In the previous chapter, I have introduced the idea of mutational signatures being
a product of interplay between DNA damage and DNA repair and described the most
striking examples of such interactions observed in the C. elegans mutagenesis screen.
Translating these findings to cancer requires a way of confidently identifying the pres-
ence and degree of DNA repair or DNA damage response impairment based on the genetic
variants or epigenetic silencing. Establishing whether a repair pathway is genetically im-
paired requires estimating the pathogenic consequences of point mutations, as well as
there allelic status. For example, for POLE exonuclease domain variants or MMR de-
fects, a heterozygous damaging variant would be su cient. However, other DNA repair
deficiencies would only be exhibited upon biallelic loss of function, conferred either by
two independent mutations, or by a loss of heterozygosity after heterozygous mutation,
or via a combination of a mutation and gene silencing (Lahtz and Pfeifer 2011).
Secondly, it would require knowledge of the origins and degree of all the genotoxic ex-
posures in a given sample, which are generally unknown. Certain factors such as exposure
to UV light, smoking or consumption of genotoxins contained in food may be determined
and quantified using clinical data and patient reports, but the actual exposure in each
tissue may vary substantially in response to many biological and environmental covariates
such as ethnicity or lifestyle choices (Ward et al. 2004). For example, the incidence of
skin cancers resulting from UV-induced damage the same amount of exposure would be
dramatically di↵erent in people of Caucasian or African origin due to di↵erent amounts of
skin pigmentation (Brenner and Hearing 2008), similarly for people residing in northern
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Europe or Australia (Rivas et al. 2011), or those who use sunscreen or not (Green et al.
2011). Similarly, representatives of African Americans and Native Hawaiian ethnicity in
the USA have a higher smoking-associated lung cancer risk than the white population
adjusted for the number of cigarettes per day (Haiman et al. 2006).
Nevertheless, knowing about the variability of mutational signatures presents the
means for a more informed signature analysis in individual samples. Thus, in this chap-
ter, I will explore the frequency of DNA repair deficiencies across human cancers and the
overall contribution of defects in DNA repair-related genes to cancer development. I will
also present a statistical model for the simultaneous extraction of mutational signatures
and estimation of the e↵ects of DNA repair inactivation on the appearance of these sig-
natures, which will allow for analysing damage-repair interactions in tumours with strong
mutagenic components.
Contributions
The findings described in this chapter were submitted for publication as a part of the
following manuscript:
Volkova, N.V., Meier, B., Gonza´lez-Huici, V., Bertolini, S., Gonzalez, S., Abascal,
F., Martincorena, I., Campbell, P.J., Gartner, A. and Gerstung, M. (2019). Mutational
signatures are jointly shaped by DNA damage and repair. bioRxiv, 686295.
This chapter represents a reformulation of the second part of the manuscript, which fo-
cuses on the DNA damage-repair interactions in human cancer. The text of the manuscript
was restructured to present a full overview of DNA repair deficiencies in cancer. Section
7.2 provides an overview of frequencies and consequences of DNA repair deficiencies on
the mutational burden and spectra of tumours, section 7.3 summarises the method and
presents the results for interactions tested.
This work was conducted in collaboration with Bettina Meier and colleagues from
Anton Gartner’s research group at the University of Dundee, and Peter Campbell at the
Sanger Institute, who conceived the study. Analysis of selection in DNA repair genes was
conducted upon consultation with Inigo Martincorena and Federico Abascal at the Well-
come Trust Sanger Institute and Santiago Gonzalez at IRB. All of the analyses described
below were performed by me.
7.2 Widespread DNA repair defects in human cancer
To leverage the concept of mutational spectra being shaped jointly by mutagen ex-
posure and DNA repair status in human cancer genomes, we analysed the DNA repair
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defects across 30 cancer types from TCGA and studied the appearance of various muta-
genic processes in samples labelled as deficient or proficient in 9 DNA repair pathways:
mismatch repair (MMR), base excision repair (BER), nucleotide excision repair (NER),
homologous recombination repair (HRR), translesion synthesis (TLS), non-homologous
end-joining (NHEJ), Fanconi anemia pathway (FA), direct repair (DR) and damage sens-
ing (DS) pathways. In total, we analysed 81 core DNA repair genes across these pathways,
and for a more in-depth analysis, we looked at additional 97 genes indirectly associated
with DNA repair performed via these pathways (Knijnenburg et al. 2018, Pearl et al.
2015) (Appendix C). To assess the sample’s DNA repair status, we annotated missense
and loss-of-function mutations in these genes across 9,946 samples available from the
TCGA collection.
If not stated otherwise, data was obtained from GDC (https://cancergenome.nih.
gov) and filtered according to (Martincorena et al. 2017). Somatic and germline muta-
tions were acquired using cgpCaVEMan (http://cancerit.github.io/CaVEMan/) and
cgpPindel (https://github.com/cancerit/cgpPindel) variant callers. Copy number
profiles, purities and ploidies of TCGA samples were estimated using ASCAT (Van Loo
et al. 2010).
7.2.1 Monoallelic vs biallelic
To distinguish between the e↵ects of complete or partial inactivation of DNA re-
pair components, we classified samples with DNA repair defects into those with homozy-
gous mutations (meaning biallelic inactivation) or heterozygous (monoallelic inactivation).
Complete inactivation was considered to be a consequence of either a deep deletion, or
two independent mutations, or a combination of mutation and gene silencing (Lahtz and
Pfeifer 2011).
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Supplementary Figure 6. Somatic mutations and silencing of DNA repair pathway genes in human cancers
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Figure 7.1: (a) Monoallelic and (b) bi-allelic DNA repair pathway defects across TCGA.
Each dot represents the percentage of samples with a certain defect within the respective
cancer type. Corresponds to Supplementary Figure 6A,B in Volkova et al. 2019.
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In line with the previous reports, we found that monoallelic defects in DNA repair
were quite common - on average, over 50% of samples would have at least one gene of a
given repair pathway mutated (Knijnenburg et al. 2018) (Figure 7.1a). In contrast, our
analysis of biallelic inactivation events showed that these are rare (Figure 7.1b).
A notable exception is the damage sensing pathway, which is biallelically inactivated
in over 11% of all samples due to mutations in commonly mutated DNA damage response
genes such as TP53 tumour suppressor gene. Amongst other DNA repair genes, most
common is the biallelic inactivation of MMR (13% of adrenocortical carcinomas and 7%
of endometrial cancers), as well as complete inactivation of TLS polymerase REV3L in
testicular cancers (TGCT). Genes involved in direct damage reversal are impaired in
6% of leukaemias, and genes involved in homologous recombination repair occur to be
inactivated in 6% of ovarian cancers.
7.2.2 E↵ect on mutation burden and spectra
Given the abundance of mono- and bi-allelic defects in DNA repair genes across all
cancer types, we aimed to investigate how much of e↵ect do they have on the mutational
burden and mutational signatures present in respective tumours. To do that, we looked
at the change in mutation burden per year between wild-type samples, samples with
monoallelic inactivation, and samples with biallelic inactivation (if available) of the core
genes in a given pathway. Here we also included defects in the proofreading domain
of replicative polymerase " (POLEexo) as a separate pathway, as it is known to lead
to hypermutation (Roberts and Gordenin 2014). We observed that an elevation in the
number of mutations was not common - only 22 out of 300 combinations of cancer types
showed a significant change in the mutational burden as shown by Wilcoxon rank-sum
test (FDR 5%).
The most of the significant interactions associated with an increase in mutation burden
were produced by defects in the damage sensing pathway and mismatch repair, as well as
POLEexo defects (Figure 7.2). However, we did see some associations with direct repair
and homologous recombination repair pathways.
Association between mutations in DNA repair genes and mutation burden could be
caused simply by the fact that a higher total number of mutations means a higher chance of
hitting the respective genes with mutations. Hence, we performed simulations to establish
whether it was likely. Based on the distribution of synonymous mutations across the
exome of all samples within certain cancer types, we simulated the number of mutations
corresponding across core components of 9 DNA repair pathways such that it would
produce the same number of synonymous mutations as observed, and tested whether the
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Figure 7.2: Changes in total number of mutations / year associated with DNA repair
defects. Stars denote the cases where the presence of DNA repair defect is unlikely to be
caused simply by mutation burden elevation. Corresponds to Supplementary Figure 6C
in Volkova et al. 2019.
observed number of non-synonymous mutations in these genes across the set corresponds
to expected. Using this approach, we identified that only about 70% of the associations
we considered important could not be caused simply by the increase in mutation burden.
Among these, damage sensing pathway, POLEexo, HR and MMR deficiencies remained
significant and showed a substantial increase in mutation burden in response to damaging
mutations in respective pathways (Figure 7.2, stars).
Furthermore, we also assessed the mutational spectra of samples with and without
DNA repair pathway defects. Upon subtraction of mutations caused by endogenous or
non-DNA repair associated processes, such as signature SBS1 (associated with sponta-
neous deamination of 5meC) and APOBEC signatures (SBS2 and SBS13), we calculated
cosine distances between the median mutational spectra of samples without mutations
in a given pathway and those in the group with heterozygous mutations, and those in
the group with homozygous mutations (if those groups of samples consisted of at least 4
samples with more than 100 mutations, to ensure the meaningfulness of the analysis of
mutation spectra).
This comparison highlighted a striking di↵erence in the profiles for proofreading do-
main mutations of POLE, for MMR mutations in stomach and uterine cancers, for DR
mutations in glioblastomas and HR mutations in breast and ovarian cancers (Figure 7.3).
These findings are in line with existence of strong mutational signatures associated with
all these processes (Alexandrov et al. 2013b, Helleday, Eshtad, and Nik-Zainal 2014),
apart from DR defects in GBM: a change in mutation spectrum of these samples is actu-
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Figure 7.3: Changes in mutational spectra associated with DNA repair defects. Round
points correspond to monoallelic defects, diamond-shaped points - to biallelic. Corre-
sponds to Supplementary Figure 6D in Volkova et al. 2019.
ally caused by the presence of strong treatment signature (temozolomide) in the samples
defective in direct repair enzyme MGMT as compared to the rest of samples.
7.3 Damage-repair interactions
The observation that strong e↵ects of DNA repair deficiency on the mutational burden
and spectra are rare squares well with our experimental mutagenesis screen in which many
DNA repair deficiencies displayed relatively mild mutational phenotypes under physiolog-
ical conditions (Figure 3.2). However, several DNA repair-deficient genetic backgrounds
yielded measurable genotoxin-repair interactions (Figure 6.6). Hence, to explore the scope
and diversity of such e↵ects in cancer, we adapted the negative-binomial model used to
quantify signature changes in our mutagenesis screen to simultaneously extract signatures
reflecting generally unknown genotoxic exposures and DNA repair e↵ects thereon for a
range of cancers with suspected genotoxic exposures (Section 2.4).
7.3.1 Confirmed interactions for temozolomide, POLEexo and
APOBEC
Overall, the observed DNA repair and damage interaction e↵ects were moderate, usu-
ally following the expected distributions (Figure 7.4). However, a number of noteworthy
examples exist, shedding light on DNA damage-repair interactions also moulding cancer
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(a) (b)
Figure 7.4: Interaction e↵ects in human cancer. Fold-changes (a) in mutation rate and dis-
similarity (b) between mutational signatures associated with repair-damage interactions.
Corresponds to Figure 5A in Volkova et al. 2019.
genomes.
Temozolomide and MGMT
The strongest interaction, which is also therapeutically exploited, occurred between
the human agt-1 ortholog MGMT and alkylating chemotherapy drug temozolomide (TMZ)
in temozolomide-treated glioblastomas (Figure 7.5) (Kim et al. 2015). To quantify it, we
took the MGMT methylation data as well as the somatic mutations from exomes of
glioblastoma multiformae (GBM) samples treated with TMZ (Kim et al. 2015). Using
the model discussed in Section 2.4, we estimated the e↵ect of MGMT methylation on
one of the signatures present in glioblastoma exomes coming from 17 samples treated
with TMZ: 11 with wild-type MGMT and 6 with MGMT hypermethylation. The model
showed the best results for two signatures, one similar to COSMIC signature SBS1 and
another one flat (upper panel of Figure 7.5), and suggested that the estimated change of
the second signature was greater than 100-fold.
This is in good agreement with our experimental findings that the nature of mutation
spectra detected upon EMS, DMS or MMS alkylation depends on the status of agt-1
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(Figure 6.2b). We note that the signature associated with temozolomide exposure in
MGMT deficient cancers leads to a more characteristic C>T spectrum in an NpCpY
context (Y = C or T).
Figure 7.5: Interaction between temozolomide treatment and MGMT status. Top panel
represents signature 2 in samples without MGMT silencing, middle panel - in samples
with silenced MGMT. Lower panel represents the fold-change between these signatures.
Boxplot on the right describes the number of mutations assigned to this signature in
samples with and without MGMT silencing. Corresponds to Figure 5B in Volkova et al.
2019.
Concurrent mismatch repair deficiency and POLEexo defects
A further noteworthy interaction arose between MMR deficiency and a range of other
mutational processes. These include concurrent POLE proofreading domain mutations
manifesting in an increased C>A mutagenesis in a NpCpT context (Figure 7.6), as noted
previously (Haradhvala et al. 2018, Shlien et al. 2015).
The e↵ects of interaction between POLE and MMR defects were investigated using the
uterine cancer cohort from TCGA (UCEC TCGA project) as indicated in (Haradhvala et
al. 2018). Samples classified as MSI-H by Bethesda protocol (available in TCGA Clinical
Explorer (Lee et al. 2015)) were considered to be MMR deficient, and samples with
missense mutations in POLE proofreading domain (amino acids 267-472) were considered
to have compromised proofreading activity.
Overall, we analysed 546 samples, 167 of which were labelled as MMR deficient, 55 -
as having POLEexo defects, and 15 - as having both deficiencies. We identified five sig-
natures, with a signature that demonstrated a 0.97 cosine similarity to COSMIC SBS10
signature (the one associated with POLE proofreading domain defects) being subject to
interactions with di↵erent POLE mutations and POLE+MMR factor. In line with associ-
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Figure 7.6: Signatures associated with MMR deficiency (first panel), and with POLEexo
defects in MSI (second panel) and MSS (third panel) uterine cancers. Bottom panel repre-
sents the fold-change between the last two signatures, and the boxplot reflects the number
of mutations assigned to POLEexo signature in MSI and MSS samples. Corresponds to
Figure 5C in Volkova et al. 2019.
ations suggested previously, the transformation of POLE signature upon MMR deficiency
closely resembled COSMIC signature SBS14, and signatures C1-2 from (Haradhvala et al.
2018) (Figure 7.6).
Concurrent mismatch repair deficiency across tissues
Moreover, MMR deficiency changes the rates of mutational indel processes, causing
mononucleotide insertions and deletions in homopolymeric stretches (Figure 7.8), which
arise at variable rate across tissues in MMR proficient samples (Alexandrov et al. 2018).
We screened all TCGA samples for defects in MMR genesMLH1, PMS2,MSH2,MSH3
and MSH6 (we excluded MLH3 for the lack of samples with just the MLH3 mutation
and visible MMR deficiency phenotype). Samples were labelled as having MMR defects
if they had a monoallelic/biallelic defect in MMR genes (assessed as described above) or
were clinically determined to have MSI-H status as per TCGA Clinical Explorer (Lee et
al. 2015). The samples were further filtered to exclude those with less than 100 mutations
or more than 20000 mutations, and those whose mutational profile was dominated by
a strong mutagenic process: APOBEC, POLE, UV or tobacco (i.e. we excluded those
with cosine similarity higher than 0.7 to the respective signatures). From the remaining
samples, we selected data from 8 tissue types: breast (BRCA), cervical (CESC), head
and neck (HNSC), stomach (STAD), colorectal (COAD and READ), liver (LIHC), lung
(LUAD and LUSC), prostate (PRAD), and uterine cancers (UCEC).
Using this dataset of 782 samples, we looked at the tissue e↵ects (using colorectal as
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Figure 7.7: Signatures of MMR deficiency across di↵erent tissues. Corresponds to Sup-
plementary Figure 7D in Volkova et al. 2019.
default and fitting 7 interaction e↵ects for tissues - breast, cervix, head and neck, lung,
stomach, uterus, liver), and noticed a change in the relative contribution of indels and
CpG>TpG mutations in the MMR signature across some of the tissue types (Figure 7.7).
When we compared age-adjusted rates of C>T mutations at CpG sites, and single-base
deletions and insertions across samples from di↵erent cancer types with defected and wild-
type MMR genes, we noticed a definite trend (Figure 7.8): the rates of these mutations
were di↵erent across tissues, but the rate fold-changes in the respective mutation types
between MMR deficient and proficient samples were similar across cancer types.
Figure 7.8: Indel and N[C>T]G rates in MMR-proficient and deficient cancer samples
from di↵erent tissue types. Corresponds to Supplementary Figure 7D in Volkova et al.
2019.
Compared to MMR proficient samples, the rate of single-base deletions per year was on
average 5-fold higher in MMR deficient samples following the same trend across di↵erent
tissues; the rate of single-base insertions was on average 4-fold higher, and the rate of
C>T at CpG sites was 3-fold higher in the samples with MMR defects compared to the
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tissue baseline. These data also square well with the observation that MMR deficiency
is associated with some additional mutational signatures of unknown aetiology (Meier
et al. 2018), suggesting that these may reflect di↵erent mutagenic processes which are
exacerbated by MMR deficiency.
APOBEC family of enzymes and translesion synthesis
APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) fam-
ily of enzymes represented another interesting example of a mutagenic process prone to
alteration. APOBEC induces deamination of single-stranded cytosines, which is believed
to be a key contributor of C>T and C>G mutations in a TpCpN context in a variety of
cancer types. Uracil, the product of cytosine deamination, can pair with adenine, leading
to C>T mutations upon replication; alternatively, uracil may be excised by uracil DNA
glycosylase (UNG). It leaves an abasic site, which is thought to be replicated over by the
error-prone TLS polymerase REV1, leading to C>G mutations (Morganella et al. 2016,
Roberts and Gordenin 2014). Indeed, two mutational signatures involving either C>G
and C>T mutations have been attributed to APOBEC and a lack of C>G mutations has
been observed in a cancer cell line with UNG silencing (Kim et al. 2015, Petljak et al.
2019).
Figure 7.9: Change in APOBEC signature upon deficiency in REV1/UNG system along
with the associated fold-change. The boxplot on the right reflects the fraction of T[C>G]N
mutations compared to all mutations per sample in samples with wild-type and mutated
REV1 or UNG. Corresponds to Figure 5D in Volkova et al. 2019
To assess the contributions of REV1 and UNG to APOBEC mutagenesis in primary
cancers, we re-analysed 842 cancers with high APOBEC activity (the ones which showed
cosine similarity of at least 0.8 to a combination of COSMIC signatures SBS2 and SBS13
and had between 50 and 15000 mutations per exome). We further stratified these samples
into REV1/UNG wild-type (794 samples) and mutated group (48 samples with at least
147
monoallelic defects in REV1 or UNG). Analysis of APOBEC-specific T[C>A/C/T]N mu-
tations showed an 8% decrease in the relative fraction of C>G mutations compared to
C>T transversions in samples with defective REV1, indicating that translesion synthesis
is indeed a critical contributor to APOBEC driven C>G mutagenesis (Figure 7.9).
7.3.2 No e↵ects on mutagenesis for NER defects
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Figure 7.10: (a) Signature of UV-light in samples with wild-type NER genes (top) and
those with defects in NER genes (middle panel), along with the fold-change (bottom
panel). Corresponds to Supplementary Figure 7B in Volkova et al. 2019. (b-c) Simulations
of silent (b) and non-silent (c) mutations within NER genes across SKCM dataset, showing
that the observed values (dashed red line) fall into the distribution simulated based on
the UV-associated spectrum of mutations and mutational burden per sample.
Notably, no significant e↵ect was observed for NER variants in lung and skin cancers,
although one might expect NER being involved in repairing bulky DNA adducts derived
from tobacco smoke and UV light (Figure 7.4). Similarly, NER-deficient bladder cancers
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with recurrent mutations in ERCC2/XPD did not show a strong e↵ect of the mutation
burden, despite reports of a mild increase of a signature similar to COSMIC signature 5
(Kim et al. 2016).
NER e↵ects in UV-associated melanomas were estimated using samples from the
TCGA cutaneous skin melanoma (SKCM) project (Cancer Genome Atlas Network 2015),
where the similarity to a combination of COSMIC signatures SBS7a and SBS7b (previ-
ously associated with UV) was higher than 0.8. 397 patients were tested for having either
a low expression of any of the NER genes in the tumour sample (below 20% of the median
level in the dataset) or a somatic biallelic inactivation of a core NER gene in the tumour
sample as described above. As the numbers were low, we also included samples with a
high impact germline variant (homozygous or heterozygous) as predicted using Ensembl
VEP (McLaren et al. 2016). The final set contained 9 samples labelled as NER defective.
We estimated the e↵ects of having defects in NER pathway using a single signature.
NER did not show a dramatic change in the profile of UV signature, only produced a 5%
increase in C>T mutations, but led to an overall 2-fold increase in the mutation burden
per year (Figure 7.10a). To check whether this is an e↵ect of NER defects, or simply a
consequence of increased mutational burden, we simulated UV-induced mutations in NER
genes according to each sample’s total burden of synonymous mutations and tested if the
observed number of mutations in these genes across the dataset was in line with expected
(Figure 7.10b). The observed number of nonsynonymous mutations across NER genes
followed the distribution we generated via simulations (Figure 7.10c), which indicated
that most of the signal was coming from the di↵erence in the mutational burden. Together
with the high variability of this fold-change e↵ect, it led to the conclusion that there is no
detectable e↵ect of mutations in NER genes on the appearance of UV exposure signature.
E↵ects of DNA repair machinery defects on the signature of tobacco smoke were
estimated using samples from LUAD and LUSC projects (Cancer Genome Atlas Research
Network 2014b, Cancer Genome Atlas Research Network 2012). Out of 905 samples across
the two datasets, we selected 219 samples with a high presence of COSMIC signature SBS4
(cosine similarity over 0.8), associated with tobacco smoking. Of these, 82 samples were
labelled as being NER deficient (mono- or biallelically). Having extracted two signatures
most similar to smoking and APOBEC associated signatures, we did not find a significant
e↵ect of NER defects on the exposure coe cient or mutational distribution of the signature
associated with smoking (Figure 7.11).
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Figure 7.11: Change in tobacco signature upon NER defects. Corresponds to Supplemen-
tary Figure 7C in Volkova et al. 2019
7.4 DNA repair deficiency and somatic evolution of
cancer
7.4.1 Selective pressure across DNA repair genes
A high level of recurrence of non-silent variants in a gene across cancer samples in-
dicated that the given gene is positively selected and promotes cancer progression. To
assess whether DNA repair mutations were positively or negatively selected in cancers, we
calculated the dN/dS ratio of non-silent to silent mutations relative to its expected ratio
based on silent variants and epigenetic covariates (Greenman et al. 2006, Martincorena
et al. 2017). A value of dN/dS = 1 implies having the same ratio of non-silent to silent
variants as expected, indicating no selection, while values greater than 1 signify positive
selection, and negative values correspond to negative selection.
We analysed the dN/dS ratios of DNA repair genes of interest using the trinucleotide
model according to (Martincorena et al. 2017). Background mutation rates were estimated
using all genes except for consistently under-covered ones (Wang, Kim, and Chuang 2018).
The significance of selection was assessed by comparing the relevant  2 statistic of the
dN/dS ratio to  2-distribution with df = 1.
To study global selection across DNA repair pathways, we ran dNdSCV analysis sep-
arately within each cancer type using the samples with less than 1000 coding mutations.
For gene-level analyses, we estimated the global and per-gene dN/dS values across all can-
cer types including all samples with less than 1000 coding mutations, using the extended
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Figure 7.12: Selection across DNA repair pathways and individual genes. Corresponds to
Figure 6A in Volkova et al. 2019.
set of 248 DNA repair associated genes (Appendix C). On the pathway level, we estimated
the global dN/dS ratio over the list of core genes within each pathway in each cancer type.
dN/dS ratios for missense and nonsense mutations were calculated separately. All of these
ratios were then compared to 1 using  2-statistic of the squared z-score of log (dN/dS).
Resulting p-values were adjusted for multiple testing within corresponding groups using
the Benjamini-Hochberg procedure (Benjamini and Hochberg 1995).
Indeed, most of the DNA repair genes and pathways showed a high dN/dS ratio,
indicating positive selection typical for driver gene mutations (Figure 7.12). The pathway-
level analysis confirmed the pan-cancer excess of non-silent mutations in genes encoding for
DNA damage sensing (DS) proteins including TP53, ATR and ATM (Table ??). Equally,
high impact mutations predominate in MMR genes in uterine and stomach cancers.
In single-gene analysis, 10/276 DNA repair genes displayed significant signs of positive
selection in missense mutations, and 16/276 DNA repair genes were enriched in truncating
mutations (FDR ¡ 10%; Figure 7.12, Table ??). Among these the majority were known
cancer genes such as TP53, IDH1, PTEN, ATM, ATRX, SMARCA4, BRCA1/2, MLH1,
but we also detected new genes with mild signs of positive selection, namely the DNA
damage sensing protein kinase PRKDC (dN/dS = 2 for nonsense variants; q-value =
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0.01), the pre-mRNA processing factor PRPF19, involved in TC-NER, (dN/dS = 4.6
for nonsense variants; q-value = 0.005) and the homologous recombination repair gene
SWI5 (dN/dS = 3.2 for missense and 5.3 for nonsense variants; q-value = 0.05 and 0.07,
respectively).
Negative selection for non-silent mutations is generally rare in cancer genomes and re-
stricted to essential genes in haploid regions (Martincorena et al. 2017, Weghorn and Sun-
yaev 2017). However, missense mutations in POLR2A which encodes the DNA-directed
RNA polymerase II subunit RPB1, showed a weak evidence of negative selection when
analysed across samples with less than 500 mutations(dN/dS = 0.62, 95% CI 0.44  0.92;
q-value = 0.4), which was further exacerbated when analysed across the samples with a
single copy of POLR2A (dN/dS = 0.26), suggesting that non-silent mutations in this gene
are deleterious to cancer cell survival. Negative selection requires much greater statistical
power to be detected compared to positive; hence, the q-value for this gene is high, and
no other gene showed a clear indication of negative selection. However, negative selection
in this gene is not surprising since POLR2A is an essential gene located on chromosome
arm 17p, in cis with the tumour suppressor gene TP53. As 17p loss is common in cancers,
this leaves a↵ected cancer cells with only one copy of this essential gene in 20% of cancers
rendering them sensitive to deleterious mutations. Thus, this genetic signal underscores
the rationale that POLR2A might constitute a therapeutically exploitable vulnerability
to ↵-amanitin in –17p/TP53 -deficient cancers (Liu et al. 2015).
7.4.2 Relationship between mutation rate and cancer risk
The apparent discrepancy between the strong genetic evidence for DNA repair defi-
ciency driving cancer both in inherited cancer syndromes, but also through somatically
acquired mutations and the moderate phenotypes can, in fact, be explained from the per-
spective of somatic evolution. Given that mutations occur throughout a cancer patient’s
lifetime (Gerstung et al. 2017, Tomasetti, Vogelstein, and Parmigiani 2013), a DNA repair
deficiency acquired at a late stage during tumour development may not have enough time
to impact the mutational burden or signature substantially. In addition, it is important to
consider the relationship between mutation rate and cancer risk, mindful that a number
of driver mutations are needed for cancer transformation. Classic studies by (Armitage
and Doll 1954) postulated that there exist about five rate-limiting steps needed for cancer
formation, based on the observation that cancer risk increases approximately as the fifth
power of age, a prediction in good agreement with recent estimates of 2-10 driver gene
mutations in cancer genomes (Martincorena et al. 2017; Vogelstein and Kinzler 2015).
As the chance to independently mutate multiple driver genes in the same cell becomes a
152
power of the mutation rate, a relatively small change in the mutation rate leads to a dra-
matic increase in the incidence rate of a cancer at any given age: Increasing the mutation
rate by a factor of 2 leads to an approximately 25 = 32 fold increased probability of 5
co-occurring mutations; clonal expansions reduce the exponent, but preserve the overall
exponential scaling between mutation rate and cancer risk (Tomasetti et al. 2015).
Figure 7.13: Relationship between fold-changes in cancer incidence and mutation rate
for skin cancers and xeroderma pigmentosum (XP), colorectal cancers and MMR defects,
lung cancer and smoking, breast cancer and smoking. The grey line denotes the region of
expected mutation rate fold-change for NER gene defects considered in the analysis.
Indeed, the observed relation of relative risk and mutation rate increases in several
cancer predisposition syndromes, but also smoking-related lung cancers follow this trend
(Figure 7.13). As noted previously, MMR-deficient colorectal cancers have an 8-10 fold
higher mutation burden than MMR-proficient carcinomas, but a⇠115 times higher burden
in MMR-deficient patients. Similarly, HR-deficient breast cancers display a roughly 3-fold
higher mutation burden, despite 20-40 fold increased risks for BRCA1/2 mutation carriers
(Antoniou et al. 2003). Even more so, XP patients display a 100-fold increase of mutation
rate (Zheng et al. 2014) but have an approximately 10,000 fold increased rate of skin
cancers (Bradford et al. 2011). Under this model, high-impact SNPs in NER genes, which
lead to a ⇠ 2-fold increase in skin cancer risk (Wheless et al. 2012) would be expected to
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cause a 20% increase in mutation rate, in agreement with our observations (Figure 7.13).
While the exact number of driver gene mutations remains unknown in each cancer type,
these data imply that small changes in mutation rates can have a large impact on cancer
risk, and conversely noticeable risk factors may derive from rather moderate mutagenic
e↵ects.
Moderate e↵ect sizes of genotoxin-repair interactions below a factor of 2 were found
in our C. elegans screen in 25% of cases (Figure 6.6). Identifying small mutation rate
changes in primary cancers proves di cult, especially as a DNA repair deficiency e↵ect
often only consists of an increase in mutation burden without any change to the mutational
spectrum (Figure 7.2). Lastly, our analysis shows that the dN/dS ratio is around 2 for
most DNA repair genes (Figure 7.12) implicating that only half of non-silent variants are
truly cancer-causing, further diluting what may be a weak mutational signal.
7.5 Discussion
Our experimental data suggested that mutagenesis is fundamentally driven by the
antagonism between DNA damage and repair; however, in the cancer genome, the mani-
festation of this principle may be masked by fluctuations in exposure doses, mutual timing
of DNA repair deficiency and genotoxin exposure, as well as other confounding processes.
Our cancer genome analysis showed that only the most extreme cases be reliably detected
with the data currently available, and suggested that it is likely an issue of statistical
power – the e↵ects which would be expected based on evolutionary considerations have a
magnitude similar to the current inter-personal variation, hence more genomes with longer
exposures and tumour development times would be necessary to observe the actual di-
versity of damage-repair interactions. Nevertheless, there is a general selection process
favouring mutations that inactivate DNA repair and DNA damage response genes during
carcinogenesis but do not necessarily have a measurable e↵ect on the mutational burden
or mutational spectrum.
Indeed, while non-silent mutations in DNA repair genes are common, bi-allelic inac-
tivation of both copies, which is generally required for loss of function, appears to be a
relatively rare phenomenon. Frequent lack of strong mutational signature may appear
confusing, however it becomes less surprising in light of timing and evolutionary consid-
erations: to accumulate a substantial amount of mutations and manifest in a measurably
increased mutation rate or altered spectrum, the DNA repair deficiency has to happen
early enough to be in place when a mutagenic process starts to introduce damage to the
DNA.
The notion of DNA damage and repair interactions shaping the mutational landscape
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is critical from the perspective of DNA repair deficiency conditions because the same
deficiency will yield a variety of spectra depending on the DNA damage (or replication
errors) the genome experiences. Knowing the way how DNA repair deficiencies a↵ect the
mutational signatures of mutagens can also inform diagnostics and treatment choice, as it
presents additional means of detecting clinically relevant DNA repair deficiencies, quan-
tifying their onset timing and fraction of the tumour carrying this deficiency. Many DNA
repair deficiencies indicate higher sensitivity to particular therapies, including PARP in-
hibition in case of HR deficiency, temozolomide treatment for DR-deficient glioblastomas,
immunotherapy for MMR-deficient tumours, and platinum agent treatment for NER-
deficient tumours (Hosoya and Miyagawa 2014).
Thus, to ascertain the status of a DNA repair pathway, a search for potential genetic
and epigenetic defects in the DNA repair genes should be accompanied by a careful
mutational signature analysis. Each of these parts alone can fail to indicate a DNA repair
deficiency due to timing limitations or ambiguity in variant interpretation. Both of these
limitations should be addressed by analysing larger datasets containing diverse variants
across DNA repair-related genes and conducting experiments to validate the presence of
functional consequences of DNA repair gene inactivation.
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Chapter 8
Discussion
8.1 Summary of the main findings
In this thesis, I aimed to characterise a range of experimental mutational signatures
induced by DNA repair deficiencies and genotoxins and to explore and quantify the factors
a↵ecting variation in mutational spectra. These goals were achieved by applying statistical
modelling and investigating the genomic features of DNA damage and repair in nearly
3,000 samples from C. elegans and 10,000 cancer exomes from TCGA.
In brief, the results of the thesis are:
1. A catalogue of experimental mutational signatures of DNA repair deficiencies and
genotoxin exposures. We described the genome-wide mutational spectra accumu-
lated in 70 C. elegans lines with di↵erent DNA repair knockouts. Our analysis
demonstrated the importance of TLS polymerases for the genome stability main-
tenance upon propagation over generations, suggested that defects in HRR com-
ponents participating in di↵erent stages of HRR yield di↵erent mutations, charac-
terised structural variation in the absence of crosslink repair, and quantified the
protective capacity of apoptosis regulators. In addition, we showed that clustered
mutations in the absence of specific exposures are almost exclusively arising due to
mutagenic end-joining repair.
2. A high-resolution picture of the mutagenesis induced by MMR deficiency in C.
elegans and gastrointestinal cancers. The comparison between the experimental
and computational signatures helped to resolve the mixture between non-canonical
MMR repair of mismatches produced by the deamination of 5-meC as well as in-
dicates that other MMR signatures observed in cancers are likely to stem from the
interactions of some mutational processes.
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3. Characterisation of the experimental signatures of 12 genotoxins and comparison
between genotoxin-induced mutagenesis in C. elegans, human iPS cell lines and
cancer. While not being fully comparable, experimental and computational signa-
tures demonstrated important similarities and discrepancies indicating the scopes
of applicability of these systems.
4. A systematic and comprehensive analysis of how the interactions between mutagens
and inactivations of DNA repair pathways shape the rate and spectra of muta-
tions demonstrating that a third of all combinations of DNA repair deficiency and
genotoxin exposure yield a change in the mutation rate or the spectrum.
5. Describing the range and mutational e↵ects of DNA repair defects in cancer. Apart
from confirming previously described interactions, we were able to quantify the
reduction in C>G mutations induced by APOBEC in the absence of REV1 or UNG
and demonstrate the tissue-specific di↵erences in rates of base substitutions and
indels caused by MMR deficiency. The distribution of damage-repair interaction
e↵ects observed in cancer was similar to the one observed in the experimental work:
there are very few strong interactions, while the majority demonstrate weak e↵ects.
However, evolutionary considerations suggested that even small changes in mutation
rates can lead to a steady increase in cancer incidence.
In general, this work demonstrated how a large-scale mutagenesis screen in a model
system could inform and help to disentangle the components contributing to mutagenesis
in cancer. More importantly, we also described the variability of mutational spectra of mu-
tagenic processes across di↵erent genetic backgrounds, which demonstrated the prevalence
of interaction e↵ects between DNA repair components and damaging agents. Methodolog-
ically, this work presents two models for signature analysis in a controlled and uncontrolled
environment incorporating the interactions of factors and allowing quantification of their
contributions.
8.2 Conclusions
The analysis we conducted has several important implications. A comprehensive cat-
alogue of high-resolution profiles for a wide range of genetic knockouts and mutagens will
be a valuable resource for both C. elegans DNA repair biology and toxicology research
and cancer genomics investigations as it presents the first set of experimentally derived
interaction spectra.
First of all, our analysis demonstrated that C. elegans this a suitable model system
to study genome-wide mutagenesis patterns and inform cancer research. The dramatic
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di↵erence in the magnitude of interaction e↵ects observed in the screen and cancers also
indicates the power of C. elegans model system over the aggregation of cancer data with
unknown genotoxic exposure and timing of repair deficiencies. Additionally, the simplicity
of the experimental setup allowed us to conduct a large-scale experiment covering many
possible combinations of factors which would be tedious to perform in human cell lines,
where only the analyses of either genotoxic or genetic factors were conducted up to date
(Zou et al. 2018, Kru¨ger and Piro 2019). Nevertheless, following on from our study,
we expect that analysing DNA repair-defective model organisms and human cell lines,
alone or in conjunction with defined genotoxic agents, will contribute to a more precise
definition of mutational signatures occurring in cancer genomes and to establishing the
aetiology of these signatures.
Demonstration of the complex relationship between mutagenic processes and DNA
repair pathway status has the potential to change one of the main assumptions behind
the mutational signature analysis stating the stability of signatures. The central insight of
the interaction analysis is that a surprising 30% of experiments combining DNA damage
and DNA repair deficiency demonstrated altered mutagenesis manifesting via a change in
mutation rate or mutational spectrum. It is a correction to the widespread expectation in
cancer genomics that there should be a one-to-one correspondence between the mutational
signatures found in human cancers and a single genetic or genotoxic cause.
The high frequency yet the low impact of DNA repair defects observed in the TCGA
collection of cancer exomes suggests that except for rare and extreme cases, the e↵ect of
these mutations appear small compared to the observed inter-sample heterogeneity. The
presence of positive selection in several pathways across di↵erent cancer types, however,
suggests that they can drive carcinogenesis without causing a substantial change in muta-
genicity. This contradiction can be explained by the fact that the process of carcinogenesis
usually requires a set of 2-10 driver gene mutations to occur in the right order (Tomasetti
et al. 2015, Martincorena et al. 2018, Gerstung et al. 2018), with the chances of each
next mutation rising steeply even for a small increase in mutation rates. Hence, small
changes in mutation rate or pathogenicity of mutations, despite being undetectable due
to technical or statistical limitations, can have a high impact on cancer development.
The analysis of mutational signatures has drawn much interest recently and dramat-
ically extended our knowledge of the range and types of mutation patterns observed in
human cancer and healthy tissues. However, one needs to recognise the variable nature
of mutational spectra caused by the underlying dichotomy of damage and repair. This
variability stems from the large di↵erence between the amount of damage and amount
of observed mutations which is defined by the e ciency and redundancy of DNA repair
processes.
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From the clinical point of view, our results may seem to diminish the value of muta-
tional signature analysis. However, it instead suggests that simply associating signatures
with genetic and clinical variables post-hoc is not enough, and some additional informa-
tion about samples should be included to inform the signature analysis. A first attempt to
employ clinical information to improve signature fitting was made by Robinson, Sharan,
and Leiserson 2019 via tying the signature exposures to sample properties. The model
suggested in this thesis aimed to accommodate for a spectrum change in a mutational
signature attributable to these additional factors.
Overall, the insights described in this thesis bind together to deliver one important
idea: a spectrum of mutations which can be observed upon sequencing is only a final sum
of several damaging and repair processes acting with di↵erent signs. Hence, both these
sides have to be taken into account when studying mutations in cancer or any other system.
The actual range of potential interactions a↵ecting the mutational spectra in cancer is
still to be explored. Thus, one has to acknowledge this additional variation and integrate
it into mutational signature analysis to ensure reliable interpretation and applicability in
clinical oncology. Otherwise, unsupervised extraction of mutational signatures is likely
only ever to represent the most striking exemplars of specific mutagenic constellations.
Lastly, the success of cross-species comparison shows that the fundamental laws of
mutagenesis are acting in the same way across eukaryotic organisms from nematodes
to humans. It reminds us that many mutational processes considered responsible for
tumorigenesis are, in fact, not exclusive to cancer: these are the same forces as the ones
driving variation and evolution of species.
8.3 Limitations of the analysis and potential improve-
ments
The mutagenesis screen in C. elegans revealed a vast amount of details about the
underlying mechanisms and provided the opportunity to quantify the mutagenic contri-
butions and interactions of DNA damage and repair. However, like any other model
system, C. elegans has some disadvantages which a↵ect the scale of the alterations which
can be observed.
The self-fertilising mode and high coding fraction of C. elegans genome do not allow
it to accumulate as many mutations as a typical tumour. An average sample in the
screen only carried 0.5 mutations per Mbps, whereas a typical tumour would have about
3-5 mutations per Mbps (as per ICGC March 2019 data release, https://dcc.icgc.
org). Samples with the largest observed mutation rate – pole-4; pms-2 double mutants –
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could not be propagated beyond the 10-th generation, indicating that having more than
13-15 mutations/Mbps is lethal for C. elegans (although still normal for cancer). The
experimental setup was adjusted to avoid as much negative selection as possible, but it
still did not allow observing any genomic alterations which were too damaging to obtain
a viable progeny. Moreover, aggregation of large-scale rearrangements was also limited
as they tend to have a tremendous impact on the embryonic development of C. elegans.
Therefore, it was not possible to observe as many rearrangements as typically observed
in cancers.
Analysis of human data also posed its challenges. Interpersonal variability creates
much noise in the data. The information which could account for some of it – data on the
relevant exposures and age – was missing for many samples. Estimation of the interaction
e↵ects was further complicated by the lack of an accurate estimate of the mutual timing
of the exposures and DNA deficiency onset as well as the clonal heterogeneity within
the tumour, as both these factors define the amount of interaction-associated mutations
which can be confidently detected.
Hence, there are some suggestions which could improve the analysis but did not fit
into the scope of the projects I worked on:
• Generating and sequencing more replicates. The majority of the experiments had
three biological replicates to estimate the variability of mutational spectra. However,
even after pulling the data from di↵erent experiments together and estimating the
variance of the signatures, some of the most variable interactions did not produce a
feasible estimate due to insu cient data.
• Controlling for batch e↵ects. Genotoxin exposure experiments were performed in
batches, and the genotoxin solution or irradiation exposure were set up separately
for each batch. Some of the mutagens were problematic in exploitation and caused
some discrepancies in dose response between the sets of experiments performed at
di↵erent times. Introducing better batch design and a high number of wild-type
controls would help to avoid this issue.
• Adjusting the set of genotoxins and the list of tested combinations in light of the
cases with observed interactions and the frequency of DNA repair gene mutations in
cancer. It may be beneficial to produce more samples with a focus on the interactions
between TLS polymerases and various carcinogens or chemotherapy agents as well
as study more double mutants defective in more than one pathway.
• Applying a more sophisticated algorithm for the identification of DNA damage-
repair interaction e↵ects in cancer. A model which could accommodate more noise
as well as handle the correlation between the factors could potentially capture more
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signal.
• Finally, incorporating additional considerations in the analysis of interactions in
cancer. Using more clinical variables such as nationality and gender and taking into
account the timing of mutations could yield better patient stratification, but would
also require even more data than is available now.
8.4 Outlook and future research
The work described in this thesis was performed in the scope of a project conceived over
four years ago. With the scientific progress accelerating dramatically over the last decade
(introduction of CRISPR-Cas9 system for targeted genome editing, the development of
numerous single-cell techniques, advances in accuracy, speed and quality of sequencing,
just to list a few), there is no doubt the same project, if it started today, would have even
a larger scale and could potentially employ di↵erent experimental and computational
methods.
The introduction of human organoids as model systems (Blokzijl et al. 2016, Drost
et al. 2017) and the establishment of genome-wide mutagenesis experiments in CRISPR-
modified human iPSCs and cancer cell lines (Zou et al. 2018, Petljak et al. 2019) allows
exploring the damage-repair interactions in a human-based system. Although these ex-
periments seem to be the closest reflection of the mutagenesis in human tissues, they are
highly labour- and resource-demanding and prone to limitations. Organoids still represent
a simplified model of tissue as they lack the proper structure and full set of cell types;
it is also di cult to make organoids reach full maturation, and they often can not be
expanded for as long as need (Xu et al. 2018). iPS cells have a similar issue with matu-
rity and are also not fully representative of di↵erent human cell types (Hockemeyer and
Jaenisch 2016). Hence, the simplicity and e ciency of other model systems, C. elegans
in particular, will remain advantageous for creating large-scale screens.
Taking into account these aspects, one can suggest several avenues of improvement
and enrichment of the current analysis, which could be undertaken by the successive
researchers working on the quantification of DNA repair and damage signatures.
As mentioned in the previous section, generating more samples using the potentially
impactful interactions could enhance the dataset. In addition, conducting confirmatory
experiments for the strongest interactions using human-based model systems could in-
crease the potential of this dataset for cancer research. Combining DNA repair deficiency
and genotoxin exposure in human cells would highlight the di↵erences and similarities
between the model systems which should be taken into account when translating the
findings from one to another.
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Despite the availability of a massive catalogue of cancer data, many combinations of
exposures and DNA repair defects could not be found in a su cient number of samples.
Hence, analysis of the datasets such as the data on metastatic tumours by the Hartwig
medical foundation (Priestley et al. 2018), or the future datasets containing the mutational
spectra of carcinogen-induced cancers, or cancers and cancer cell lines after exposure to
genotoxic agents could expand the range of detectable interactions and reveal some new
mutational signatures stemming from these interactions. Especially having a snapshot of
the mutations present in a tumour before and after treatment could substantially enrich
the analysis of interactions in cancer.
To produce a better quantitative model of DNA damage induction, removal of damage
via DNA repair, and introduction of mutations, a deeper understanding of damage and
repair specificities is required. Strong interactions, such as the alteration of the MMS
signature under polk-1 deficiency, pose a question: where do both the original and altered
spectrum stem from? Is any of them reflecting the real distribution of the damage along
the genome or only the context preferences of the TLS polymerases and repair enzymes?
Hence, one of the directions of exploration should be experimental work on directly mea-
suring the distribution and rate of damage induced by genotoxins (Sykora et al. 2018)
as well as then the activity and success rate of DNA repair (Gassman and Holton 2019,
Azqueta et al. 2019). Integrating these data with the observed spectra of mutations will
provide a full quantitative description of the mutational input of the DNA damaging
agents and repair systems.
Our screen, as well as other studies (Lange, Takata, and Wood 2011), suggested that
DNA polymerases often serve as the primary agents introducing mutations. From that
perspective, another prospective avenue of research would be to characterise the high-
resolution genome-wide mutational spectra generated by all human polymerases on dif-
ferent substrates, including both normal and damaged substrates. Such a study could help
to refine the role of polymerases and their defects in cancer and disease as well as give a
better picture of the background mutagenesis in healthy tissues. Additionally, a better
resolution of the genome-wide patterns of background mutagenesis could be achieved by
analysing an extensive collection of normal tissues using high-sensitivity sequencing tech-
niques such as BotSeq (Hoang et al. 2016, Dou et al. 2018). Confidently quantifying the
distribution of rare mutations creating the somatic mosaicism in healthy individuals will
improve the current understanding of carcinogenesis and ageing.
The development of these research directions could provide the building blocks for
forming an exhaustive and accurate model of mutation acquisition upon di↵erent condi-
tions. The current trends in the biomedical field suggest that whole-genome sequencing
will be more and more common for all kinds of diseases which involve mutagenic pro-
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cesses, and the fundamental knowledge of mutagenesis enhanced by the understanding of
damage-repair interactions will provide the means to interpret and utilise these mutational
spectra for better treatment and prevention of human diseases.
Bibliography
Abou-Zied, Osama K, Ralph Jimenez, and Floyd E Romesberg (2001). “Tautomerization
dynamics of a model base pair in DNA”. In: Journal of the American Chemical Society
123.19, pp. 4613–4614.
Abyzov, Alexej et al. (2012). “Somatic copy number mosaicism in human skin revealed
by induced pluripotent stem cells”. In: Nature 492.7429, p. 438.
Akaike, Hirotogu (1992). “Information Theory and an Extension of the Maximum Likeli-
hood Principle”. In: Springer Series in Statistics, pp. 610–624.
Aksenova, Anna et al. (2010). “Mismatch repair-independent increase in spontaneous
mutagenesis in yeast lacking non-essential subunits of DNA polymerase ✏”. en. In:
PLoS Genet. 6.11, e1001209.
Alberts, Bruce et al. (2007). Molecular Biology of the Cell.
Albertson, Tina M et al. (2009). “DNA polymerase epsilon and delta proofreading sup-
press discrete mutator and cancer phenotypes in mice”. en. In: Proc. Natl. Acad. Sci.
U. S. A. 106.40, pp. 17101–17104.
Alexandrov, Ludmil et al. (2018). “The Repertoire of Mutational Signatures in Human
Cancer”. In: bioRxiv.
Alexandrov, Ludmil B et al. (2013a). “Deciphering signatures of mutational processes
operative in human cancer”. en. In: Cell Rep. 3.1, pp. 246–259.
Alexandrov, Ludmil B et al. (2013b). “Signatures of mutational processes in human can-
cer”. en. In: Nature 500.7463, pp. 415–421.
Alexandrov, Ludmil B et al. (2015). “Clock-like mutational processes in human somatic
cells”. en. In: Nat. Genet. 47.12, pp. 1402–1407.
Alexandrov, Ludmil B et al. (2016). “Mutational signatures associated with tobacco smok-
ing in human cancer”. en. In: Science 354.6312, pp. 618–622.
Alkodsi, Amjad et al. (2019). “Distinct subtypes of di↵use large B-cell lymphoma defined
by hypermutated genes”. In: Leukemia, p. 1.
Antoniou, A et al. (2003). “Average risks of breast and ovarian cancer associated with
BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a
combined analysis of 22 studies”. en. In: Am. J. Hum. Genet. 72.5, pp. 1117–1130.
165
Antoshechkin, Igor and Paul W Sternberg (2007). “The versatile worm: genetic and ge-
nomic resources for Caenorhabditis elegans research”. In: Nature Reviews Genetics
8.7, p. 518.
Arlt, Volker M, Marie Stiborova, and Heinz H Schmeiser (2002). “Aristolochic acid as a
probable human cancer hazard in herbal remedies: a review”. In: Mutagenesis 17.4,
pp. 265–277.
Armitage, P and R Doll (1954). “The Age Distribution of Cancer and a Multi-stage
Theory of Carcinogenesis”. In: British Journal of Cancer 8.1, pp. 1–12.
Armstrong, Bruce K, Anne Kricker, and Dallas R English (1997). “Sun exposure and skin
cancer”. In: Australasian journal of dermatology 38.S1, S1–S6.
Attaluri, Sivaprasad et al. (2009). “DNA adducts of aristolochic acid II: total synthesis
and site-specific mutagenesis studies in mammalian cells”. In: Nucleic acids research
38.1, pp. 339–352.
Azqueta, Amaya et al. (2019). “DNA repair as a human biomonitoring tool; comet assay
approaches”. In: Mutation Research/Reviews in Mutation Research.
Baez-Ortega, Adrian and Kevin Gori (2017). “Computational approaches for discovery of
mutational signatures in cancer”. In: Briefings in bioinformatics 20.1, pp. 77–88.
Baross-Francis, Agnes et al. (2001). “Elevated mutant frequencies and increased C : G!T
: A transitions in Mlh1/ versus Pms2/ murine small intestinal epithelial cells”. In:
Oncogene 20.5, pp. 619–625.
Baskar, Rajamanickam et al. (2012). “Cancer and radiation therapy: current advances
and future directions”. In: International journal of medical sciences 9.3, p. 193.
Behjati, Sam et al. (2014). “Genome sequencing of normal cells reveals developmental
lineages and mutational processes”. In: Nature 513.7518, p. 422.
Behjati, Sam et al. (2016). “Mutational signatures of ionizing radiation in second malig-
nancies”. en. In: Nat. Commun. 7, p. 12605.
Bellacosa, A (2001). “Functional interactions and signaling properties of mammalian DNA
mismatch repair proteins”. en. In: Cell Death Di↵er. 8.11, pp. 1076–1092.
Benjamini, Yoav and Yosef Hochberg (1995). “Controlling the False Discovery Rate: A
Practical and Powerful Approach to Multiple Testing”. In: Journal of the Royal Sta-
tistical Society: Series B (Methodological) 57.1, pp. 289–300.
Bernstein, Carol et al. (2013). “DNA damage, DNA repair and cancer”. In: New Research
Directions in DNA Repair. IntechOpen.
Betancourt, Michael and Mark Girolami (2015). “Hamiltonian Monte Carlo for hierarchi-
cal models”. In: Current trends in Bayesian methodology with applications 79, p. 30.
Bhargava, Ragini, David O Onyango, and Jeremy M Stark (2016). “Regulation of single-
strand annealing and its role in genome maintenance”. In: Trends in Genetics 32.9,
pp. 566–575.
Blei, David M, John D La↵erty, et al. (2007). “A correlated topic model of science”. In:
The Annals of Applied Statistics 1.1, pp. 17–35.
Blei, David M, Andrew Y Ng, and Michael I Jordan (2003). “Latent dirichlet allocation”.
In: Journal of machine Learning research 3.Jan, pp. 993–1022.
Blokzijl, Francis et al. (2016). “Tissue-specific mutation accumulation in human adult
stem cells during life”. In: Nature 538.7624, p. 260.
Blokzijl, Francis et al. (2018). “MutationalPatterns: comprehensive genome-wide analysis
of mutational processes”. In: Genome medicine 10.1, p. 33.
Boer, Jan de and Jan HJ Hoeijmakers (2000). “Nucleotide excision repair and human
syndromes”. In: Carcinogenesis 21.3, pp. 453–460.
Bo↵etta, Paolo, Nadia Jourenkova, and Per Gustavsson (1997). “Cancer risk from occupa-
tional and environmental exposure to polycyclic aromatic hydrocarbons”. In: Cancer
Causes & Control 8.3, pp. 444–472.
Boissie`re-Michot, Florence et al. (2016). “Immunohistochemical staining for p16 and
BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-
related) microsatellite instable colorectal carcinomas”. en. In: Virchows Arch. 469.2,
pp. 135–144.
Boland, C R et al. (1998). “A National Cancer Institute Workshop on Microsatellite In-
stability for cancer detection and familial predisposition: development of international
criteria for the determination of microsatellite instability in colorectal cancer”. en. In:
Cancer Res. 58.22, pp. 5248–5257.
Bonneville, Russell et al. (2017). “Landscape of Microsatellite Instability Across 39 Cancer
Types”. en. In: JCO Precis Oncol 2017.
Boot, Arnoud et al. (2018). “In-depth characterization of the cisplatin mutational signa-
ture in human cell lines and in esophageal and liver tumors”. en. In: Genome Res.
28.5, pp. 654–665.
Boulton, Simon J (2010). “DNA repair: Decision at the break point”. In: Nature 465.7296,
p. 301.
Boulton, Simon J et al. (2004). “BRCA1/BARD1 orthologs required for DNA repair in
Caenorhabditis elegans”. In: Current Biology 14.1, pp. 33–39.
Boysen, Gunnar et al. (2009). “The formation and biological significance of N7-guanine
adducts”. In: Mutation Research/Genetic Toxicology and Environmental Mutagenesis
678.2, pp. 76–94.
Bradford, Porcia T et al. (2011). “Cancer and neurologic degeneration in xeroderma pig-
mentosum: long term follow-up characterises the role of DNA repair”. en. In: J. Med.
Genet. 48.3, pp. 168–176.
Brenner, Michaela and Vincent J Hearing (2008). “The protective role of melanin against
UV damage in human skin”. In: Photochemistry and photobiology 84.3, pp. 539–549.
Bronner, C E et al. (1994). “Mutation in the DNA mismatch repair gene homologue
hMLH1 is associated with hereditary non-polyposis colon cancer”. en. In: Nature
368.6468, pp. 258–261.
Brookes, Peter and Philip D Lawley (1961). “The reaction of mono-and di-functional
alkylating agents with nucleic acids”. In: Biochemical Journal 80.3, p. 496.
Brouwer, Judith R, Rob Willemsen, and Ben A Oostra (2009). “Microsatellite repeat
instability and neurological disease”. In: Bioessays 31.1, pp. 71–83.
Brunet, Jean-Philippe et al. (2004). “Metagenes and molecular pattern discovery using
matrix factorization”. en. In: Proc. Natl. Acad. Sci. U. S. A. 101.12, pp. 4164–4169.
Bryan, D Suzi et al. (2014). “High resolution mapping of modified DNA nucleobases using
excision repair enzymes”. In: Genome research 24.9, pp. 1534–1542.
Buhard, Olivier et al. (2006). “Multipopulation analysis of polymorphisms in five mononu-
cleotide repeats used to determine the microsatellite instability status of human tu-
mors”. en. In: J. Clin. Oncol. 24.2, pp. 241–251.
Cadet, Jean and Thierry Douki (2018). “Formation of UV-induced DNA damage con-
tributing to skin cancer development”. In: Photochemical & Photobiological Sciences
17.12, pp. 1816–1841.
Cadet, Jean et al. (2014). “One-electron oxidation reactions of purine and pyrimidine
bases in cellular DNA”. In: International journal of radiation biology 90.6, pp. 423–
432.
Caldecott, Keith W (2008). “Single-strand break repair and genetic disease”. In: Nature
Reviews Genetics 9.8, p. 619.
Campbell, Peter J et al. (2017). “Pan-cancer analysis of whole genomes”. In: BioRxiv,
p. 162784.
Cancer Genome Atlas Network (2012). “Comprehensive molecular characterization of
human colon and rectal cancer”. en. In: Nature 487.7407, pp. 330–337.
— (2015). “Genomic Classification of Cutaneous Melanoma”. en. In: Cell 161.7, pp. 1681–
1696.
Cancer Genome Atlas Research Network (2012). “Comprehensive genomic characteriza-
tion of squamous cell lung cancers”. en. In: Nature 489.7417, pp. 519–525.
— (2014a). “Comprehensive molecular characterization of gastric adenocarcinoma”. en.
In: Nature 513.7517, pp. 202–209.
— (2014b). “Comprehensive molecular profiling of lung adenocarcinoma”. en. In: Nature
511.7511, pp. 543–550.
Cancer Genome Atlas Research Network et al. (2013). “Integrated genomic characteriza-
tion of endometrial carcinoma”. en. In: Nature 497.7447, pp. 67–73.
Cemgil, Ali Taylan (2009). “Bayesian inference for nonnegative matrix factorisation mod-
els”. en. In: Comput. Intell. Neurosci. P. 785152.
Chadt, Jiri et al. (2008). “Monitoring of dimethyl sulphate-induced N3-methyladenine,
N7-methylguanine and O6-methylguanine DNA adducts using reversed-phase high
performance liquid chromatography and mass spectrometry”. In: Journal of Chro-
matography B 867.1, pp. 43–48.
Chahwan, Richard et al. (2012). “AIDing antibody diversity by error-prone mismatch
repair”. In: Seminars in immunology. Vol. 24. 4. Elsevier, pp. 293–300.
Chakraborty, Anirban et al. (2016). “Classical non-homologous end-joining pathway uti-
lizes nascent RNA for error-free double-strand break repair of transcribed genes”. In:
Nature communications 7, p. 13049.
Chan, Kin and Dmitry A Gordenin (2015). “Clusters of multiple mutations: incidence
and molecular mechanisms”. In: Annual review of genetics 49, pp. 243–267.
Chang, Howard HY et al. (2017). “Non-homologous DNA end joining and alternative
pathways to double-strand break repair”. In: Nature reviews Molecular cell biology
18.8, p. 495.
Chen, Jian-Min, Claude Fe´rec, and David N Cooper (2013). “Patterns and mutational
signatures of tandem base substitutions causing human inherited disease”. In: Human
mutation 34.8, pp. 1119–1130.
Christensen, Sharon et al. (2019). “5-Fluorouracil treatment induces characteristic T¿ G
mutations in human cancer”. In: bioRxiv, p. 681262.
Ciccia, Alberto and Stephen J Elledge (2010). “The DNA damage response: making it
safe to play with knives”. In: Molecular cell 40.2, pp. 179–204.
Cohen, Seth M and Stephen J Lippard (2001). “Cisplatin: from DNA damage to cancer
chemotherapy”. In:
Comon, Pierre and Christian Jutten (2010). Handbook of Blind Source Separation: Inde-
pendent component analysis and applications. Academic press.
Connor, Frances et al. (2018). “Mutational landscape of a chemically-induced mouse
model of liver cancer”. In: Journal of hepatology 69.4, pp. 840–850.
Conrad, Donald F et al. (2011). “Variation in genome-wide mutation rates within and
between human families”. In: Nature genetics 43.7, p. 712.
Cortes-Ciriano, Isidro et al. (2017). “A molecular portrait of microsatellite instability
across multiple cancers”. en. In: Nat. Commun. 8, p. 15180.
Davidson, Philip R et al. (2017). “A pooled mutational analysis identifies ionizing radiation-
associated mutational signatures conserved between mouse and human malignancies”.
In: Scientific reports 7.1, p. 7645.
Davies, Helen et al. (2017). “HRDetect is a predictor of BRCA1 and BRCA2 deficiency
based on mutational signatures”. In: Nature medicine 23.4, p. 517.
Davis, Anthony J and David J Chen (2013). “DNA double strand break repair via non-
homologous end-joining”. In: Translational cancer research 2.3, p. 130.
De Bont, Rinne and Nik Van Larebeke (2004). “Endogenous DNA damage in humans: a
review of quantitative data”. In: Mutagenesis 19.3, pp. 169–185.
Deem, Angela et al. (2011). “Break-induced replication is highly inaccurate”. In: PLoS
biology 9.2, e1000594.
Degtyareva, Natalya P et al. (2019). “Mutational signatures of redox stress in yeast single-
strand DNA and of aging in human mitochondrial DNA share a common feature”. In:
PLoS biology 17.5, e3000263.
Degtyareva, Natasha P et al. (2002). “Caenorhabditis elegans DNA mismatch repair gene
msh-2 is required for microsatellite stability and maintenance of genome integrity”.
en. In: Proc. Natl. Acad. Sci. U. S. A. 99.4, pp. 2158–2163.
Delaney, James C and John M Essigmann (2004). “Mutagenesis, genotoxicity, and re-
pair of 1-methyladenine, 3-alkylcytosines, 1-methylguanine, and 3-methylthymine in
alkB Escherichia coli”. In: Proceedings of the National Academy of Sciences 101.39,
pp. 14051–14056.
Denissenko, Mikhail F et al. (1998). “Slow repair of bulky DNA adducts along the non-
transcribed strand of the human p53 gene may explain the strand bias of transversion
mutations in cancers”. In: Oncogene 16.10, p. 1241.
Denver, Dee R et al. (2004). “Abundance, distribution, and mutation rates of homopoly-
meric nucleotide runs in the genome of Caenorhabditis elegans”. en. In: J. Mol. Evol.
58.5, pp. 584–595.
Denver, Dee R et al. (2005). “Mutation rates, spectra and hotspots in mismatch repair-
deficient Caenorhabditis elegans”. en. In: Genetics 170.1, pp. 107–113.
Denver, Dee R et al. (2009). “A genome-wide view of Caenorhabditis elegans base-
substitution mutation processes”. In: Proceedings of the National Academy of Sciences
106.38, pp. 16310–16314.
Devarajan, Karthik (2008). “Nonnegative matrix factorization: an analytical and inter-
pretive tool in computational biology”. In: PLoS computational biology 4.7, e1000029.
Devasagayam, TPA et al. (2004). “Free radicals and antioxidants in human health: current
status and future prospects”. In: Japi 52.794804, p. 4.
Ding, Li et al. (2008). “Somatic mutations a↵ect key pathways in lung adenocarcinoma”.
In: Nature 455.7216, p. 1069.
Dong, Hongbin et al. (2015). “Update of the human and mouse Fanconi anemia genes”.
In: Human genomics 9.1, p. 32.
Dou, Yanmei et al. (2018). “Detecting somatic mutations in normal cells”. In: Trends in
Genetics 34.7, pp. 545–557.
Dow, Michelle et al. (2018). “Integrative genomic analysis of mouse and human hepa-
tocellular carcinoma”. In: Proceedings of the National Academy of Sciences 115.42,
E9879–E9888.
Drabløs, Finn et al. (2004). “Alkylation damage in DNA and RNA—repair mechanisms
and medical significance”. In: DNA repair 3.11, pp. 1389–1407.
Drost, Jarno et al. (2017). “Use of CRISPR-modified human stem cell organoids to study
the origin of mutational signatures in cancer”. In: Science 358.6360, pp. 234–238.
Drummond, J T et al. (1995). “Isolation of an hMSH2-p160 heterodimer that restores
DNA mismatch repair to tumor cells”. en. In: Science 268.5219, pp. 1909–1912.
Dudley, J C et al. (2016). “Microsatellite Instability as a Biomarker for PD-1 Blockade”.
In: Clinical Cancer Research 22.4, pp. 813–820.
Durno, Carol A et al. (2015). “Phenotypic and genotypic characterisation of biallelic mis-
match repair deficiency (BMMR-D) syndrome”. en. In: Eur. J. Cancer 51.8, pp. 977–
983.
Engert, Andreas, JurgenWolf, and Volker Diehl (1999). “Treatment of advanced Hodgkin’s
lymphoma: standard and experimental approaches.” In: Seminars in hematology. Vol. 36.
3, pp. 282–289.
Faili, Ahmad et al. (2002). “Induction of somatic hypermutation in immunoglobulin genes
is dependent on DNA polymerase iota”. In: Nature 419.6910, p. 944.
Figueroa-Gonza´lez, Gabriela and Carlos Pe´rez-Plasencia (2017). “Strategies for the eval-
uation of DNA damage and repair mechanisms in cancer”. In: Oncology letters 13.6,
pp. 3982–3988.
Fischer, Andrej et al. (2013). “EMu: probabilistic inference of mutational processes and
their localization in the cancer genome”. In: Genome biology 14.4, R39.
Fishel, R et al. (1994). “The human mutator gene homolog MSH2 and its association with
hereditary nonpolyposis colon cancer”. en. In: Cell 77.1, 1 p following 166.
Flibotte, Stephane et al. (2010). “Whole-genome profiling of mutagenesis in Caenorhab-
ditis elegans”. en. In: Genetics 185.2, pp. 431–441.
Forbes, Simon A et al. (2015). “COSMIC: exploring the world’s knowledge of somatic
mutations in human cancer”. In: Nucleic Acids Research 43.D1, pp. D805–D811.
Forment, Josep V, Abderrahmane Kaidi, and Stephen P Jackson (2012). “Chromothripsis
and cancer: causes and consequences of chromosome shattering”. In: Nature Reviews
Cancer 12.10, p. 663.
Fredriksson, Nils Johan et al. (2017). “Recurrent promoter mutations in melanoma are
defined by an extended context-specific mutational signature”. In: PLoS genetics 13.5,
e1006773.
Fronza, Gilberto and Barry Gold (2004). “The biological e↵ects of N3-methyladenine”.
In: Journal of cellular biochemistry 91.2, pp. 250–257.
Funkhouser Jr, William K et al. (2012). “Relevance, pathogenesis, and testing algorithm
for mismatch repair-defective colorectal carcinomas: a report of the association for
molecular pathology”. en. In: J. Mol. Diagn. 14.2, pp. 91–103.
Funnell, Tyler et al. (2019). “Integrated structural variation and point mutation signatures
in cancer genomes using correlated topic models”. In: PLoS computational biology 15.2,
e1006799.
Gan, Gregory N et al. (2008). “DNA polymerase zeta (pol ⇣) in higher eukaryotes”. In:
Cell research 18.1, p. 174.
Gandini, Sara et al. (2008). “Tobacco smoking and cancer: A meta-analysis”. In: Inter-
national journal of cancer 122.1, pp. 155–164.
Garry, Vincent F et al. (1979). “Ethylene oxide: evidence of human chromosomal e↵ects”.
In: Environmental mutagenesis 1.4, pp. 375–382.
Gassman, Natalie R and Nathaniel W Holton (2019). “Targets for repair: detecting and
quantifying DNA damage with fluorescence-based methodologies”. In: Current opinion
in biotechnology 55, pp. 30–35.
Genschel, J et al. (1998). “Isolation of MutSbeta from human cells and comparison of
the mismatch repair specificities of MutSbeta and MutSalpha”. en. In: J. Biol. Chem.
273.31, pp. 19895–19901.
Georgieva, Daniela et al. (2019). “Detection of Base Analogs Incorporated During DNA
Replication by Nanopore Sequencing”. In: bioRxiv, p. 549220.
Gerber, Christoph and Heinz-Gerhard Toelle (2009). “What happened: The chemistry side
of the incident with EMS contamination in Viracept tablets”. In: Toxicology letters
190.3, pp. 248–253.
Gerstung, Moritz et al. (2017). “The evolutionary history of 2,658 cancers”. In: bioRxiv.
Gerstung, Moritz et al. (2018). “The evolutionary history of 2,658 cancers”. In: BioRxiv,
p. 161562.
Giglia-Mari, Giuseppina, Angelika Zotter, and Wim Vermeulen (2011). “DNA damage
response”. In: Cold Spring Harbor perspectives in biology 3.1, a000745.
Goellner, Eva M, Christopher D Putnam, and Richard D Kolodner (2015). “Exonuclease
1-dependent and independent mismatch repair”. en. In: DNA Repair 32, pp. 24–32.
Golding, Nick (2018). greta: Simple and Scalable Statistical Modelling in R.
Gori, Kevin and Adrian Baez-Ortega (2018). “sigfit: flexible Bayesian inference of muta-
tional signatures”. In: bioRxiv, p. 372896.
Gradia, S et al. (1999). “hMSH2-hMSH6 forms a hydrolysis-independent sliding clamp on
mismatched DNA”. en. In: Mol. Cell 3.2, pp. 255–261.
Grasso, Francesca and Teresa Frisan (2015). “Bacterial genotoxins: merging the DNA
damage response into infection biology”. In: Biomolecules 5.3, pp. 1762–1782.
Greaves, Mel and Carlo C Maley (2012). “Clonal evolution in cancer”. In: Nature 481.7381,
p. 306.
Green, Ade`le C et al. (2011). “Reduced melanoma after regular sunscreen use: randomized
trial follow-up”. In: Journal of clinical oncology 29.3, pp. 257–263.
Greenblatt, Marc S et al. (2001). “TP53 mutations in breast cancer associated with
BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distri-
bution”. In: Cancer research 61.10, pp. 4092–4097.
Greenman, Chris et al. (2006). “Statistical analysis of pathogenicity of somatic mutations
in cancer”. In: Genetics 173.4, pp. 2187–2198.
Greer, Eric Lieberman et al. (2015). “DNA Methylation on N6-Adenine in C. elegans”.
In: Cell 161.4, pp. 868–878.
Gregory, T Ryan (2005). “Synergy between sequence and size in large-scale genomics”.
In: Nature Reviews Genetics 6.9, p. 699.
Grin, Inga and Alexander A Ishchenko (2016). “An interplay of the base excision repair
and mismatch repair pathways in active DNA demethylation”. en. In: Nucleic Acids
Res. 44.8, pp. 3713–3727.
Guengerich, F Peter (1992). “Metabolic activation of carcinogens”. In: Pharmacology &
therapeutics 54.1, pp. 17–61.
Habraken, Y et al. (1996). “Binding of insertion/deletion DNA mismatches by the het-
erodimer of yeast mismatch repair proteins MSH2 and MSH3”. en. In: Curr. Biol. 6.9,
pp. 1185–1187.
Haiman, Christopher A et al. (2006). “Ethnic and racial di↵erences in the smoking-related
risk of lung cancer”. In: New England Journal of Medicine 354.4, pp. 333–342.
Hanawalt, Philip C and Graciela Spivak (2008). “Transcription-coupled DNA repair: two
decades of progress and surprises”. In: Nature reviews Molecular cell biology 9.12,
p. 958.
Hanford, Marsha G et al. (1998). “Microsatellite mutation rates in cancer cell lines defi-
cient or proficient in mismatch repair”. In: Oncogene 16.18, pp. 2389–2393.
Haradhvala, N J et al. (2018). “Distinct mutational signatures characterize concurrent loss
of polymerase proofreading and mismatch repair”. en. In: Nat. Commun. 9.1, p. 1746.
Haradhvala, Nicholas J et al. (2016). “Mutational strand asymmetries in cancer genomes
reveal mechanisms of DNA damage and repair”. In: Cell 164.3, pp. 538–549.
Harr, B, B Zangerl, and C Schlo¨tterer (2000). “Removal of microsatellite interruptions by
DNA replication slippage: phylogenetic evidence from Drosophila”. en. In: Mol. Biol.
Evol. 17.7, pp. 1001–1009.
Hartman, Phil S et al. (2014). “Ethyl methanesulfonate induces mutations in Caenorhab-
ditis elegans embryos at a high frequency”. In: Mutation Research/Fundamental and
Molecular Mechanisms of Mutagenesis 766, pp. 44–48.
Hartman, Philip S et al. (1989). “Excision repair of UV radiation-induced DNA damage
in Caenorhabditis elegans.” In: Genetics 122.2, pp. 379–385.
Hashimoto, Satoru, Hirofumi Anai, and Katsuhiro Hanada (2016). “Mechanisms of inter-
strand DNA crosslink repair and human disorders”. In: Genes and Environment 38.1,
p. 9.
Hayward, Nicholas K et al. (2017). “Whole-genome landscapes of major melanoma sub-
types”. In: Nature 545.7653, p. 175.
Health, US Department of, Human Services, et al. (2016). 14th report on carcinogens
(RoC).
Hecht, Jonathan L and George L Mutter (2006). “Molecular and pathologic aspects of
endometrial carcinogenesis”. en. In: J. Clin. Oncol. 24.29, pp. 4783–4791.
Hegi, Monika E et al. (2005). “MGMT gene silencing and benefit from temozolomide in
glioblastoma”. In: New England Journal of Medicine 352.10, pp. 997–1003.
Helleday, Thomas, Saeed Eshtad, and Serena Nik-Zainal (2014). “Mechanisms underlying
mutational signatures in human cancers”. en. In: Nat. Rev. Genet. 15.9, pp. 585–598.
Helleday, Thomas et al. (2008). “DNA repair pathways as targets for cancer therapy”. In:
Nature Reviews Cancer 8.3, p. 193.
Herman, J G et al. (1998). “Incidence and functional consequences of hMLH1 promoter
hypermethylation in colorectal carcinoma”. en. In: Proc. Natl. Acad. Sci. U. S. A.
95.12, pp. 6870–6875.
Herman, JR et al. (1996). “UV-B increases (1979–1992) from decreases in total ozone”.
In: Geophysical Research Letters 23.16, pp. 2117–2120.
Hess, Marin T et al. (1997). “Base pair conformation-dependent excision of benzo [a]
pyrene diol epoxide-guanine adducts by human nucleotide excision repair enzymes.”
In: Molecular and cellular biology 17.12, pp. 7069–7076.
Hillier, LaDeana W et al. (2005). “Genomics in C. elegans: so many genes, such a little
worm”. In: Genome research 15.12, pp. 1651–1660.
Hoang, Margaret L et al. (2016). “Genome-wide quantification of rare somatic mutations
in normal human tissues using massively parallel sequencing”. In: Proceedings of the
National Academy of Sciences 113.35, pp. 9846–9851.
Hockemeyer, Dirk and Rudolf Jaenisch (2016). “Induced pluripotent stem cells meet
genome editing”. In: Cell stem cell 18.5, pp. 573–586.
Hoeijmakers, Jan HJ (2009). “DNA damage, aging, and cancer”. In: New England Journal
of Medicine 361.15, pp. 1475–1485.
Hollstein, M et al. (2017). “Base changes in tumour DNA have the power to reveal the
causes and evolution of cancer”. en. In: Oncogene 36.2, pp. 158–167.
Hollstein, Monica et al. (1991). “p53 mutations in human cancers”. In: Science 253.5015,
pp. 49–53.
Hope, Ian A (1999). C. elegans: a practical approach. Vol. 213. OUP Oxford.
Hosoya, Noriko and Kiyoshi Miyagawa (2014). “Targeting DNA damage response in cancer
therapy”. In: Cancer science 105.4, pp. 370–388.
Hsieh, Peggy and Kazuhiko Yamane (2008). “DNA mismatch repair: molecular mecha-
nism, cancer, and ageing”. In:Mechanisms of ageing and development 129.7-8, pp. 391–
407.
Hu, Jinchuan et al. (2015). “Genome-wide analysis of human global and transcription-
coupled excision repair of UV damage at single-nucleotide resolution”. In: Genes &
development 29.9, pp. 948–960.
Huang, Haimei (1981). “Ethyl Methanesulfonate (Ems) and Diethylnitrosamine (Den)
E↵ect on Germ Cells of Drosophila Melanogaster.” In:
Huang, Mi Ni et al. (2015). “MSIseq: Software for Assessing Microsatellite Instability
from Catalogs of Somatic Mutations”. en. In: Sci. Rep. 5, p. 13321.
Huang, Mi Ni et al. (2017a). “Genome-scale mutational signatures of aflatoxin in cells,
mice, and human tumors”. en. In: Genome Res. 27.9, pp. 1475–1486.
Huang, Tze-Yun et al. (2017b). “Parity-dependent hairpin configurations of repetitive
DNA sequence promote slippage associated with DNA expansion”. In: Proceedings of
the National Academy of Sciences 114.36, pp. 9535–9540.
Huang, Xiaoqing, Damian Wojtowicz, and Teresa M Przytycka (2017). “Detecting pres-
ence of mutational signatures in cancer with confidence”. In: Bioinformatics 34.2,
pp. 330–337.
Huang, Yaling and Lei Li (2013). “DNA crosslinking damage and cancer-a tale of friend
and foe”. In: Translational cancer research 2.3, p. 144.
Ikehata, Hironobu and Tetsuya Ono (2011). “The mechanisms of UV mutagenesis”. In:
Journal of radiation research 52.2, pp. 115–125.
International, India Project Team of the et al. (2013). “Mutational landscape of gingivo-
buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molec-
ular subgroups”. In: Nature communications 4, p. 2873.
Izsva´k, Zsuzsanna, Yongming Wang, and Zolta´n Ivics (2009). “Interactions of transposons
with the cellular DNA repair machinery”. In: Transposons and the Dynamic Genome.
Springer, pp. 133–176.
Jackson, Stephen P (2002). “Sensing and repairing DNA double-strand breaks”. In: Car-
cinogenesis 23.5, pp. 687–696.
Jackson, Stephen P and Jiri Bartek (2009). “The DNA-damage response in human biology
and disease”. In: Nature 461.7267, p. 1071.
Jager, Myrthe et al. (2019). “Deficiency of nucleotide excision repair is associated with
mutational signature observed in cancer”. In: Genome Research.
Johnson, Robert E et al. (2001). “Role of DNA polymerase ⌘ in the bypass of a (6-4) TT
photoproduct”. In: Molecular and cellular biology 21.10, pp. 3558–3563.
Jonnalagadda, Vidya S, Tetsuya Matsuguchi, and Bevin P Engelward (2005). “Interstrand
crosslink-induced homologous recombination carries an increased risk of deletions and
insertions”. In: Dna Repair 4.5, pp. 594–605.
Kadyrov, Farid A et al. (2006). “Endonucleolytic function of MutLalpha in human mis-
match repair”. en. In: Cell 126.2, pp. 297–308.
Kaletta, Titus and Michael O Hengartner (2006). “Finding function in novel targets: C.
elegans as a model organism”. In: Nature reviews Drug discovery 5.5, p. 387.
Kalisperati, Polyxeni et al. (2017). “Inflammation, DNA damage, Helicobacter pylori and
gastric tumorigenesis”. In: Frontiers in genetics 8, p. 20.
Karran, Peter and Tomas Lindahl (1980). “Hypoxanthine in deoxyribonucleic acid: gen-
eration by heat-induced hydrolysis of adenine residues and release in free form by a
deoxyribonucleic acid glycosylase from calf thymus”. In: Biochemistry 19.26, pp. 6005–
6011.
Kasar, S et al. (2015). “Whole-genome sequencing reveals activation-induced cytidine
deaminase signatures during indolent chronic lymphocytic leukaemia evolution”. In:
Nature communications 6, p. 8866.
Kato, Niyo et al. (2017). “Sensing and processing of DNA interstrand crosslinks by the
mismatch repair pathway”. In: Cell reports 21.5, pp. 1375–1385.
Kelderman, Sander, Ton N Schumacher, and Pia Kvistborg (2015). “Mismatch Repair-
Deficient Cancers Are Targets for Anti-PD-1 Therapy”. en. In: Cancer Cell 28.1,
pp. 11–13.
Kew, Michael C (2013). “Aflatoxins as a cause of hepatocellular carcinoma.” In: Journal
of Gastrointestinal & Liver Diseases 22.3.
Kim, Hoon et al. (2015). “Whole-genome and multisector exome sequencing of primary
and post-treatment glioblastoma reveals patterns of tumor evolution”. en. In: Genome
Res. 25.3, pp. 316–327.
Kim, Hyun Suk, Robert Hromas, and Suk-Hee Lee (2013). “Emerging features of dna
double-strand break repair in humans”. In: New Research Directions in DNA Repair.
IntechOpen.
Kim, Jaegil et al. (2016). “Somatic ERCC2 mutations are associated with a distinct
genomic signature in urothelial tumors”. en. In: Nat. Genet. 48.6, pp. 600–606.
Klug, William S, Michael R Cummings, et al. (2006). Concepts of genetics. Upper Saddle
River, NJ: Pearson Education,
Knijnenburg, Theo A et al. (2018). “Genomic and Molecular Landscape of DNA Damage
Repair Deficiency across The Cancer Genome Atlas”. en. In: Cell Rep. 23.1, 239–
254.e6.
Knisbacher, Binyamin A, Doron Gerber, and Erez Y Levanon (2016). “DNA editing by
APOBECs: a genomic preserver and transformer”. In: Trends in Genetics 32.1, pp. 16–
28.
Knobel, Philip A and Thomas M Marti (2011). “Translesion DNA synthesis in the context
of cancer research”. en. In: Cancer Cell Int. 11, p. 39.
Koc¸, Ahmet et al. (2004). “Hydroxyurea arrests DNA replication by a mechanism that
preserves basal dNTP pools”. In: Journal of Biological Chemistry 279.1, pp. 223–230.
Kondo, Natsuko et al. (2010). “DNA damage induced by alkylating agents and repair
pathways”. In: Journal of nucleic acids 2010.
Koren, Amnon et al. (2012). “Di↵erential relationship of DNA replication timing to dif-
ferent forms of human mutation and variation”. In: The American Journal of Human
Genetics 91.6, pp. 1033–1040.
Kramara, J, B Osia, and A Malkova (2018). “Break-induced replication: the where, the
why, and the how”. In: Trends in Genetics 34.7, pp. 518–531.
Krokan, Hans E and Magnar Bjør˚as (2013). “Base excision repair”. In: Cold Spring Harbor
perspectives in biology 5.4, a012583.
Kru¨ger, Sandra and Rosario M Piro (2019). “decompTumor2Sig: identification of muta-
tional signatures active in individual tumors”. In: BMC bioinformatics 20.4, p. 152.
Kucab, Jill E et al. (2019). “A Compendium of Mutational Signatures of Environmental
Agents”. en. In: Cell.
Kunkel, Thomas A and Katarzyna Bebenek (2000). “DNA replication fidelity”. In: Annual
review of biochemistry 69.1, pp. 497–529.
Lachaud, Christophe et al. (2016). “Ubiquitinated Fancd2 recruits Fan1 to stalled repli-
cation forks to prevent genome instability”. In: Science 351.6275, pp. 846–849.
Laghi, L, P Bianchi, and A Malesci (2008). “Di↵erences and evolution of the methods for
the assessment of microsatellite instability”. en. In: Oncogene 27.49, pp. 6313–6321.
Lahtz, Christoph and Gerd P Pfeifer (2011). “Epigenetic changes of DNA repair genes in
cancer”. en. In: J. Mol. Cell Biol. 3.1, pp. 51–58.
Lang, Gregory I, Lance Parsons, and Alison E Gammie (2013). “Mutation rates, spectra,
and genome-wide distribution of spontaneous mutations in mismatch repair deficient
yeast”. en. In: G3 3.9, pp. 1453–1465.
Lange, Sabine S, Kei-ichi Takata, and Richard D Wood (2011). “DNA polymerases and
cancer”. In: Nature reviews cancer 11.2, p. 96.
Lans, Hannes and Wim Vermeulen (2011). “Nucleotide Excision Repair inCaenorhabditis
elegans”. In: Molecular Biology International 2011, pp. 1–12.
Larsen, Nicolai B et al. (2017). “Stalled replication forks generate a distinct mutational sig-
nature in yeast”. In: Proceedings of the National Academy of Sciences 114.36, pp. 9665–
9670.
Laureti, Luisa et al. (2013). “Reduction of dNTP levels enhances DNA replication fidelity
in vivo”. In: DNA repair 12.4, pp. 300–305.
Lawes, D A, S SenGupta, and P B Boulos (2003). “The clinical importance and prognostic
implications of microsatellite instability in sporadic cancer”. en. In: Eur. J. Surg.
Oncol. 29.3, pp. 201–212.
Le, Dung T et al. (2015). “PD-1 Blockade in Tumors with Mismatch-Repair Deficiency”.
en. In: N. Engl. J. Med. 372.26, pp. 2509–2520.
Le, Dung T et al. (2017). “Mismatch repair deficiency predicts response of solid tumors
to PD-1 blockade”. In: Science 357.6349, pp. 409–413.
Lee, Daniel D and Sebastian H Seung (1999). “Learning the parts of objects by non-
negative matrix factorization”. In: Nature 401.6755, pp. 788–791.
Lee, Hojoon et al. (2015). “The Cancer Genome Atlas Clinical Explorer: a web and mobile
interface for identifying clinical-genomic driver associations”. en. In: Genome Med. 7,
p. 112.
Lee, Hye Seung et al. (2002). “Distinct clinical features and outcomes of gastric cancers
with microsatellite instability”. en. In: Mod. Pathol. 15.6, pp. 632–640.
Lee, Raymond Y N et al. (2017). “WormBase 2017: molting into a new stage”. In: Nucleic
acids research 46.D1, pp. D869–D874.
Leinonen, Rasko et al. (2010). “The European nucleotide archive”. In: Nucleic acids re-
search 39.suppl 1, pp. D28–D31.
Lelieveld, Stefan H et al. (2015). “Comparison of exome and genome sequencing technolo-
gies for the complete capture of protein-coding regions”. In: Human mutation 36.8,
pp. 815–822.
Leung, Maxwell CK et al. (2010). “Caenorhabditis elegans generates biologically relevant
levels of genotoxic metabolites from aflatoxin B1 but not benzo [a] pyrene in vivo”.
In: Toxicological Sciences 118.2, pp. 444–453.
Li, Heng and Richard Durbin (2009). “Fast and accurate short read alignment with
Burrows–Wheeler transform”. In: bioinformatics 25.14, pp. 1754–1760.
Li, Wentao et al. (2017a). “Human genome-wide repair map of DNA damage caused
by the cigarette smoke carcinogen benzo [a] pyrene”. In: Proceedings of the National
Academy of Sciences 114.26, pp. 6752–6757.
Li, XC et al. (2018). “A mutational signature associated with alcohol consumption and
prognostically significantly mutated driver genes in esophageal squamous cell carci-
noma”. In: Annals of Oncology 29.4, pp. 938–944.
Li, Xiangchun et al. (2016). “Distinct subtypes of gastric cancer defined by molecular
characterization include novel mutational signatures with prognostic capability”. In:
Cancer research 76.7, pp. 1724–1732.
Li, Xuan and Wolf-Dietrich Heyer (2008). “Homologous recombination in DNA repair and
DNA damage tolerance”. In: Cell research 18.1, p. 99.
Li, Y et al. (2017b). “Patterns of structural variation in human cancer”. In: bioRxiv.
Li, YWAN FENG, Sang-Tae Kim, and Aziz Sancar (1993). “Evidence for lack of DNA
photoreactivating enzyme in humans.” In: Proceedings of the National Academy of
Sciences 90.10, pp. 4389–4393.
Lieber, Michael R (2010). “The mechanism of double-strand DNA break repair by the
nonhomologous DNA end-joining pathway”. In: Annual review of biochemistry 79,
pp. 181–211.
Lin, Ying-Chih et al. (2014). “Molecular basis of aflatoxin-induced mutagenesis—role of
the aflatoxin B1-formamidopyrimidine adduct”. In: Carcinogenesis 35.7, pp. 1461–
1468.
Lindahl, Tomas and DE Barnes (2000). “Repair of endogenous DNA damage”. In: Cold
Spring Harbor symposia on quantitative biology. Vol. 65. Cold Spring Harbor Labora-
tory Press, pp. 127–134.
Lindahl, Tomas et al. (1993). “Instability and decay of the primary structure of DNA”.
In: nature 362.6422, pp. 709–715.
Lisby, Michael and Rodney Rothstein (2015). “Cell biology of mitotic recombination”. In:
Cold Spring Harbor perspectives in biology 7.3, a016535.
Little, John B (1993). “Cellular, molecular, and carcinogenic e↵ects of radiation”. In:
Hematology/Oncology Clinics 7.2, pp. 337–352.
Liu, David et al. (2017a). “Mutational patterns in chemotherapy resistant muscle-invasive
bladder cancer”. In: Nature communications 8.1, p. 2193.
Liu, Gang et al. (2017b). “Genomics alterations of metastatic and primary tissues across
15 cancer types”. In: Scientific reports 7.1, p. 13262.
Liu, Leroy F and James C Wang (1987). “Supercoiling of the DNA template during
transcription”. In: Proceedings of the National Academy of Sciences 84.20, pp. 7024–
7027.
Liu, Qian et al. (2019). “NanoMod: a computational tool to detect DNA modifications
using Nanopore long-read sequencing data”. In: BMC genomics 20.1, p. 78.
Liu, Yunhua et al. (2015). “TP53 loss creates therapeutic vulnerability in colorectal can-
cer”. en. In: Nature 520.7549, pp. 697–701.
Lobitz, Stephan and Eunike Velleuer (2006). “Guido Fanconi (1892–1979): a jack of all
trades”. In: Nature Reviews Cancer 6.11, p. 893.
Lomax, ME, LK Folkes, and P O’Neill (2013). “Biological consequences of radiation-
induced DNA damage: relevance to radiotherapy”. In: Clinical oncology 25.10, pp. 578–
585.
Luftig, Micah A (2014). “Viruses and the DNA damage response: activation and antago-
nism”. In: Annual Review of Virology 1, pp. 605–625.
Lujan, Scott A, Alan B Clark, and Thomas A Kunkel (2015). “Di↵erences in genome-wide
repeat sequence instability conferred by proofreading and mismatch repair defects”.
en. In: Nucleic Acids Res. 43.8, pp. 4067–4074.
Lujan, Scott A et al. (2012). “Mismatch repair balances leading and lagging strand DNA
replication fidelity”. en. In: PLoS Genet. 8.10, e1003016.
Lujan, Scott A et al. (2014). “Heterogeneous polymerase fidelity and mismatch repair bias
genome variation and composition”. en. In: Genome Res. 24.11, pp. 1751–1764.
Ma, Jennifer et al. (2018). “The therapeutic significance of mutational signatures from
DNA repair deficiency in cancer”. In: Nature communications 9.1, pp. 1–12.
Maaten, Laurens van der and Geo↵rey Hinton (2008). “Visualizing Data using t-SNE”.
In: J. Mach. Learn. Res. 9.Nov, pp. 2579–2605.
Macintyre, Geo↵ et al. (2018). “Copy number signatures and mutational processes in
ovarian carcinoma”. In: Nature genetics 50.9, p. 1262.
Maharjan, Ram and Thomas Ferenci (2014). “Mutational signatures indicative of envi-
ronmental stress in bacteria”. In: Molecular biology and evolution 32.2, pp. 380–391.
Mansour, Wael Y, Tim Rhein, and Jochen Dahm-Daphi (2010). “The alternative end-
joining pathway for repair of DNA double-strand breaks requires PARP1 but is not
dependent upon microhomologies”. In: Nucleic acids research 38.18, pp. 6065–6077.
Marsico, Giovanni et al. (2019). “Whole genome experimental maps of DNAG-quadruplexes
in multiple species”. In: Nucleic acids research 47.8, pp. 3862–3874.
Martincorena, In˜igo et al. (2015). “High burden and pervasive positive selection of somatic
mutations in normal human skin”. In: Science 348.6237, pp. 880–886.
Martincorena, In˜igo et al. (2017). “Universal Patterns of Selection in Cancer and Somatic
Tissues”. en. In: Cell 171.5, 1029–1041.e21.
Martincorena, In˜igo et al. (2018). “Somatic mutant clones colonize the human esophagus
with age”. In: Science 362.6417, pp. 911–917.
Masuda, Keiji et al. (2009). “A critical role for REV1 in regulating the induction of C:
G transitions and A: T mutations during Ig gene hypermutation”. In: The Journal of
Immunology 183.3, pp. 1846–1850.
Masutani, Chikahide et al. (1999). “The XPV (xeroderma pigmentosum variant) gene
encodes human DNA polymerase ⌘”. In: Nature 399.6737, p. 700.
Matsuda, Toshiro et al. (2001). “Error rate and specificity of human and murine DNA
polymerase ⌘”. In: Journal of molecular biology 312.2, pp. 335–346.
Matsumura, Shoji et al. (2018). “A genome-wide mutation analysis method enabling high-
throughput identification of chemical mutagen signatures”. In: Scientific Reports 8.1.
Mayles, WPM et al. (2010). “Survey of the availability and use of advanced radiotherapy
technology in the UK”. In: Clinical Oncology 22.8, pp. 636–642.
McCreery, Melissa Q et al. (2015). “Evolution of metastasis revealed by mutational land-
scapes of chemically induced skin cancers”. In: Nature medicine 21.12, p. 1514.
McGregor, W Glemm et al. (1991). “Cell cycle-dependent strand bias for UV-induced
mutations in the transcribed strand of excision repair-proficient human fibroblasts
but not in repair-deficient cells.” In: Molecular and cellular biology 11.4, pp. 1927–
1934.
McLaren, William et al. (2016). “The Ensembl Variant E↵ect Predictor”. en. In: Genome
Biol. 17.1, p. 122.
McMahill, Melissa S, Caroline W Sham, and Douglas K Bishop (2007). “Synthesis-dependent
strand annealing in meiosis”. In: PLoS biology 5.11, e299.
Meier, Bettina and Anton Gartner (2014). “Having a direct look: analysis of DNA damage
and repair mechanisms by next generation sequencing”. en. In: Exp. Cell Res. 329.1,
pp. 35–41.
Meier, Bettina et al. (2014). “C. elegans whole-genome sequencing reveals mutational
signatures related to carcinogens and DNA repair deficiency”. en. In: Genome Res.
24.10, pp. 1624–1636.
Meier, Bettina et al. (2018). “Mutational signatures of DNA mismatch repair deficiency
in C. elegans and human cancers”. en. In: Genome Res. 28.5, pp. 666–675.
Mimaki, Sachiyo et al. (2016). “Hypermutation and unique mutational signatures of oc-
cupational cholangiocarcinoma in printing workers exposed to haloalkanes”. In: Car-
cinogenesis 37.8, pp. 817–826.
Minca, Eugen C and David Kowalski (2010). “Replication fork stalling by bulky DNA
damage: localization at active origins and checkpoint modulation”. In: Nucleic acids
research 39.7, pp. 2610–2623.
Mishra, Sweta and Johnathan R Whetstine (2016). “Di↵erent facets of copy number
changes: permanent, transient, and adaptive”. In: Molecular and cellular biology 36.7,
pp. 1050–1063.
Miyaki, Michiko et al. (1997). “Germline mutation of MSH6 as the cause of hereditary
nonpolyposis colorectal cancer”. In: Nature Genetics 17.3, pp. 271–272.
Moore, Harold W and Richard Czerniak (1981). “Naturally occurring quinones as po-
tential bioreductive alkylating agents”. In: Medicinal research reviews 1.3, pp. 249–
280.
Morganella, Sandro et al. (2016). “The topography of mutational processes in breast
cancer genomes”. en. In: Nat. Commun. 7, p. 11383.
Mosteller, Frederick and John W Tukey (1968). “Data analysis, including statistics”. In:
Handbook of social psychology 2, pp. 80–203.
Neal, Radford M and Others (2011). “MCMC using Hamiltonian dynamics”. In: Handbook
of Markov Chain Monte Carlo 2.11, p. 2.
Ng, Alvin W T et al. (2017). “Aristolochic acids and their derivatives are widely implicated
in liver cancers in Taiwan and throughout Asia”. en. In: Sci. Transl. Med. 9.412.
Nicolaides, N C et al. (1994). “Mutations of two PMS homologues in hereditary nonpoly-
posis colon cancer”. en. In: Nature 371.6492, pp. 75–80.
Nik-Zainal, Serena et al. (2012a). “Mutational processes molding the genomes of 21 breast
cancers”. en. In: Cell 149.5, pp. 979–993.
Nik-Zainal, Serena et al. (2012b). “The life history of 21 breast cancers”. In: Cell 149.5,
pp. 994–1007.
Nik-Zainal, Serena et al. (2016). “Landscape of somatic mutations in 560 breast cancer
whole-genome sequences”. en. In: Nature 534.7605, pp. 47–54.
Nitiss, John L (2009). “Targeting DNA topoisomerase II in cancer chemotherapy”. In:
Nature Reviews Cancer 9.5, p. 338.
Niu, Beifang et al. (2014). “MSIsensor: microsatellite instability detection using paired
tumor-normal sequence data”. en. In: Bioinformatics 30.7, pp. 1015–1016.
Noll, David M, Tracey McGregor Mason, and Paul S Miller (2006). “Formation and repair
of interstrand cross-links in DNA”. In: Chemical reviews
Nouspikel, TDNA (2009). “DNA repair in mammalian cells”. In: Cellular and Molecular
Life Sciences 66.6, pp. 994–1009.
Nowak, Jonathan A et al. (2017). “Detection of Mismatch Repair Deficiency and Mi-
crosatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation
Sequencing”. en. In: J. Mol. Diagn. 19.1, pp. 84–91.
O’Donovan, Anne et al. (1994). “XPG endonuclease makes the 3 incision in human DNA
nucleotide excision repair”. In: Nature 371.6496, p. 432.
Olivier, Magali et al. (2014). “Modelling mutational landscapes of human cancers in vitro”.
In: Scientific reports 4, p. 4482.
Omichessan, Hanane, Gianluca Severi, and Vittorio Perduca (2019). “Computational tools
to detect signatures of mutational processes in DNA from tumours: a review and
empirical comparison of performance”. In: bioRxiv, p. 483982.
Palles, Claire et al. (2013). “Germline mutations a↵ecting the proofreading domains of
POLE and POLD1 predispose to colorectal adenomas and carcinomas”. en. In: Nat.
Genet. 45.2, pp. 136–144.
Papadopoulos, N et al. (1994). “Mutation of a mutL homolog in hereditary colon cancer”.
In: Science 263.5153, pp. 1625–1629.
Pearl, Laurence H et al. (2015). “Therapeutic opportunities within the DNA damage
response”. en. In: Nat. Rev. Cancer 15.3, pp. 166–180.
Petljak, Mia et al. (2019). “Characterizing Mutational Signatures in Human Cancer Cell
Lines Reveals Episodic APOBEC Mutagenesis”. en. In: Cell 176.6, 1282–1294.e20.
Petruseva, IO, AN Evdokimov, and OI Lavrik (2014). “Molecular mechanism of global
genome nucleotide excision repair”. In: Acta Naturae ( ) 6.1 (20).
Pettersen, Henrik Sahlin et al. (2015). “AID expression in B-cell lymphomas causes accu-
mulation of genomic uracil and a distinct AID mutational signature”. In: DNA repair
25, pp. 60–71.
Pfau, Wolfgang, Heinz H Schmeiser, and Manfred Wiessler (1990). “Aristolochic acid
binds covalently to the exocyclic amino group of purine nucleotides in DNA”. In:
Carcinogenesis 11.2, pp. 313–319.
Pfeifer, Gerd P (2010). “Environmental exposures and mutational patterns of cancer
genomes”. In: Genome medicine 2.8, p. 54.
Phillips, David H (2002). “Smoking-related DNA and protein adducts in human tissues”.
In: Carcinogenesis 23.12, pp. 1979–2004.
Pilati, Camilla et al. (2017). “Mutational signature analysis identifies MUTYH deficiency
in colorectal cancers and adrenocortical carcinomas”. In: The Journal of pathology
242.1, pp. 10–15.
Piovesan, Allison et al. (2019). “On the length, weight and GC content of the human
genome”. In: BMC research notes 12.1, p. 106.
Pleasance, Erin D et al. (2010). “A comprehensive catalogue of somatic mutations from
a human cancer genome”. In: Nature 463.7278, p. 191.
Pluciennik, Anna et al. (2010). “PCNA function in the activation and strand direction of
MutL↵ endonuclease in mismatch repair”. In: Proceedings of the National Academy of
Sciences 107.37, pp. 16066–16071.
Poetsch, Anna R, Simon J Boulton, and Nicholas M Luscombe (2018). “Genomic land-
scape of oxidative DNA damage and repair reveals regioselective protection from mu-
tagenesis”. In: Genome biology 19.1, p. 215.
Polak, Paz et al. (2017). “A mutational signature reveals alterations underlying deficient
homologous recombination repair in breast cancer”. In: Nature genetics 49.10, p. 1476.
Poon, Song Ling et al. (2013). “Genome-wide mutational signatures of aristolochic acid
and its application as a screening tool”. en. In: Sci. Transl. Med. 5.197, 197ra101.
Poon, Song Ling et al. (2014). “Mutation signatures of carcinogen exposure: genome-wide
detection and new opportunities for cancer prevention”. en. In: Genome Med. 6.3,
p. 24.
Poon, Song Ling et al. (2015). “Mutation signatures implicate aristolochic acid in bladder
cancer development”. en. In: Genome Med. 7.1, p. 38.
Pourkarimi, Ehsan, James M Bellush, and Iestyn Whitehouse (2016). “Spatiotemporal
coupling and decoupling of gene transcription with DNA replication origins during
embryogenesis in C. elegans”. In: Elife 5, e21728.
Povirk, Lawrence F and David E Shuker (1994). “DNA damage and mutagenesis induced
by nitrogen mustards”. In: Mutation research/reviews in genetic toxicology 318.3,
pp. 205–226.
Priestley, Peter et al. (2018). “Pan-cancer whole genome analyses of metastatic solid
tumors”. In: bioRxiv, p. 415133.
Prioleau, Marie-Noe¨lle and David M MacAlpine (2016). “DNA replication origins—where
do we begin?” In: Genes & development 30.15, pp. 1683–1697.
Puente, Xose S et al. (2011). “Whole-genome sequencing identifies recurrent mutations in
chronic lymphocytic leukaemia”. In: Nature 475.7354, p. 101.
Rabik, Cara A and M Eileen Dolan (2007). “Molecular mechanisms of resistance and
toxicity associated with platinating agents”. In: Cancer treatment reviews 33.1, pp. 9–
23.
Ramazzotti, Daniele et al. (2018). “De novo mutational signature discovery in tumor
genomes using SparseSignatures”. In: bioRxiv, p. 384834.
Rastogi, Rajesh P et al. (2010). “Molecular mechanisms of ultraviolet radiation-induced
DNA damage and repair”. In: Journal of nucleic acids 2010.
Rausch, Tobias et al. (2012). “DELLY: structural variant discovery by integrated paired-
end and split-read analysis”. en. In: Bioinformatics 28.18, pp. i333–i339.
Rechkoblit, Olga et al. (2002). “trans-Lesion synthesis past bulky benzo [a] pyrene diol
epoxide N 2-dG and N 6-dA lesions catalyzed by DNA bypass polymerases”. In: Jour-
nal of Biological Chemistry 277.34, pp. 30488–30494.
Reijns, Martin AM et al. (2015). “Lagging-strand replication shapes the mutational land-
scape of the genome”. In: Nature 518.7540, p. 502.
Riaz, Nadeem et al. (2017). “Pan-cancer analysis of bi-allelic alterations in homologous
recombination DNA repair genes”. In: Nature communications 8.1, p. 857.
Rippey, JCR and MI Stallwood (2005). “Nine cases of accidental exposure to dimethyl sul-
phate—a potential chemical weapon”. In: Emergency medicine journal 22.12, pp. 878–
879.
Rivas, Miguel et al. (2011). “Ultraviolet light exposure influences skin cancer in association
with latitude”. In: Oncology reports 25.4, pp. 1153–1159.
Rivlin, Noa et al. (2011). “Mutations in the p53 Tumor Suppressor Gene: Important
Milestones at the Various Steps of Tumorigenesis”. en. In: Genes Cancer 2.4, pp. 466–
474.
Roberts, Steven A and Dmitry A Gordenin (2014). “Hypermutation in human cancer
genomes: footprints and mechanisms”. en. In: Nat. Rev. Cancer 14.12, pp. 786–800.
Roberts, Steven A et al. (2012). “Clustered mutations in yeast and in human cancers can
arise from damaged long single-strand DNA regions”. In: Molecular cell 46.4, pp. 424–
435.
Roberts, Steven A et al. (2013). “An APOBEC cytidine deaminase mutagenesis pattern
is widespread in human cancers”. en. In: Nat. Genet. 45.9, pp. 970–976.
Robertson, AB et al. (2009). “DNA repair in mammalian cells”. In: Cellular and molecular
life sciences 66.6, pp. 981–993.
Robinson, Welles, Roded Sharan, and Mark DM Leiserson (2019). “Modeling clinical
and molecular covariates of mutational process activity in cancer”. In: Bioinformatics
35.14, pp. i492–i500.
Rodgers, Kasey and Mitch McVey (2016). “Error-prone repair of DNA double-strand
breaks”. In: Journal of cellular physiology 231.1, pp. 15–24.
Roerink, Sophie F, Robin van Schendel, and Marcel Tijsterman (2014). “Polymerase
theta-mediated end joining of replication-associated DNA breaks in C. elegans”. In:
Genome Res. 24.6, pp. 954–962.
Rosales, Rafael A et al. (2016). “signeR: an empirical Bayesian approach to mutational
signature discovery”. In: Bioinformatics 33.1, pp. 8–16.
Rosenthal, Rachel et al. (2016). “DeconstructSigs: delineating mutational processes in sin-
gle tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution”.
en. In: Genome Biol. 17, p. 31.
Russell, WL and EM Kelly (1982). “Mutation frequencies in male mice and the estimation
of genetic hazards of radiation in men”. In: Proceedings of the National Academy of
Sciences 79.2, pp. 542–544.
Sale, Julian E (2013). “Translesion DNA synthesis and mutagenesis in eukaryotes”. In:
Cold Spring Harbor perspectives in biology 5.3, a012708.
Sale, Julian E, Alan R Lehmann, and Roger Woodgate (2012). “Y-family DNA poly-
merases and their role in tolerance of cellular DNA damage”. In: Nature reviews
Molecular cell biology 13.3, p. 141.
Sancar, Aziz et al. (2004). “Molecular mechanisms of mammalian DNA repair and the
DNA damage checkpoints”. In: Annual review of biochemistry 73.1, pp. 39–85.
Sanders, Mathijs A et al. (2018). “MBD4 guards against methylation damage and germ
line deficiency predisposes to clonal hematopoiesis and early-onset AML”. In: Blood
132.14, pp. 1526–1534.
Sankar, T Sabari et al. (2016). “The nature of mutations induced by replication–transcription
collisions”. In: Nature 535.7610, p. 178.
Schendel, Robin van et al. (2016). “Genomic scars generated by polymerase theta reveal
the versatile mechanism of alternative end-joining”. In: PLoS genetics 12.10, e1006368.
Schiller, John T and Douglas R Lowy (2010). “Vaccines to prevent infections by on-
coviruses”. In: Annual review of microbiology 64, pp. 23–41.
Schimmel, Joost et al. (2017). “Mutational signatures of non-homologous and polymerase
theta-mediated end-joining in embryonic stem cells”. In: The EMBO journal 36.24,
pp. 3634–3649.
Schumacher, April J, Dwight V Nissley, and Reuben S Harris (2005). “APOBEC3G hyper-
mutates genomic DNA and inhibits Ty1 retrotransposition in yeast”. In: Proceedings
of the National Academy of Sciences 102.28, pp. 9854–9859.
Secrier, Maria et al. (2016). “Mutational signatures in esophageal adenocarcinoma define
etiologically distinct subgroups with therapeutic relevance”. In: Nature genetics 48.10,
p. 1131.
Segovia, Romulo, Annie S Tam, and Peter C Stirling (2015). “Dissecting genetic and
environmental mutation signatures with model organisms”. en. In: Trends Genet. 31.8,
pp. 465–474.
Seki, Mineaki, Federica Marini, and Richard D Wood (2003). “POLQ (Pol ✓), a DNA
polymerase and DNA-dependent ATPase in human cells”. In: Nucleic acids research
31.21, pp. 6117–6126.
Seol, Ja-Hwan, Eun Yong Shim, and Sang Eun Lee (2018). “Microhomology-mediated
end joining: Good, bad and ugly”. In: Mutation Research/Fundamental and Molecular
Mechanisms of Mutagenesis 809, pp. 81–87.
Seplyarskiy, Vladimir B et al. (2016). “APOBEC-induced mutations in human cancers are
strongly enriched on the lagging DNA strand during replication”. In: Genome research
26.2, pp. 174–182.
Sequencing Consortium*, The C. elegans (1998). “Genome Sequence of the Nematode
C. elegans: A Platform for Investigating Biology”. In: Science 282.5396, pp. 2012–
2018. issn: 0036-8075. doi: 10 . 1126 / science . 282 . 5396 . 2012. eprint: https :
//science.sciencemag.org/content/282/5396/2012.full.pdf. url: https:
//science.sciencemag.org/content/282/5396/2012.
Shah, DJ, RK Sachs, and DJ Wilson (2012). “Radiation-induced cancer: a modern view”.
In: The British journal of radiology 85.1020, e1166–e1173.
Shaheen, Montaser et al. (2011). “Synthetic lethality: exploiting the addiction of cancer
to DNA repair”. In: Blood 117.23, pp. 6074–6082.
Shaye, Daniel D and Iva Greenwald (2011). “OrthoList: a compendium of C. elegans genes
with human orthologs”. In: PloS one 6.5, e20085.
Sherry, Stephen T et al. (2001). “dbSNP: the NCBI database of genetic variation”. In:
Nucleic acids research 29.1, pp. 308–311.
Shinbrot, Eve et al. (2014). “Exonuclease mutations in DNA polymerase epsilon reveal
replication strand specific mutation patterns and human origins of replication”. en.
In: Genome Res. 24.11, pp. 1740–1750.
Shiraishi, Yuichi et al. (2015). “A simple model-based approach to inferring and visualizing
cancer mutation signatures”. In: PLoS genetics 11.12, e1005657.
Shlien, Adam et al. (2015). “Combined hereditary and somatic mutations of replication
error repair genes result in rapid onset of ultra-hypermutated cancers”. en. In: Nat.
Genet. 47.3, pp. 257–262.
Sidorenko, Victoria S et al. (2012). “Lack of recognition by global-genome nucleotide
excision repair accounts for the high mutagenicity and persistence of aristolactam-
DNA adducts”. en. In: Nucleic Acids Res. 40.6, pp. 2494–2505.
Simpson, AndrewJ G (1997). “The natural somatic mutation frequency and human car-
cinogenesis”. In: Advances in cancer research. Vol. 71. Elsevier, pp. 209–240.
Strand, M et al. (1993). “Destabilization of tracts of simple repetitive DNA in yeast by
mutations a↵ecting DNA mismatch repair”. en. In: Nature 365.6443, pp. 274–276.
Stratton, Michael R, Peter J Campbell, and Andrew P Futreal (2009). “The cancer
genome”. In: Nature 458.7239, pp. 719–724.
Supek, Fran and Ben Lehner (2015). “Di↵erential DNA mismatch repair underlies muta-
tion rate variation across the human genome”. en. In: Nature 521.7550, pp. 81–84.
— (2017). “Clustered mutation signatures reveal that error-prone DNA repair targets
mutations to active genes”. In: Cell 170.3, pp. 534–547.
Swenberg, James A et al. (2010). “Endogenous versus exogenous DNA adducts: their
role in carcinogenesis, epidemiology, and risk assessment”. In: Toxicological sciences
120.suppl 1, S130–S145.
Sykora, Peter et al. (2018). “Next generation high throughput DNA damage detection
platform for genotoxic compound screening”. In: Scientific reports 8.1, p. 2771.
Szikriszt, Bernadett et al. (2016). “A comprehensive survey of the mutagenic impact of
common cancer cytotoxics”. en. In: Genome Biol. 17, p. 99.
Taira, Kentaro et al. (2013). “Distinct pathways for repairing mutagenic lesions induced
by methylating and ethylating agents”. en. In: Mutagenesis 28.3, pp. 341–350.
Tam, Annie S, Je↵rey SC Chu, and Ann M Rose (2016). “Genome-wide mutational signa-
ture of the chemotherapeutic agent mitomycin C in Caenorhabditis elegans”. In: G3:
Genes, Genomes, Genetics 6.1, pp. 133–140.
Tasaki, Eisuke et al. (2018). “High expression of the breast cancer susceptibility gene
BRCA1 in long-lived termite kings”. In: Aging (Albany NY) 10.10, p. 2668.
Taylor, Benjamin Jm et al. (2013). “DNA deaminases induce break-associated mutation
showers with implication of APOBEC3B and 3A in breast cancer kataegis”. en. In:
Elife 2, e00534.
Taylor, Martin RG et al. (2015). “Rad51 paralogs remodel pre-synaptic Rad51 filaments
to stimulate homologous recombination”. In: Cell 162.2, pp. 271–286.
The 1000 Genomes Project Consortium (2015). “A global reference for human genetic
variation”. In: Nature 526.7571, pp. 68–74.
Thompson, Owen et al. (2013). “The million mutation project: a new approach to genetics
in Caenorhabditis elegans”. In: Genome research 23.10, pp. 1749–1762.
Tian-Shung, Wu et al. (2005). “Chemical constituents and pharmacology of Aristolochi
species”. In: Studies in Natural Products Chemistry. Vol. 32. Elsevier, pp. 855–1018.
Tijsterman, Marcel, Joris Pothof, and Ronald H A Plasterk (2002). “Frequent germline
mutations and somatic repeat instability in DNAmismatch-repair-deficient Caenorhab-
ditis elegans”. en. In: Genetics 161.2, pp. 651–660.
Tomasetti, Cristian, Bert Vogelstein, and Giovanni Parmigiani (2013). “Half or more of
the somatic mutations in cancers of self-renewing tissues originate prior to tumor
initiation”. In: Proc. Natl. Acad. Sci. U. S. A. 110.6, pp. 1999–2004.
Tomasetti, Cristian et al. (2015). “Only three driver gene mutations are required for the
development of lung and colorectal cancers”. In: Proc. Natl. Acad. Sci. U. S. A. 112.1,
pp. 118–123.
Tomkova, Marketa et al. (2018). “Mutational signature distribution varies with DNA
replication timing and strand asymmetry”. In: Genome biology 19.1, p. 129.
Tricarico, Rossella et al. (2015a). “Involvement of MBD4 inactivation in mismatch repair-
deficient tumorigenesis”. In: Oncotarget 6.40, p. 42892.
Tricarico, Rossella et al. (2015b). “Involvement of MBD4 inactivation in mismatch repair-
deficient tumorigenesis”. en. In: Oncotarget 6.40, pp. 42892–42904.
Trucco, Lucas D et al. (2019). “Ultraviolet radiation–induced DNA damage is prognostic
for outcome in melanoma”. In: Nature medicine 25.2, p. 221.
Tung, Emily WY et al. (2014). “Benzo [a] pyrene increases DNA double strand break
repair in vitro and in vivo: a possible mechanism for benzo [a] pyrene-induced toxic-
ity”. In: Mutation Research/Genetic Toxicology and Environmental Mutagenesis 760,
pp. 64–69.
Uringa, Evert-Jan et al. (2010). “RTEL1: an essential helicase for telomere maintenance
and the regulation of homologous recombination”. In: Nucleic acids research 39.5,
pp. 1647–1655.
Van Hoeck, Arne et al. (2019). “Portrait of a cancer: mutational signature analyses for
cancer diagnostics”. In: BMC cancer 19.1, p. 457.
Van Loo, Peter et al. (2010). “Allele-specific copy number analysis of tumors”. en. In:
Proc. Natl. Acad. Sci. U. S. A. 107.39, pp. 16910–16915.
Van Schendel, Robin et al. (2015). “Polymerase ⇥ is a key driver of genome evolution and
of CRISPR/Cas9-mediated mutagenesis”. In: Nature communications 6, p. 7394.
Viel, Alessandra et al. (2017). “A specific mutational signature associated with DNA 8-
oxoguanine persistence in MUTYH-defective colorectal cancer”. In: EBioMedicine 20,
pp. 39–49.
Vineis, Paolo and Christopher P Wild (2014). “Global cancer patterns: causes and pre-
vention”. In: The Lancet 383.9916, pp. 549–557.
Viterbi, Andrew (1967). “Error bounds for convolutional codes and an asymptotically
optimum decoding algorithm”. In: IEEE transactions on Information Theory 13.2,
pp. 260–269.
Vogelstein, Bert and Kenneth W Kinzler (2015). “The Path to Cancer –Three Strikes and
You’re Out”. In: N. Engl. J. Med. 373.20, pp. 1895–1898.
Vogelstein, Bert, Drew M Pardoll, and Donald S Co↵ey (1980). “Supercoiled loops and
eucaryotic DNA replication”. In: Cell 22.1, pp. 79–85.
Volkova, Nadezda V et al. (2019). “Mutational signatures are jointly shaped by DNA
damage and repair”. In: bioRxiv, p. 686295.
Wakelin, Laurence PG (1986). “Polyfunctional DNA intercalating agents”. In: Medicinal
research reviews 6.3, pp. 275–340.
Wang, Man-Tzu et al. (2015). “K-Ras Promotes Tumorigenicity through Suppression of
Non-canonical Wnt Signaling”. en. In: Cell 163.5, pp. 1237–1251.
Wang, Victor G, Hyunsoo Kim, and Je↵rey H Chuang (2018). “Whole-exome sequencing
capture kit biases yield false negative mutation calls in TCGA cohorts”. en. In: PLoS
One 13.10, e0204912.
Ward, Elizabeth et al. (2004). “Cancer disparities by race/ethnicity and socioeconomic
status”. In: CA: a cancer journal for clinicians 54.2, pp. 78–93.
Ward, JF (1994). “The complexity of DNA damage: relevance to biological consequences”.
In: International journal of radiation biology 66.5, pp. 427–432.
Watson, William AF (1964). “Evidence of an essential di↵erence between the genetical
e↵ects of mono-and bi-functional alkylating agents”. In: Zeitschrift fu¨r Vererbungslehre
95.4, pp. 374–378.
Weghorn, Donate and Shamil Sunyaev (2017). “Bayesian inference of negative and positive
selection in human cancers”. en. In: Nat. Genet. 49.12, pp. 1785–1788.
Weinstein, John N et al. (2013). “The cancer genome atlas pan-cancer analysis project”.
In: Nature genetics 45.10, p. 1113.
Westcott, Peter MK et al. (2015). “The mutational landscapes of genetic and chemical
models of Kras-driven lung cancer”. In: Nature 517.7535, p. 489.
Wheless, Lee et al. (2012). “A community-based study of nucleotide excision repair poly-
morphisms in relation to the risk of non-melanoma skin cancer”. en. In: J. Invest.
Dermatol. 132.5, pp. 1354–1362.
Wijen, John PH, Madeleine JM Nivard, and Ekkehart W Vogel (2000). “The in vivo
genetic activity profile of the monofunctional nitrogen mustard 2-chloroethylamine
di↵ers drastically from its bifunctional counterpart mechlorethamine”. In: Carcino-
genesis 21.10, pp. 1859–1867.
Willers, H, J Dahm-Daphi, and SN Powell (2004). “Repair of radiation damage to DNA”.
In: British Journal of Cancer 90.7, p. 1297.
Wilson III, David M and Vilhelm A Bohr (2007). “The mechanics of base excision repair,
and its relationship to aging and disease”. In: DNA repair 6.4, pp. 544–559.
Wojtowicz, Damian et al. (2019). “Hidden Markov models lead to higher resolution maps
of mutation signature activity in cancer”. In: Genome medicine 11.1, p. 49.
Wyatt, Michael D and Douglas L Pittman (2006). “Methylating agents and DNA repair
responses: Methylated bases and sources of strand breaks”. In: Chemical research in
toxicology 19.12, pp. 1580–1594.
Xu, Hanxiao et al. (2018). “Organoid technology and applications in cancer research”. In:
Journal of hematology & oncology 11.1, pp. 1–15.
Xue, Weiling and David Warshawsky (2005). “Metabolic activation of polycyclic and
heterocyclic aromatic hydrocarbons and DNA damage: a review”. In: Toxicology and
applied pharmacology 206.1, pp. 73–93.
Yadav, Vinod Kumar, James DeGregori, and Subhajyoti De (2016). “The landscape of
somatic mutations in protein coding genes in apparently benign human tissues carries
signatures of relaxed purifying selection”. In: Nucleic acids research 44.5, pp. 2075–
2084.
Yang, Y et al. (1999). “Analysis of yeast pms1, msh2, and mlh1 mutators points to dif-
ferences in mismatch correction e ciencies between prokaryotic and eukaryotic cells”.
en. In: Mol. Gen. Genet. 261.4-5, pp. 777–787.
Yao, X et al. (1999). “Di↵erent mutator phenotypes in Mlh1- versus Pms2-deficient mice”.
en. In: Proc. Natl. Acad. Sci. U. S. A. 96.12, pp. 6850–6855.
Ye, Kai et al. (2009). “Pindel: a pattern growth approach to detect break points of large
deletions and medium sized insertions from paired-end short reads”. en. In: Bioinfor-
matics 25.21, pp. 2865–2871.
Yoon, Jung-Hoon, Louise Prakash, and Satya Prakash (2010). “Error-free replicative by-
pass of (6–4) photoproducts by DNA polymerase ⇣ in mouse and human cells”. In:
Genes & development 24.2, pp. 123–128.
Yoon, Jung-Hoon et al. (2017). “Translesion synthesis DNA polymerases promote error-
free replication through the minor-groove DNA adduct 3-deaza-3-methyladenine”. en.
In: J. Biol. Chem. 292.45, pp. 18682–18688.
Yoon, Jung-Hoon et al. (2019). “Error-Prone Replication through UV Lesions by DNA
Polymerase # Protects against Skin Cancers”. In: Cell 176.6, 1295–1309.e15.
Zapatka, Marc et al. (2018). “The landscape of viral associations in human cancers”. In:
bioRxiv, p. 465757.
Zeng, Xianmin et al. (2001). “DNA polymerase ⌘ is an AT mutator in somatic hypermu-
tation of immunoglobulin variable genes”. In: Nature immunology 2.6, p. 537.
Zˇgur-Bertok, Darja (2013). “DNA damage repair and bacterial pathogens”. In: PLoS
pathogens 9.11, e1003711.
Zhang, Ye, Larry H Rohde, and Honglu Wu (2009). “Involvement of nucleotide excision
and mismatch repair mechanisms in double strand break repair”. In: Current genomics
10.4, pp. 250–258.
Zheng, Christina L et al. (2014). “Transcription restores DNA repair to heterochro-
matin, determining regional mutation rates in cancer genomes”. en. In: Cell Rep.
9.4, pp. 1228–1234.
Zheng, Huyong et al. (2003). “Nucleotide excision repair-and polymerase ⌘-mediated error-
prone removal of mitomycin C interstrand cross-links”. In: Molecular and cellular
biology 23.2, pp. 754–761.
Zhivagui, Maria et al. (2019). “Experimental and pan-cancer genome analyses reveal
widespread contribution of acrylamide exposure to carcinogenesis in humans”. In:
Genome research 29.4, pp. 521–531.
Zou, Xueqing et al. (2018). “Validating the concept of mutational signatures with isogenic
cell models”. In: Nature communications 9.1, p. 1744.
192
Appendix A
List of DNA repair associated genes
used in C. elegans mutagenesis
screen
Gene
name
Pathway Function of the corresponding pro-
tein
Human ortholog
agt-1 Alkylguanine
DNA-
alkyltransferase
MGMT
agt-2 Alkylguanine
DNA-
alkyltransferase,
predicted to
have transferase
activity
-
brc-1 DSBR Ubiquitin protein ligase, required for
HRR
BRCA1
brd-1 DSBR Ubiquitin protein ligase, required for
HRR
BARD1
bub-3 Spindle assembly
checkpoint
Mitotic checkpoint protein BUB3
ced-3 Damage check-
point
Caspase, a cysteine-aspartate protease,
required for execution of apoptosis
CASP3
ced-4 Damage check-
point
Required for initiation of programmed
cell death
ARAF1
193
cep-1 Damage check-
point
P-53-like protein, promotes DNA-
damage induced germ cell apoptosis,
required for normal meiotic segregation
in the germ line
p53
cku-80 DSBR Predicted to contribute to double-
stranded DNA binding activity; is in-
volved in NHEJR
KU80
csb-1 NER Functions in the transcription coupled
NER, essential for overcoming deleteri-
ous e↵ects of UV radiation
CSB/ERCC6
dna-2 Helicase DNA replication helicase DNA2
dog-1 Helicase, ICLR Required for interstrand cross-link re-
pair and for maintenance of poly-G
tracts of germline and somatic DNA by
resolving the secondary structure that
can occur in G-rich DNA during lagging-
strand DNA synthesis
BRIP-1
exo-1 BER, MMR Exonuclease, implicated in MMR and
DNA recombination
EXO1
exo-3 BER Exhibits DNA-(apurinic or apyrimidinic
site) endonuclease activity and phospho-
ric diester hydrolase activity
APEX1
fan-1 ICLR Fanconi anemia-associated nuclease FAN1
fcd-2 NER, ICLR Predicted to have DNA polymerase
binding activity, involved in NER and
regulation of DNA-dependent DNA
replication
FANCD2
fnci-1 ICLR Predicted to have DNA polymerase
binding activity
FANCI
fncm-1 ICLR Required for resistance to DNA inter-
strand crosslinking agents
FANCM
gen-1 DSBR Exhibits crossover junction endo-
deoxyribonuclease activity, is involved
in HRR
FANCD
194
helq-1 ICLR Putative DNA helicase, may unwind re-
gions of cross-linked DNA before their
repair by other proteins or resolve Holl-
iday junctions after homologous recom-
bination
HELQ
him-6 Helicase RecQ-like ATP-dependent DNA heli-
case, required for replication
BLM
lem-3 Damage check-
point
Protein containing ankyrin repeats,
a LEM (LAP2-emerin-MAN1) domain
and a GIY-YIG nuclease domain, in-
volved in mediating DNA damage re-
sponse
ANKLE1
lig-4 DSBR Predicted to have ATP binding activity,
DNA binding activity, and DNA ligase
(ATP) activity, is invlved in NHEJR
LIG4
mlh-1 MMR MutL homolog 1 MLH1
mus-81 DSBR, ICLR Exhibits enzyme binding activity, is pre-
dicted to contribute to crossover junc-
tion endodeoxyribonuclease activity
MUS81
ndx-4 BER Exhibits 5-phosphoribosyl 1-
pyrophosphate pyrophosphatase activity
and bis(5’-nucleosyl)-tetraphosphatase
(asymmetrical) activity
NUDT2
parp-1 BER Exhibits NAD+ ADP-ribosyltransferase
activity; is involved in protein poly-
ADP-ribosylation
PARP1
parp-2 BER Exhibits NAD+ ADP-ribosyltransferase
activity, is involved in protein poly-
ADP-ribosylation
PARP2
pms-2 MMR Mismatch repair endonuclease PMS2
pole-4 Replicative poly-
merase
Accessory subunit of DNA polymerase
epsilon
POLE4
polh-1 TLS Ortholog of human DNA-directed DNA
polymerase eta
POLH
polk-1 TLS Ortholog of human DNA-directed DNA
polymerase kappa
POLK
195
polq-1 DSBR, TLS Ortholog of human DNA-directed
DNA polymerase theta, involved in
microhomology-mediated end joining
repair
POLQ, POLN
rad-51 DSBR Ortholog of human RAD51 recombinase,
involved in multiple processes including
HRR
RAD51
rcq-5 Helicase Predicted to have several functions, in-
cluding DNA binding activity, RNA
polymerase II complex binding activity,
and nucleoside-triphosphatase activity
REQ5
rev-1 TLS Ortholog of human REV1 - DNA-
directed translesion synthesis poly-
merase
REV1
rev-3 TLS Ortholog of human REV3L - DNA-
directed REV3-like DNA polymerase
zeta, catalytic subunit
REV3L
rfs-1 DSBR Rad-51 like protein, exhibits ATPase
binding activity, involved in HR
RAD51D
rip-1 DSBR RFS-1 interacting protein, involved in
HRR
-
rtel-1 Helicase ortholog of human RTEL1 (regulator of
telomere elongation helicase 1), is pre-
dicted to have ATP binding activity,
ATP-dependent DNA helicase activity,
and DNA polymerase binding activity
RTEL1
san-1 Spindle assembly
checkpoint
Ortholog of human BUB1 mitotic check-
point serine/threonine kinase B, is pre-
dicted to have protein kinase activity
BUB1B
slx-1 DSBR, ICLR Exhibits enzyme binding activity; con-
tributes to 3’-flap endonuclease activ-
ity, 5’-flap endonuclease activity, and
crossover junction endodeoxyribonucle-
ase activity
SLX1
196
smc-5 DSBR Ortholog of human SMC5 (structural
maintenance of chromosomes 5) protein,
is predicted to have ATP binding activ-
ity
SMC5
smc-6 DSBR Ortholog of human SMC6 (structural
maintenance of chromosomes 6) protein,
is predicted to have ATP binding activ-
ity
SMC6
smg-1 Damage check-
point
Ortholog of human SMG1 nonsense me-
diated mRNA decay associated PI3K re-
lated kinase
SMG1
tdp-1 BER Ortholog of human TARDBP (TAR
DNA binding protein), exhibits single-
stranded RNA binding activity
TDP1
ung-1 BER Exhibits uracil DNA N-glycosylase ac-
tivity
UNG
wrn-1 Helicase Exhibits ATP-dependent 3’-5’ DNA
helicase activity, involved in DNA
metabolic process, determination of
adult lifespan, and response to ionising
radiation
WRN
xpa-1 NER Ortholog of human XPA protein, DNA
damage recognition and repair factor
XPA
xpc-1 NER Ortholog of human XPC complex sub-
unit, DNA damage recognition and re-
pair factor
XPC
xpf-1 NER Ortholog of the endonuclease catalytic
subunit of human ERCC excision repair
protein 4
XPF/ERCC4
xpg-1 NER Ortholog of human ERCC excision re-
pair protein 5
XPG/ERCC5
Table A.1: List of DNA repair genes knocked out in the screen.
Comments. bub-3 and polh-1 knockouts were made for two alleles each. All of the
brc-1 mutants also had a knockout of brd-1, and can be considered double knockouts
brc-1, brd-1.
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Appendix B
Mutational signatures of DNA repair
deficiencies and genotype-genotoxin
interactions in C. elegans
Experimental signatures of DNA repair deficiencies for all genetic backgrounds are
available among other Supplementary Materials of Volkova et al. 2019 at the project’s
GitHub page: http://github.com/nvolkova/signature-interactions/Supplementary_
tables (Supplementary Note Figure 1).
List of estimated interaction e↵ects for 113/196 combinations of genetic backgrounds
and genotoxins that showed a fold-change in mutation rate (total mutation rate, base sub-
stitution, indel or structural variant rates) di↵erent from 1 (FDR 10% in each category)
is available among other Supplementary Materials of Volkova et al. 2019 at the project’s
GitHub page: http://github.com/nvolkova/signature-interactions/Supplementary_
tables (Supplementary Note Figure 2).
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Appendix C
Selection in DNA repair related
genes and pathways across cancers
The list of DNA repair genes used in the study is available among other Supplementary
Materials of Volkova et al. 2019 at the project’s GitHub page: http://github.com/
nvolkova/signature-interactions/Supplementary_tables (Supplementary Table 5).
The tables with dN/dS values per gene across cancer types and per DNA repair path-
way per cancer type are available among other Supplementary Materials of Volkova et al.
2019 at the project’s GitHub page: http://github.com/nvolkova/signature-interactions/
Supplementary_tables (Supplementary Table 5).
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Appendix D
Publications
List of publications during PhD studies
Bettina Meier, Nadezda V Volkova, Ye Hong, Pieta Schonfield, Peter J Campbell,
Moritz Gerstung, Anton Gartner. (2018). Mutational signatures of DNA mismatch repair
deficiency in C. elegans and human cancers. Genome Research 28, pp. 666-675.
Santiago Gonza´lez,Nadezda Volkova, Philip Beer, Moritz Gerstung. (2018). Immuno-
oncology from the perspective of somatic evolution. Seminars in cancer biology 52, pp.
75-85.
List of submitted manuscripts
Nadezda V Volkova, Bettina Meier, Vı´ctor Gonza´lez-Huici, Simone Bertolini, San-
tiago Gonzalez, Federico Abascal, In˜igo Martincorena, Peter J Campbell, Anton Gartner,
Moritz Gerstung. (2019). Mutational signatures are jointly shaped by DNA damage and
repair. bioRxiv, doi: https://doi.org/10.1101/686295.
List of manuscripts in preparation
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J Campbell, Moritz Gerstung, Anton Gartner. Systematic characterization of genome-
wide mutagenesis conferred by ionizing radiation in wild-type and DNA repair defective
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